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1.1 Introduction: 
Skeletal muscle is a remarkably heterogeneous tissue with a vast capacity to adapt and 
respond to its external environment [1-4]. It is therefore not surprising that the intense 
muscular contractions common to resistance exercise results in a marked increase in muscle 
size, commonly termed hypertrophy [5, 6]. However, following most bouts of intense exercise, 
there is often considerable muscle damage, inflammation and muscle soreness. Human studies 
exploring the physiological mechanisms of exercise-induced muscle damage date back to the 
beginning of the 20th century [7]. Early works with muscle preparations and animal models 
demonstrated that physical exercise causes damage to muscle cells including the mechanical 
disruption of sarcomeres and adjacent cellular membranes, and disturbed excitation 
contraction coupling and calcium signalling. [8-15]. Pioneering work using human skeletal 
muscle biopsy samples reported muscle damage at the ultrastructural level and changes in 
circulating leucocytes [16-22].  These studies identified a role for inflammatory white blood 
cells in post-exercise muscle recovery. Modern molecular biology has superimposed additional 
layers of complexity by, identifying functional roles for protein and lipid derivatives including 
cytokines, acute phase proteins and eicosanoids, in exercise-induced inflammation. Whilst 
precise cellular and molecular signalling pathways remain poorly understood, post-exercise 
muscle recovery occurs according to a well-described temporal scheme: (1) tissue injury via 
mechanical and metabolic stress, (2) release of vasoactive and chemotactic substances from 
damaged tissue, (3) migration and adhesion of systemic leucocytes to the injury site, and (4) 
tissue repair and adaptation (Figure 1). Research efforts over the last few decades have sought 
to understand the physiological significance of acute post-exercise inflammation and its 
functional role in muscle recovery and adaptation. Developing an understanding of the 
molecular mechanisms that regulate this phenomenon may permit the development of 
therapeutic treatment strategies to manipulate selective events of muscle inflammation and 
optimise the cellular processes of muscle repair. 
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Figure 1.1: A schematic of the process of acute exercise-induced muscle damage, inflammation and 
repair. This figure was adapted from Pillon et al. and demonstrates the interaction between skeletal 
muscle and both local and systemic immune cells [23]. 
 
1.2 Exercise-induced inflammation: 
It appears that cellular events occurring early in exercise-induced muscle damage engage a 
biologically active and tightly regulated acute inflammatory process that is of critical 
importance to post-exercise muscle recovery. While the complexity of inflammation is 
currently acknowledged herein, the fundamental objective of any inflammatory program is to 
repair injury and restore tissue function. Historically, the paradigm that exercise-induced 
muscle damage is linked to an acute inflammatory response has been driven by reports from 
various animal reports and in-vitro study designs, and has been extensively reviewed [9, 12, 13, 
24-30]. Because of the various physiological and anatomical differences between species, and 
the extent of muscle damage that can be caused in in-vitro research models, findings from 
these studies may or may not be applicable to voluntary physical activity in humans.  
   
Localized inflammation is initiated by damage to the extracellular matrix, increasing the 
permeability of the sarcolemmal membrane, causing a rapid extravasation of fluid and blood-
borne polymorphonuclear neutrophils (PMNs) into the damaged tissue [31-33]. It is well 
accepted that neutrophils play a critical role in acute inflammation, removing necrotic tissue 
and cellular debris via a process termed phagocytosis [31, 34]. Phagocytosis triggers a 
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respiratory burst and subsequent release of cytotoxic granulocyte products, reactive oxygen 
species and inflammatory cytokines, which cause further tissue damage and exacerbate the 
inflammatory response [35-38]. Neutrophil infiltration appears to peak between 3-24 h post-
exercise. Interestingly this time point is associated with a rise in histological and functional 
markers of muscle damage. This suggests that neutrophil function may lead to secondary 
tissue injury, a phenomenon termed delayed onset muscle soreness (DOMS) [8, 39-43].  Peak 
accumulation of PMNs is overlapped in time by the accumulation of monocyte/macrophages. 
These are highly versatile cell types whose function depends largely on the extracellular 
environment [44, 45]. Two sub-types of macrophages exist within skeletal muscle, and perform 
multiple and largely disparate functions within the contraction-induced inflammatory cascade 
[25, 34, 46-48]. Classically activated, or M1 macrophages, appear to peak between 12 and 24 h 
post exercise [49] and are most prominent within necrotic muscle fibres [50, 51]. The 
distribution of M1 cells is consistent with their capability of phagocytosis [52]. This precedes a 
shift in macrophage phenotype to an alternatively activated, or M2 macrophage. This shift in 
phenotype coincides with a change from the proliferative stage to the early differentiation 
stage of myogenesis, and substantiates a long suspected concept that M2 macrophages 
regulate key pathways in muscle regeneration [25, 33, 47, 53-60]. These findings rationalize 
the concept that cellular events occurring early in the acute inflammatory cascade, trigger a 
series of cellular processes that are a key regulatory component of muscle regeneration and 
tissue repair.  
 
More recent human research identified two key concepts that have challenged the paradigm 
of exercise-induced muscle damage, DOMS, and muscle regeneration. Firstly, a tissue may be 
influenced by pro-inflammatory signaling molecules, including cytokines and eicosanoids, in 
the absence of inflammatory cell invasion. Subsequently, humans can experience symptoms of 
exercise-induced muscle damage without presenting with cellular signs of inflammation [61-
65]. Radionuclide imaging techniques have confirmed large changes in circulating leucocytes 
(primarily neutrophils) immediately following exercise [63, 66]. However, these techniques 
give no information about the infiltration of leucocytes into skeletal muscle tissue. 
Investigations of exercise-induced muscle inflammation that explore the infiltration of 
leucocytes in to skeletal muscle tissue are relatively scarce, and conflicting results have often 
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been attributed to variations in exercise protocols, muscle sampling procedures, individual 
responsiveness to exercise stress. Additionally, the use of non-specific nomenclature to 
identify and describe muscle damage and inflammation [17, 19, 67-74] has also created some 
confusion in the field. The main criticism of these studies is the risk of the muscle biopsy 
procedure triggering local inflammatory responses that could confound the effects of the 
exercise protocol. Muscle biopsy procedures have been shown to cause an increase in the 
activity of mean arterial pressure kinase (MAPK) [75] and the expression of leucocyte specific 
antigens [62], while impairing adenosine triphosphate (ATP) and glycogen re-synthesis [76]. 
Alternatively, indirect proxy measures of muscle damage and inflammation including 
subjective DOMS, swelling and serum measures of blood-borne proteins have been used, 
however these markers do not accurately reflect the extent of cellular muscle damage and 
show poor correlation with each other [20, 77-82]. In order to determine a functional role for 
acute inflammation in exercise-induced muscle damage, further research including a non-
exercise control group, and measuring direct markers of cellular inflammation are required. 
  
The presence of a post-exercise inflammatory response remains well accepted, however its 
relationship with myofibrillar disruption, cellular damage and muscle soreness remains 
speculative [19, 65, 83, 84]. A review from Paulsen et al. [85] suggested that when intracellular 
damage exceeds a specific threshold, leucocytes infiltrate the damaged tissue and this 
manifests itself as a reduction in muscle force generating capacity. A reduction in muscle force 
generating capacity of greater than 20% appears necessary to initiate leucocyte accumulation 
in skeletal muscle tissue, however results remain inconsistent [19, 84, 86-92]. Studies reporting 
a reduction of muscle force generating capacity greater than 50%, consistently resulted in an 
increase in intramuscular leucocyte infiltration [69, 70, 84, 93-96]. 
 
Immunohistochemical staining of leucocyte specific antigens has become the gold standard for 
the temporal profiling of the appearance of leucocyte populations in human muscle following 
exercise. While animal and in-vitro studies present a highly predictable sequence of cellular 
events in acute inflammation, these findings have yet to be replicated in human in-vivo 
exercise clinical trials. Pioneering works from Paulsen et al. [84] attempted to profile the time 
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course appearance of leucocyte populations by staining muscle cells for CD16 (primarily a 
neutrophil marker) and CD68 (primarily a monocyte/macrophage marker). This study showed 
increased numbers of both CD16 and CD68 localised to the endomysium and perimysium as 
soon as 0.5 h post-exercise and persisting until 4 d post-exercise [84]. Further, this study 
established a strong correlation between the individual changes in muscle function and the 
accumulation of radiolabelled leucocytes, providing further justification for a role of exercise-
induced inflammation in delaying the restoration of muscle function post-exercise. The 
appearance of monocyte/macrophage populations has been a consistent histological finding 
and appears common in both early stage [86, 88, 89, 92, 93, 97] and late stage inflammation 
[32, 70, 98]. Among those publications exclusively examining neutrophil infiltration only two 
studies have identified an increase in both early stage [68, 84] and late stage inflammation [84, 
98]. Further research profiling the time-course of leucocyte recruitment and infiltration in 
human subjects is required to understand the complexity of the exercise-induced inflammation 
response. 
 
1.3 Anti-inflammatory treatments and muscle recovery: 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a commonly used as a treatment strategy 
in exercise and sports medicine to assist with recovery from exercise-induced inflammation, 
particularly following soft-tissue injury [99]. NSAIDs inhibit the cyclooxygenase (COX-1 and -2) 
enzymes and consequently the formation prostanoids derived from mobilised free intracellular 
arachidonic acid (AA) [100]. The COX pathway converts AA to prostaglandin G2 (PGG2), and 
subsequently catalyses the reduction of PGG2 to form PGH2 [101]. Various synthase enzymes 
convert PGH2 to form five primary prostanoids that play a diverse role in acute inflammation, 
including; thromboxane A2, PGD2, PGF2ɑ, PGE2 and PGI2. These prostaglandin species are often 
ascribed to the cardinal signs of acute inflammation through their effects on local blood flow, 
vascular permeability, leucocyte infiltration, and triggering sensations of pain [102, 103]. 
However, more recent information from both animal [104-106] and human research [87, 107, 
108], suggests a role for prostaglandin species in skeletal muscle regeneration.  
 
7 
 
1.3.1. Prostaglandin response to exercise. 
Research in to the prostaglandin response to muscle loading and exercise-induced muscle 
damage has produced equivocal findings that appear to be influenced by the nature of the 
exercise stimulus. Early studies implementing a prolonged submaximal exercise protocol 
demonstrated heightened levels of various circulating prostaglandin species including PGE2 
[109-112], PGF2ɑ [102, 109], PGI2 [113-116] and thromboxane [113, 116]. Fewer studies have 
investigated the prostaglandin response to muscle damaging resistance exercise protocols. The 
limited studies available demonstrated an increase in circulating PGE2 and 13,-14-dihydro-15-
keto-PGF2ɑ following both stretch-shortening cycling exercise [117] and traditional resistance 
exercise [118-120]. No such effect was observed in isolated eccentric knee extension [121, 122] 
and elbow extension exercise [123-125], or downhill running protocols [126]. Similarly, few 
studies have attempted to profile intramuscular prostaglandin responses to exercise-induced 
muscle damage. Skeletal muscle cells express both COX-1 and -2. Few studies have reported an 
increase in skeletal muscle COX mRNA expression and enzymatic activity during exercise 
recovery [127-130], while others have found no change [87, 131]. Eccentric resistance exercise 
triggers an increase in intramuscular PGF2ɑ at 24 h post-exercise [132], while a more traditional 
bout of resistance exercise increases PGF2ɑ in muscle microdialysates at 5-6 and 8-9 h post-
exercise, with no increase in PGE2 [133]. Likewise, an incremental cycling based intervention 
triggered an increase in PGE2 concentration during exercise, measured using microdialysis, 
however an intermittent plantar flexion protocol elicited no such response [134, 135]. Further, 
unilateral arm exercise including 70 maximal eccentric contractions, achieved no change in 
PGE2 levels in tissue dialysate [93]. The reason for such conflicting findings remains unclear, 
however may relate to differences in the exercise protocol, specifically in the intensity of 
muscle load, or the volume of active muscle mass in the respective exercise trials.  
   
1.3.2. The effect of NSAIDs on muscle inflammation and recovery. 
Administration of non-selective NSAIDs (e.g. ibuprofen) effectively blocks the exercise-induced 
rise in prostaglandins in both skeletal muscle [132, 136, 137] and peripheral blood [102]. 
Therefore, NSAID treatment has been used as a research model to explore the physiological 
role of prostaglandin species in exercise-induced inflammation, and the biological link between 
acute inflammation and skeletal muscle regeneration. Research into the effects of NSAIDs on 
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exercise-induced muscle damage and inflammation has produced largely controversial 
findings. Many studies have explored the short term effects of NSAID treatment on indirect 
markers of muscle damage and inflammation and produced disparate findings for an effect on 
muscle swelling [93, 138, 139], circulating creatine kinase [42, 119-121, 140-146], restoration 
of muscle function [42, 93, 122, 138, 140, 142, 144, 146-150] and subjective muscle soreness 
[42, 71, 87, 93, 107, 119, 138-158]. While these markers often represent the symptoms of 
exercise-induced muscle damage, many of these parameters have a relatively weak association 
with structural muscle damage or, more specifically, cellular inflammation. In animal models of 
acute muscle damage, treatment with NSAIDs blunts the infiltration of leucocytes into muscle 
tissue [104, 159], however this finding has not been replicated in human subjects [147, 160]. 
Oral consumption of both ibuprofen, and acetaminophen, an analgesic also known as 
paracetamol, had no effect on skeletal muscle macrophage infiltration at 24 h following an 
eccentric exercise protocol [160]. Similarly treatment with naproxen, another non-selective 
NSAID, had no effect on the infiltration of leucocyte common antigen positive cells following a 
unilateral, isotonic resistance exercise protocol [147]. Interestingly, Paulsen et al., (2010) 
suggested a blunting effect of the COX-2 specific celecoxib following maximum eccentric 
muscle contractions [93]. This research identified a tendency for higher monocyte/macrophage 
numbers in subjects within the placebo group, and within those subjects who were identified 
as ‘high-responders’ to the exercise protocol based on the number of inflammatory leucocytes 
[93]. Although this is not a particularly robust finding, it has led to the hypothesis that NSAIDs 
may influence leucocyte infiltration in skeletal muscle when a sufficiently strong and early 
inflammatory reaction is present [93]. This hypothesis would suggest that the intensity of the 
exercise stimulus and the consequent muscle-damage response would be largely influential in 
determining the effect of a pharmacologically based anti-inflammatory intervention.    
 
Experimental evidence also indicates that NSAID administration can influence the regenerative 
capacity of skeletal muscle following exercise-induced muscle damage. The non-selective COX 
inhibitor ibuprofen, blunted skeletal muscle protein synthesis [107], while local intramuscular 
infusion of indomethacin inhibited satellite cell proliferation following maximum eccentric 
exercise protocols [87]. Similarly, oral administration of indomethacin attenuated the exercise-
induced increase in satellite cell number following an endurance running protocol. Further, 
9 
 
treatment with ibuprofen inhibited early translational signaling responses involved in post-
exercise muscle hypertrophy following a bout of traditional resistance exercise [161]. These 
findings support earlier in-vitro research models that implicate a role for prostaglandin species 
in stimulating skeletal muscle adaptive pathways [162, 163]. However, follow up studies using 
selective COX-2 specific NSAID celecoxib showed no effect on the exercise-induced increase in 
skeletal muscle protein turnover [130] or satellite cell number [93] following an eccentric 
exercise protocol. These findings present two potential alternatives. Firstly, despite the well-
established role for the inducible COX-2 enzyme in the animal muscle reparative response to 
acute damage [104-106, 111, 164], the constitutively active COX-1 may play an important 
function in the human adaptive response to exercise. Alternatively, NSAID administration may 
have the capacity to influence alternative signalling pathways within the exercise-induced 
inflammation-tissue repair paradigm. Markworth et al. employed a targeted lipidomics 
approach to characterize temporal changes in the human peripheral blood fatty acyl lipid 
mediator profile in response to acute resistance exercise [102]. This research demonstrated 
that ibuprofen administration has the capacity to influence the appearance of a series of lipid-
derived mediators that have the potential to engage a biologically active inflammatory 
resolution programme that may provide a crucial physiological link between inflammatory and 
adaptive signaling pathways. 
 
1.4 Resolution of exercise-induced inflammation: 
Historically, the label of inflammation has been ascribed to a distinct group of symptoms 
including heat, redness, swelling, pain and a loss of function [165]. The resolution of 
inflammation was previously thought to be a passive process whereby chemotactic gradients 
were thought to dissipate and the exodus of inflammatory leucocytes through lymphatic 
drainage enabled muscle tissue to return to homeostatic function. However, the discovery of a 
novel class of lipid-derived mediators has established the resolution of inflammation as an 
active biochemical and metabolic process. The profiling of these bioactive lipids was pioneered 
by Serhan et al. [166-174] and represents an area of critical importance in understanding the 
biological significance of the inherent self-resolving nature of acute skeletal muscle 
inflammation.  
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Lipid mediators are biosynthesized endogenously from numerous polyunsaturated fatty acid 
(PUFA) precursors including essential omega-3 fatty acids (n-3) eicosapentaenoic (EPA) and 
docosahexaenoic acid (DHA), and major omega-6 (n-6) arachidonic acid (AA). Under basal 
conditions PUFA substrates remain esterfied within cell membrane phospholipids. In response 
to injury or inflammatory insult hundreds of distinct lipid species can be synthesized via 3 
major enzymatic pathways: (1) cyclooxygenase, (2) lipoxygenase, and (3) epoxygenase which is 
catalysed by cytochrome P450 (CYP) [101]. The development of mass spectrometry (MS)-based 
lipidomic profiling has identified and quantified large numbers of pro-inflammatory, pro-
resolution and anti-inflammatory mediators, and enabled the sequential profiling of lipid 
species in a variety of acute inflammatory models. The majority of research has focussed on 
classic prostaglandin and leuokotriene species which are pro-inflammatory in nature and 
derived from omega-6 AA. These lipids play a diverse role in stimulating acute inflammation by 
controlling local blood flow, cytokine production, cell membrane permeability and leucocyte 
infiltration [102]. More recently, a secondary class of eicosanoids also generated from AA, 
termed lipoxins [172, 175, 176], as well as newly identified EPA (E-Series) and DHA (D-Series) 
derived resolvins, protectins [166, 169-171, 177, 178], play dual anti-inflammatory and pro-
resolution functions in acute inflammation. These endogenous mediators possess potent 
immunoregulatory actions via several pathways including the inhibition of pro-inflammatory 
cytokines and the chemotaxis neutrophils, and stimulating the recruitment of monocytes and 
the nonphlogistic phagocytosis of apoptotic neutrophils [175, 177-182]. Evidence from in-vitro 
models suggests that the phagocytosis of apoptotic neutrophils can trigger a phenotypic shift 
in macrophages from the classical M1 macrophage, to the alternative M2 macrophage [181]. 
This process may suppress the release of pro-inflammatory agents and increase the 
macrophage release of anti-inflammatory mediators such as transforming growth factor-β 
(TGF-β) and vascular endothelial growth factor (VEGF) [44, 183]. 
 
Lipoxins, resolvins and protectins are formed during inflammatory transcellular interactions, 
involving the sequential actions of two or more LOX and/or COX enzymes. During inflammation 
cell-cell interactions between platelets, leucocytes and resident tissue cells facilitates the 
transcellular biosynthesis of unique lipid derivatives [101]. For example, LX biosynthesis 
involves cellular interactions between 5-LOX expressing PMNs with 12-LOX expressing platelets 
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or 15-LOX expressing M2 monocytes [184].  The complex signalling network that exists within 
damaged skeletal musculature remains poorly understood, and it appears from other models 
of acute inflammation that the temporal regulation of lipids and their role in inflammation is 
likely to be cell-type and stimulus specific.  
 
Our understanding of pro-resolving lipid mediator circuits has been limited to in-vitro assays 
utilizing blood borne immune cell populations and pharmacologically induced models of acute 
inflammation. The first study to explore the time-course appearance of lipid mediators 
implemented a TNF-ɑ-stimulated model of acute inflammation in the murine air pouch [185]. 
Within this model, early formation of LTB4 and PGE2 at the onset of inflammation was 
succeeded by a class-switching of eicosanoids to LXA4 which was concurrent with spontaneous 
inflammatory resolution. During this process, interactions between inflammatory and host 
tissue cells enabled the biosynthesis of resolution mediators [185]. Human PMN exposed to 
PGE2 switched eicosanoid biosynthesis from predominately LTB4 to a LXA4 product, establishing 
a pathway termed lipid mediator class switching. Alternatively, in a model of zymosan-A 
stimulated murine peritonitis, the onset of inflammation was characterized by a concomitant 
increase in LTB4 and LXA4 followed by a late appearance of PGE2 at the onset of resolution 
[186]. The discrepancies in the temporal patterns of eicosanoid generation likely reflect 
differences in the nature of the experimental models (microbial-initiated vs wound model) 
and/or the stimulus specific signalling pathways (zymosan A vs TNF-ɑ).  
 
In the first study to explore the appearance of lipid derived resolution mediators in an in-vivo 
exercise model, maximal physical exertion on a cycle ergometer caused a rapid increase in the 
urinary excretion of LXA4 immediately post-exercise [187]. These findings led the author to 
suggest that the enhanced LX biosynthesis may represent a protective pro-resolving 
mechanism programmed in to the early stages of acute inflammation to act as a self-regulatory 
defence against exercise-induced cellular stress [187]. More recently Markworth et al. [102] 
undertook an unbiased metabololipidomic profiling of human peripheral blood serum samples 
obtained during the first 24 h of muscle recovery following an acute bout of unaccustomed 
resistance exercise. This study showed an increase in key prostaglandin, leukotriene, lipoxin 
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and E-series resolvin species during the early stages of acute post-exercise inflammation (0-3 
h). Subsequently D-series resolvins and protectins, along with 15-LOX derivatives and some 
prostaglandin metabolites (6-keto-PGF1ɑ and 13,14dh-15kPGE2) remained elevated within the 
circulation following 24 h of recovery [102]. Collectively these results indicate that pro-
resolving lipid mediator biosynthesis is increased in humans in response to an exercise stress 
and the concept of an active inflammatory resolution model must be considered. Distinct 
classes of pro-resolution lipid mediators appear to exhibit specific temporal patterns 
throughout the time-course of post-exercise muscle recovery. Therefore, future research 
needs to establish the profile of resolution mediators, and the transcriptional mechanisms that 
regulate this pathway, in skeletal muscle tissue in models of exercise-induced inflammation.  
 
1.5 Transcriptional regulation of exercise-induced inflammation: 
To understand the link between inflammatory and regenerative processes requires the 
identification of molecular signalling pathways coupling cellular stress with tissue adaptation. 
NF-κB is a pleiotropic transcription factor that acts as a central regulator of stress signaling 
pathways by mediating a wide array of cellular responses including immune cell recruitment, 
cellular survival, proliferation and differentiation (Figure 2) [188-195]. The regulation of NF-κB 
is implicated in many of the physiological processes that occur in response to tissue injury, 
specifically: (1) the onset of inflammation, (2) the resolution of inflammation and (3) skeletal 
muscle myogenesis.   
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Figure 1.2: NF-κB acts as a central regulator of stress signaling pathways and is involved in a diverse 
number of stress signaling pathways. The function of NF-κB within cellular physiology depends on the 
inciting stimulus and the tissue type. 
 
1.5.1 Nuclear Factor-kappa B: 
In mammalian tissue the Rel/NF-κB family of eukaryotic transcription factors is composed of 
five structurally related subunits, RelA (p65), cREL, RelB, NF-κB1 (p50) and NF-κB2 (p52) [191, 
192]. These proteins bind to form hetero- and homodimers that produce diverse combinations 
of dimeric complexes [196, 197]. Each dimer possesses different DNA binding specificities, thus 
different complexes can induce distinct signaling pathways specific to the activating stimulus 
and cell type [196, 197]. Under basal conditions NF-κB remains sequestered within the 
cytoplasm in an inactive complex bound to the inhibitor protein IκB [190, 193, 198]. There are 
seven mammalian IκBs; IκBα, IκBβ, IκBε and IκBγ, BCL-3 and precursor proteins p100 and p105 
that interact with specific NF-κB dimers. Upon stimulation the IκB kinase (IKK) complex 
regulates the degradation of IκB proteins via phosphorylation and subsequent 
polyubiquitination. The IKK complex is composed of two catalytic subunits IKK-α and IKKβ and a 
regulatory subunit IKK-γ [192]. The activation and subsequent nuclear translocation of NF-κB 
dimeric complexes occurs via two well described mechanisms; the classic and alternative NF-κB 
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signaling pathways. Briefly, activation signals are channelled through intracellular adaptive 
proteins which permit receptor induced activation of IKK. Within the classical activation 
pathway, the activation of IKKβ and IKK-γ induces the phosphorylation and consequent 
degradation of IκBα and IκBβ via the proteosome ubiquitination pathway [192, 199]. 
Dissociation from IκB permits the nuclear localization of NF-κB subunits p50 and p65 to 
transcriptionally regulate the activation of specific target genes (Figure 3). Alternative NF-κB 
signaling proceeds through the activation of IKK-α which triggers the phosphorylation and 
partial proteolysis of precursor protein p100 to form the p52 subunit via a co-translation 
mechanism [194]. Once processed, p52 forms a dimeric complex with RelB which, upon 
activation, translocates to the nucleus to regulate the transcription of genes that may be 
distinctly different from those targeted by the classical pathway [194] (Figure 3). 
  
Figure 1.3: Classical and alternative NF-κB signaling pathways [194]. 
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1.5.2 NF-κB and inflammation: 
NF-κB regulates the expression of various genes that play a pivotal role in both acute and 
chronic inflammatory conditions. In response to a diverse range of pro-inflammatory stimuli 
including; cytokines, oxidative and thermal stress, ischemia and apoptotic mediators, NF-κB 
induces pro-inflammatory genes including cytokines [200], chemokines [192], vascular and 
intracellular adhesion molecules [201, 202], and acute phase proteins [203]. NF-κB also plays a 
role in the promoting the cessation of an inflammatory program via the inhibition of neutrophil 
apoptosis [204]. Dysregulation of apoptosis inevitably leads to the disintegration of 
extravasated neutrophils. This in turn exposes surrounding tissue to large quantities of 
histotoxic products causing further damage and prolonging the inflammatory response [183]. 
Not surprisingly chronic up regulation of NF-κB is implicated in the pathogenesis of several 
inflammatory myopathies [205, 206] establishing NF-κB as a prospective target for 
manipulation in the treatment of chronic inflammatory disorders [207]. However recent 
research has identified a role for NF-κB in the active resolution program of acute inflammation 
[208-210]. Homodimers of the alternative NF-κB activation pathway (p50 subunit) which lack a 
transactivation domain, are associated with the expression of anti-inflammatory genes, the 
inhibition of pro-inflammatory stimuli and the induction of apoptosis [210-212]. In a model of 
rodent carageenin-induced pleurisy NF-κB activation was biphasic in nature [210]. Early 
activation of the classical NF-κB pathway coincided with the onset of inflammation and the 
expression of pro-inflammatory cytokines, while a secondary activation of the alternative NF-
κB pathway comprising p50 homodimers corresponded with the resolution of inflammation 
[210]. 
 
1.5.3 NF- κB and skeletal muscle myogenesis: 
The role of NF-κB in this process remains enigmatic and appears to be specific to the duration 
of NF-κB activation, the inducing stimuli and the dimeric complex activated. Accumulating 
evidence suggests that NF-κB may be essential in both inhibiting and promoting skeletal 
muscle myogenesis. Evidence for a direct role of NF-κB in the inhibition of satellite cell 
differentiation is well documented. Inhibition of NF-κB either via the administration of known 
suppressors such as curcumin [213], or genetic manipulation [214], accelerates myogenesis, as 
well as myotube formation. Likewise, pharmacological activation of NF-κB inhibits myogenesis 
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in response to severe muscle trauma and in skeletal muscle myopathies [193, 207, 215]. 
Further, chronic inflammation activates skeletal muscle degradation pathways involved in the 
pathology of chronic disease. Chronic activation of NF-κB is observed in several diseased states 
and the activation of downstream inflammatory targets are linked to skeletal muscle wasting 
and suppressed myogenesis [207, 216-218]. Mechanistically, NF-κB can act through multiple 
pathways to block muscle growth and repair. Recent investigations have indicated that NF-κB 
inhibits myogenesis via the up regulation of transcriptional factor Ying Yang1 (YY1) which acts 
as a repressor of late stage differentiation genes MyoD and MHC [193]. Alternative pathways 
that have been explored include the NF-κB regulation of cyclinD1. CyclinD1 is a cyclin-
dependent kinase complex that can cause myoblasts to undergo irreversible growth arrest 
[214]. Further, activation of NF-κB by a supraphysiological dose of TNF-α  has deleterious 
effects on satellite cell signaling [200]. Contrary to these initial findings, numerous in vitro 
reports have established a positive association between NF-κB activation and skeletal muscle 
myogenesis. Pharmacological inhibition of NF-κB impairs myogenesis in L6 rodent myoblasts 
[219, 220]. Both lactacystin [220] and three dimensional clinorotation [219] attenuated 
signaling through the classical NF-κB pathway and concomitantly inhibited the expression of 
muscle-specific proteins and myoblast differentiation. Whilst our understanding of precise 
signaling pathways remains poor, several different mechanisms have been proposed. Briefly, 
several mitogenic precursors stimulate or are induced by NF-κB. Growth factors such as PDGF 
and VEGF appear to function via an autocrine loop, acting both upstream and downstream of 
NF-κB [192, 221]. Further, IGF-II signaling promotes NF-κB DNA binding during C2C12 
differentiation via IKKα activation, a key component of the alternative NF-κB signaling pathway 
[192]. Correspondingly, NF-κB activity increases the transcription of IGF-BP1 [222, 223] and 
IGF-BP2 [224] which is required for terminal myogenic differentiation in the presence of IGF-II. 
A number of reports have further identified promyogenic factor p38 MAPK as an activator of 
NF-κB signaling through the classical signaling pathway [225-227]. Baeza-Raja et al. [225-227] 
established a p38-dependent increase in NF-κB DNA binding activity during myogenic 
differentiation in C2C12 cells. It was proposed that NF-κB activation is required for IL-6 
production, a cytokine implicated in myogenesis and satellite cell signaling [225]. It is also 
plausible to consider a role for TNF-α in this pathway. This cytokine is a known transcriptional 
target of NF-κB and at high levels acts as a potent inhibitor of myogenesis in skeletal muscle 
myopathies. However, recent in-vitro research discovered low levels of TNF-α promotes 
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myogenesis via signaling through the myogenic activity of p38 MAPK [228], establishing a 
conceivable link between NF-κB and TNF-α in skeletal muscle satellite cell activation [229]. This 
premise is validated by the role of TNF- α as a positive regulator of myogenesis in cardiotoxin-
injured muscle [230]. Additionally NF-κB induces hypertrophic growth in cardiomyocytes in-
vitro [231]. The discrepancies that exists within the literature suggest that the effects NF-κB 
and TNF-α signaling exert on myogenic pathways is likely to be specific to the activating 
stimulus, the timing and duration of activation and the precise NF-κB pathway that is activated. 
 
1.5.4 NF- κB and exercise: 
Acute exercise triggers a transient rise in various components of the NF-κB signaling pathway 
in various cell types [232-236]. However, a precise functional role for NF-κB in contraction-
induced muscle damage remains speculative. Key components of the NF-κB signaling pathway 
are up regulated in human peripheral blood lymphocytes and rodent skeletal muscle tissue 
immediately post exercise, implicating a potential role for NF-κB in acute muscle damage [232, 
234, 235]. Further, this rise appears to peak between 1 and 5 h post exercise, a time point that 
coincides with the recruitment and activation of inflammatory neutrophils [232, 235]. Protein 
expression of p50/p65 complex and NF-κB DNA binding remains activated at 24 h post-exercise 
[232, 234], however a functional role for NF-κB at this time point was not established. 
Interestingly Ho et al. [233] observed no change in NF-κB DNA binding activity at 5 h post 
exercise in rodent skeletal muscle tissue whilst Ji et al. [234] employed a similar research 
model, and identified an increase in NF-κB DNA binding at 4 and 24 h. Collectively these two 
experiments may provide an insight into the regulatory patterns of NF-κB following exercise. 
Models of TNF-α induced activation of NF-κB and ischemic reperfusion injury, have identified a 
biphasic activation pattern of NF-κB in response to cellular stress [216, 237]. The first phase is 
transient in nature and appears to peak between 30 min and 3 h post exercise. Activation of a 
secondary phase differs between studies, with TNF-α triggering an increase in NF-κB 
transactivation function between 24 and 36 h post exposure [216] and ischemic reperfusion 
injury causing an increase NF-κB DNA binding between 6 and 16 h [237]. The discrepancy in the 
literature is likely to reflect a difference in the stress induced stimulus. This also highlights a 
need for further research to examine the time course activation of both the classical and 
alternative NF-κB signaling pathways following exercise-induced muscle damage. 
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Understanding the complexity of this pathway and the potential interactions between classical 
and alternative NF-κB pathways will provide new insights into the mechanistic link between 
exercise-induced inflammation and cellular regeneration pathways. 
 
Remarkably, a paucity of research exists examining the effect of exercise on NF-κB signaling in 
human skeletal muscle tissue. Durham et al. [238] conducted an initial trial examining the 
effect of an acute resistance exercise bout on the activation of the NF-κB pathway. This 
research established a 44% decrease in NF-κB DNA binding activity at 10 min post exercise and 
no change at 1 h post [238]. Contrastingly, Tantiwong et al. [236] used a moderate intensity 
cycling protocol and observed no change in DNA binding activity immediately post exercise and 
a 90% increase at 210 min post.  It is likely that the observed disparities between the two trials 
may be caused by the differences in exercise protocol or the difference in the time course of 
muscle biopsy sampling. Further research from Vella et al. [239] demonstrated a significant 
increase in NF-κB (p65) in response to traditional resistance exercise at 2 h post-exercise. 
These findings led to the novel exploration for a potential target of NF-κB (p65) in response to 
a resistance exercise stimulus and identified NF-κB as a transcriptional regulator of pro-
inflammatory myokines MCP-1, IL-6 and IL-8. EMSA data revealed that NF-κB binding to the 
promoter region on all three respective genes increased significantly at 2 h post exercise and 
returned to basal levels by 4 h. While these findings establish NF-κB as a key regulator of post-
exercise inflammatory pathways, the regulatory circuitry of the NF-κB pathway, and the 
heterogeneity of NF-κB target genes, suggests that our understanding of NF-κB signaling 
following exercise is incomplete. Future research needs to consider the activation of both 
classical and alternative NF-κB pathways beyond the 4 h time point examined in human 
research, and further explore the role of NF-κB in post-exercise inflammatory resolution and 
skeletal muscle myogenesis.       
 
1.6 Summary: 
The human response to resistance exercise presents a highly complex paradigm. Simplistically, 
the outcome of post-exercise inflammation can be regarded as a battle between those 
mechanisms that augment the inflammatory response and cause further injury, against those 
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that tend to promote the resolution of inflammation and skeletal muscle repair. The skeletal 
muscle response to exercise-induced muscle damage occurs in a well described schematic of 
events; degeneration, inflammation and, regeneration. While processes of degeneration and 
inflammation can exacerbate symptoms of muscle injury and promote sensations of pain, a 
considerable body of literature has established a clear link between signaling pathways in 
inflammation and skeletal muscle adaptation. Developing an understanding of the molecular 
mechanisms regulating this physiological link is vital in establishing therapeutic treatment 
strategies to optimise muscle recovery from exercise-induced tissue injury. 
 
The acute post-exercise inflammatory response is self-resolving in nature and recent works 
have identified a series of novel lipid derivatives that play a role in regulating a biologically 
active inflammatory resolution program. While this concept remains largely unexplored in 
humans post-exercise, initial research demonstrates these lipids are increased in human serum 
samples following exercise and may provide a novel mechanism in understanding the link 
between inflammation and tissue adaptation [102]. Further, NF-κB is a transcription factor 
shown to couple cellular stress with an adaptive or maladaptive response. It has been 
implicated in post-exercise inflammation and also demonstrated to be involved in an in-vitro 
model of acute inflammatory resolution. The concept that events occurring early in acute 
inflammation engage an active cellular resolution program that is intimately necessary for the 
activation tissue adaptive pathways, presents a novel and unexplored link between cellular 
stress and tissue regeneration that may provide insight into the mechanisms that regulate 
post-exercise muscle recovery. 
 
1.7 General hypothesis:  
The overall hypothesis of this thesis is that an acute inflammatory resolution pathway exists in 
post-exercise inflammation. A biologically active inflammatory resolution pathway provides a 
potential mechanism through which cellular events occurring early within an acute 
inflammation engage a complex cascade that ultimately leads to the restoration of tissue 
homeostasis and skeletal muscle adaptation. NF-κB presents a transcription factor involved in 
processes of acute inflammation, inflammatory resolution and myogenesis. Interactions 
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between classical and alternative NF-κB signaling pathways may provide a transcriptional 
target that links these cellular processes and plays an integral role in recovery from exercise-
induced muscle damage. This hypothesis will be tested by investigating the specific aims 
outlined below. 
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1.8 Specific Aims: 
1)  
a) To investigate if oral administration of ibuprofen influences skeletal muscle leucocyte 
infiltration during the first 24 h after muscle-damaging resistance exercises.   
 
b) To determine if individual changes in leucocyte infiltration are correlated to markers of 
muscle damage, including circulating muscle proteins CK and myoglobin, and subjective 
markers of muscle soreness. 
 
2) To determine the effect of acute resistance exercise on a novel family of lipid derived 
eicosanoids and docosanoids that play a key role in driving a biologically active 
inflammatory resolution program. 
 
3) To examine the effect of an acute bout of resistance exercise on regulating members of the 
classical and alternative NF-κB signaling pathways in skeletal muscle of young untrained 
men. 
 
1.9 Hypothesis: 
1. The ingestion of ibuprofen following acute resistance exercise will not influence the 
infiltration of leucocytes, however it will attenuate sensations of muscle soreness. 
 
2. Acute resistance exercise will trigger an increase in a novel series of lipid-derived 
inflammatory mediators that are involved in regulating an active inflammatory 
resolution pathway. 
 
3. Acute resistance exercise will trigger an increase in key parameters of the NF- κB 
signaling pathways. The activation of NF-κB will be biphasic in nature, involving the 
activation of the classical NF-κB pathway at the onset of inflammation, and the 
alternative NF-κB pathway coincident with the resolution of acute inflammation. 
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CHAPTER 2: 
 
Ibuprofen ingestion does not affect markers of post-exercise muscle inflammation. 
 
Vella L, Markworth JF, Paulsen G, Raastad T, Peake JM, Snow RJ, Cameron-Smith D, Russell 
AP. Ibuprofen ingestion does not affect markers of post-exercise muscle inflammation. 
Frontiers in Exercise Physiology, 2016 Mar 29;7:86. doi: 10.3389/fphys.2016.00086 
(Appendix A). 
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2.1 Abstract: 
 
Purpose: Chapter 2 investigated if oral ingestion of ibuprofen influenced leucocyte recruitment 
and infiltration following an acute bout of traditional resistance exercise. Methods: Sixteen 
male subjects were divided into two groups that received the maximum over-the-counter dose 
of ibuprofen (1200 mg d-1) or a similarly administered placebo following lower body resistance 
exercise. Muscle biopsies were taken from m.vastus lateralis and blood serum samples were 
obtained before and immediately after exercise, and at 3 h and 24 h after exercise. Muscle 
cross-sections were stained with antibodies against neutrophils (CD66b and MPO) and 
macrophages (CD68). Muscle damage was assessed via creatine kinase and myoglobin in blood 
serum samples, and muscle soreness was rated on a ten-point pain scale. Results: The 
resistance exercise protocol stimulated a significant increase in the number of CD66b+ and 
MPO+ cells when measured at 3 h post exercise. Serum creatine kinase, myoglobin and 
subjective muscle soreness all increased post-exercise. Muscle leucocyte infiltration, creatine 
kinase, myoglobin and subjective muscle soreness were unaffected by ibuprofen treatment 
when compared to placebo. There was also no association between increases in inflammatory 
leucocytes and any other marker of cellular muscle damage. Conclusion: Ibuprofen 
administration had no effect on the accumulation of neutrophils, markers of muscle damage or 
muscle soreness during the first 24 h of post-exercise muscle recovery. 
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2.2 Introduction: 
Unaccustomed resistance exercise often results in tissue damage and inflammation, leading to 
delayed onset muscle soreness (DOMS) and a consequent reduction in force production [31, 
240]. Animal models and in vitro studies have identified that local and systemic inflammation 
exerts a regulatory influence during the different phases of muscle recovery, including 
myofibrillar disruption, cellular necrosis, satellite cell activation, maturation and subsequent 
regeneration and adaptation [17, 24]. Thus, post-exercise inflammation is intimately necessary 
and a key feature of the normal process of tissue regeneration and adaptation following acute 
muscle damage. However, excessive inflammation is considered a potential cause of prolonged 
post-exercise muscle soreness and may have a negative effect on muscle recovery [24, 25]; 
consequently strategies to reduce or counteract inflammation are commonly implemented to 
aid in improving muscle recovery after exercise [103].  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used as a treatment strategy in 
exercise and sports medicine to assist with recovery from exercise-induced inflammation, 
particularly following soft-tissue injury. NSAIDs inhibit the cyclooxygenase (COX-1 and 2) 
enzymes and consequently the formation of prostanoids (prostaglandins, prostacyclins and 
thromboxanes) that play a diverse roll in acute inflammation [102]. Prostanoids stimulate an 
acute inflammatory process by controlling local blood flow, vascular permeability, leucocyte 
infiltration, and triggering sensations of pain [102, 103]. In animal models of acute muscle 
damage, treatment with NSAIDs blunts the infiltration of leucocytes into muscle tissue [104, 
159] and causes a reduction in creatine kinase (CK) [106]. Consequently, NSAIDs can also 
inhibit myofiber regeneration, satellite cell proliferation and differentiation, and overload-
induced muscle hypertrophy [104-106]. These findings provide preliminary evidence that 
NSAIDs compromise the physiological link between processes of acute muscle damage, 
inflammation and cellular regeneration.  
 
Research into the effects of NSAIDs on exercise-induced muscle damage and inflammation has 
produced equivocal findings. In exercise models, NSAID administration has been shown to 
attenuate post-exercise DOMS in some [93, 140, 241], but not all studies [87, 107, 151, 152]. 
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While a precise cellular mechanism for an analgesic effect of NSAIDs remains unclear, it has 
been largely ascribed to their effect on prostaglandin synthesis and the capacity of NSAIDs to 
interfere with aspects of inflammatory cell function [160, 242]. Previous research has 
demonstrated that oral consumption of both ibuprofen, a non-selective NSAID and 
acetaminophen, an analgesic also known as paracetamol, had no effect on macrophage 
infiltration at 24 h following an eccentric exercise protocol [160]. Similarly treatment with 
naproxen, another non-selective NSAID, had no effect on the infiltration of leucocyte common 
antigen positive cells following a unilateral, isotonic resistance exercise protocol [147]. 
Interestingly, Paulsen et al., (2010) suggested a blunting effect of the COX-2 specific celecoxib 
following maximum eccentric muscle contractions [93]. This research identified a tendency for 
higher monocyte/macrophage numbers in subjects within the placebo group, and those 
subjects who were identified as ‘high-responders’ to the exercise protocol based on the 
number of inflammatory leucocytes [93]. Although this is not a particularly robust finding, it 
has led to the hypothesis that NSAIDs may influence leucocyte infiltration in skeletal muscle 
when a sufficiently strong and early inflammatory reaction is present [93]. This hypothesis 
would suggest that the intensity of the exercise stimulus and the consequent muscle-damage 
response would be largely influential in determining the effect of a pharmacologically based 
anti-inflammatory intervention.    
 
Conflicting findings also exist with regard to the effect of NSAIDs on the regenerative capacity 
of skeletal muscle following exercise-induced muscle damage. The non-selective COX inhibitor 
ibuprofen blunted skeletal muscle protein synthesis [107] while local intramuscular infusion of 
indomethacin [243] and the oral administration of the COX-2 selective NSAID celecoxib [93, 
130] had no such effect. Similarly, treatment with indomethacin inhibited post-exercise 
satellite cell proliferation [87]. Recent work from our group demonstrated that treatment with 
ibuprofen inhibited early translational signalling responses involved in post-exercise muscle 
hypertrophy [161]. A clear mechanistic pathway for NSAIDs to influence the physiological link 
between post-exercise inflammation and skeletal muscle regeneration remains elusive. 
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These discrepancies in the research to date are likely due to differences in the exercise 
protocol (concentric vs. eccentric muscle contractions), the training status of subjects, the 
timing of muscle biopsies, and the type of NSAID, the dosage administered, and method of 
administration.  Further research is required to determine whether NSAID administration 
affects the infiltration of leucocyte populations following exercise-induced muscle damage and 
how this influences post-exercise adaptive pathways. The aim of the present study was to 
investigate if oral administration of the NSAID ibuprofen influenced skeletal muscle leucocyte 
infiltration during the first 24 h after muscle-damaging resistance exercises. A further aim was 
to explore how any changes in leucocyte infiltration were related to markers of muscle 
damage, including circulating muscle proteins CK and myoglobin, and subjective markers of 
muscle soreness. It was hypothesized that the ingestion of ibuprofen following acute 
resistance exercise would not influence the infiltration of leucocytes, however it would 
attenuate sensations of DOMS.  
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2.3 Methods: 
2.3.1 Participants: 
Sixteen healthy male subjects were recruited to participate in the study (Table 1) [102]. 
Exclusion criteria included participation in a lower body resistance exercise program within the 
last 6 months to ensure a muscle damage response from the exercise stimulus, and/or 
previous chronic treatments with anti-inflammatory medication. Participants also completed a 
medical screening to identify any potential risk factors for them to perform strenuous physical 
activity. 
 
Table 2.1: Subject characteristics and strength testing data. Values are mean values ± SEM. No 
significant differences were observed between the two groups. 
  Characteristics Strength (1RM) 
  Age (y) Height 
(m) 
Body mass 
(kg) 
BMI Squat (kg) Leg Press 
(kg) 
Leg 
Extension 
(kg) 
PLA 23.9                              
± 1.3 
1.89                        
± 0.1 
86.9                          
± 4.5 
24.5                    
± 1.2 
94.9                             
± 5.4 
237                            
± 17 
236                           
± 18 
IBU 23.0                 
± 0.5 
1.89                                    
± 0.1 
89.1                          
± 4.4 
24.8                 
± 0.8 
91.9                                  
± 6.0 
240                           
± 15 
196                                      
± 22 
PLA, placebo; IBU, Ibuprofen; BMI, body mass index 
 
2.3.2 Ethics approval: 
All procedures involved in this study were approved by the Deakin University Human Research 
Ethics Committee (DUHREC 2010-019) and muscle sampling procedures were performed in 
accordance with the Helsinki declaration. Each participant was provided with written and oral 
details of the nature and requirements of the study and provided written consent to 
participate.  
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2.3.3 Familiarization: 
Each participant completed a familiarization and strength testing session at least 7 days prior 
to completing the exercise protocol. Briefly, subjects performed repetition maximum testing 
for the Smith machine-assisted squat, the leg press and the leg extension to determine their 
experimental exercise load (80% of a 1 repetition maximum (1RM)). The maximum weight the 
subject could lift for 5-8 reps was determined, and these data were entered into the Brzycki 
equation to predict 1RM [1 RM = 100 X load rep/(102.78 – 2.78 X reps completed] [244]. 
Subjects were asked to abstain from any further activity until the completion of the trial. 
 
2.3.4 Experimental Procedures: 
The participants reported to the laboratory on the morning of the trial in an overnight fasted 
state. They were asked to abstain from caffeine, tobacco and alcohol for the 24 h preceding 
the trial.  Participants rested in a supine position for 30 min, following which the first muscle 
biopsy sample was taken. Each participant then completed a 10-min warm-up protocol 
comprised of 5 min of low intensity cycling on a stationary bike, and one low-intensity set of 
each exercise at a weight of each subject’s own choice within the range of 30-50% 1RM. The 
resistance exercise session consisted of 3 sets of 8-10 repetitions performed on a Smith 
machine assisted squat, a 45-degree leg press and a leg extension at 80% of a predicted 1RM. 
The exercises were performed as a circuit with 1 min rest permitted between exercises and 3 
min rest between sets. This protocol has been used previously and has been a sufficient 
stimulus to activate inflammatory signalling pathways [239] and was implemented to replicate 
a commonly used exercise routine. After exercise, the subjects rested while subsequent muscle 
biopsy samples were collected. After the 3 h biopsy, participants were provided a standardized 
meal and could go home. The following morning, participants reported to the laboratory in an 
over-night fasted state for a 24 h muscle biopsy and blood sample. 
 
2.3.5 Standardized meals: 
Standardized meals were provided to participants on the night before the trial, (carbohydrate 
57%, fat 22%, protein 21%), immediately following the 3 h muscle biopsy (carbohydrate 71%, 
fat 13%, protein 16%), and in the evening (carbohydrate 64%, fat 27%, protein 18%) on the day 
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of the exercise trial. All participants received the same meal and individualised energy content 
based on body mass was not provided. Participants were permitted to drink water ad libitum 
and were asked to report if they could not finish their allocated meals. This nutrition plan was 
included to ensure that each participant received the same relative percentage of macro- and 
micro-nutrients.  
 
2.3.6 NSAID Administration: 
Prior to exercise, participants were randomly assigned in a double-blind method, to consume 
either the maximum recommended dose of ibuprofen (IBU, n = 8) or a placebo control (gelatin 
capsules identical in appearance containing powdered sugar in place of ibuprofen) (PLA, n = 8). 
The IBU group consumed three doses of 400 mg of ibuprofen throughout the trial day. The first 
dose was administered immediately prior to the first muscle biopsy sample. Participants were 
instructed to consume the following two doses at 6 h and 12 h following the exercise protocol. 
Follow-up phone calls from the research team ensured compliance. To ensure this dosing 
structure was appropriate to maintain biologically active levels of ibuprofen, ibuprofen 
concentration was measured in blood serum samples and these data are reported elsewhere 
[102]. 
 
2.3.7 Sample collection: 
Venous blood samples were drawn prior to exercise, within 5 min post exercise (here-after 
referred to as 0 h post-exercise), and at 1, 2, 3 and 24 h post-exercise. Blood samples were 
drawn through an indwelling catheter into VACUETTE serum tubes (Greiner,Bio-One, 
Stonehouse UK). Whole blood was allowed to clot at room temperature. Samples were then 
centrifuged at 1,000  g for 10 min. The serum layer was collected and stored at -80°C for 
subsequent analysis.  
 
Muscle biopsy samples were obtained from the vastus lateralis muscle under local anaesthesia 
(Xylocaine 1%) using a percutaneous needle biopsy technique modified to include suction 
[245]. To minimize interference from the biopsy procedure, samples prior to exercise and at 24 
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h post exercise were taken from the same leg, while samples taken at 0 and 3 h post-exercise 
were taken from the contralateral leg. Samples obtained within the same leg were taken at 
least 5cm from the previous incision site. A section of excised tissue was immersed in Tissue-
Tek and stored at -80°C until further analysis.  We have previously reported that this technique 
is effective for minimizing the risk of any inflammation arising from the biopsy procedure 
confounding exercise-induced inflammation [239]. This research showed no effect of the 
biopsy protocol on mRNA expression of acute phase inflammatory cytokines, however did not 
directly investigate a potential effect on leucocyte infiltration or markers of cellular muscle 
damage. The absence of a non-exercise control group is a limitation of the present study. 
 
2.3.8 Immunohistochemistry: 
Cross sections (8 μm) of muscle tissue were cut using a microtome at -20 ⁰C (CM3050, Leica, 
Germany) and mounted on microscope slides (Superfrost Plus, Thermo Scientific, MA, USA), 
air-dried and stored at -80 °C. Each subject’s muscle sections from all time points were 
mounted on the same microscope slide. Serial muscle cross-sections were stained with three 
different leucocyte antibodies, MPO (#0398, DakoCytomation, Glostrup, Denmark; dilution 
1:2000), CD66b (#CLB-B13.9, Sanquin Reagents, Amsterdam, The Netherlands; dilution 1:500) 
and CD68 (#EBM-11, DakoCytomation, Glostrup, Denmark; dilution 1:300). Furthermore, the 
sections were also stained with dystrophin antibody (ab15277, Abcam, Cambridge, UK) for 
visualizing borders of muscle fibers 
. 
Sections were fixed in 4 % paraformaldehyde solution in a staining jar for 5 min at room 
temperature and rinsed twice for 10 min in phosphate buffered saline (PBS) containing 0.5 % 
Tween 20 (Sigma-Aldrich). The microscope slides were moved into a humidified chamber and 
non-specific binding sites were blocked with 1% bovine serum albumin (BSA) on the section for 
45 min at room temperature. Sections were incubated overnight with leucocyte and 
dystrophin antibodies diluted in 1% BSA at 4°C. After overnight incubation, the slides were 
washed three times for 10 min in PBS-Tween in a staining jar. Slides were moved back to the 
humidified chamber and sections were incubated for 45 min with secondary antibodies diluted 
1:200 in 1% BSA at room temperature. Alexa Fluor® 594 F(ab’)2 fragment of goat anti-rabbit 
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and Alexa Fluor®488 anti-mouse IgG  (Invitrogen, Eugene, Oregon, USA) were used as a 
secondary antibodies. The fluorochrome-stained sections were washed three times for 10 min 
in PBS-Tween. After the last washing in PBS-Tween, the sections were mounted on ProLong® 
Gold Antifade reagent with DAPI (Invitrogen, Eugene, Orgeon, USA). 
  
Muscle sections were visualized using a high-resolution camera (DP72, Olympus, Japan) 
mounted on a microscope (BX61, Olympus, Japan) with a fluorescence light source (X-Cite 
120PCQ, EXFO, Canada). The number of MPO, CD66b and CD68 positive cells (as well as the 
total number of muscle fibres from the area included) was counted. Data was calculated as 
percentage of MPO, CD66b or CD68 positively stained cells per 100 skeletal muscle fibres. 
Areas of sections that contained freeze damage or were folded due to the cutting procedure 
were not included in the analysis. 
 
2.3.9 Biochemical assays:  
Serum creatine kinase activity in pre- and post-exercise blood samples was analyzed using an 
enzymatic assay (CK-NAC kit, CDT14010, Thermo-Fisher Scientific Clinical Diagnostics, Sydney, 
Australia) and an automated clinical analyser (Cobas Mira, Roche Diagnostics, Germany). 
Serum myoglobin concentration was also measured in these samples using an immunoassay 
(Roche Diagnostics, Germany) and an automated clinical analyzer (Cobas E411, Roche 
Diagnostics, Germany). The intra-assay coefficient of variation was 10.4% for creatine kinase 
and 1.7% for myoglobin.  
 
2.3.10 Muscle soreness assessment: 
Upon arrival at the laboratory and prior to the first muscle biopsy procedure subjects were 
asked to rate their subjective muscle soreness on a 0-10 visual analogue scale. The subjects 
were instructed to contract, stretch and palpate the quadriceps muscle to assess general 
muscle soreness. In both instances 0 was considered to represent no pain and correspondingly 
a rating of 10 was considered to represent intense pain. 
 
32 
 
2.3.11 Statistics: 
Data are expressed as means ± SEM. Prior to analysis the data displaying a lack of normality 
were log transformed to stabilise variance. Data were analysed using a two-way ANOVA with 
repeated measures for time. The sphericity adjustment was checked, and if required, a 
Greenhouse-Geisser epsilon correction was applied. Where no significant effect for treatment 
was observed, we explored pair-wise comparisons between individual time-points using the 
Least Significant Difference (LSD) of means. Bivariate relationships were examined with a 
Spearman rank correlation test. Confidence intervals were calculated at 90% using a 
bootstrapping technique for non-normally distributed data. Statistical analyses were 
performed using GenStat for Windows 16th Edition (VSN International, Hemel Hempstead, UK). 
Statistical significance was set at P < 0.05. 
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2.4 Results: 
2.4.1 Muscle Soreness: 
Muscle soreness showed a main effect for time (p < 0.01), suggesting that the exercise protocol 
was sufficient to induce a DOMS response. No effect of the ibuprofen treatment was observed 
(Figure 2.1). 
 
 
Figure 2.1: Subjective rating for delayed onset muscle soreness (DOMS) (B). Values depicted are 
mean values ± SEM. * denotes statistical significance from pre-exercise values (p<0.05). White bars 
= PLA group; black bars = IBU group. This figure has been adapted from Vella et al. (2014) [246]. 
 
2.4.2 Immunohistochemistry: 
The number of MPO+ cells per 100 myofibres analysed showed a main effect for time (P < 
0.01). No main effect for treatment (P = 0.250) or time x treatment (P = 0.709) was observed 
(Figure 2.2A). LSD pairwise comparisons indicated a significant increase in MPO+ cells at all 
sampling time points post-exercise. The greatest increase in MPO+ cells was observed at 3 h 
post-exercise (Figure 2.2B). Similarly, the number of CD66b+ cells per 100 myofibres showed a 
main effect for time (P < 0.05), with no main effect for treatment (P = 0.149) or time x 
treatment interaction (P = 0.907) (Figure 2.2C). LSD pairwise comparisons indicated a 
significant increase in the number of CD66b+ cells at 3 h post exercise (Figure 2D). The number 
of CD68+ cells per 100 myofibres analysed showed no effect for time (P = 0.061), treatment (P 
= 0.530) or time x treatment interaction (P = 0.688) (Figure 2.2D). MPO+, CD66b+, and CD68+ 
cells were observed within the endomysium and the perimysium, with no cellular infiltration 
occurring at any time point (Figure 2.2E). Representative images for each cell surface marker 
are presented in Figure 3. 
34 
 
 
 
Figure 2.2: Immunohistochemistry data for muscle cells staining positive for myeloperoxidase 
(MPO), showing group specific data (A) and collapsed data (B), CD66b showing group specific data 
(C) and collapsed data (D), and CD68 showing group data only (E). Data represent the mean number 
of positively stained cells per 100 fibres analysed ± SEM. ** denotes statistical significance from 
pre-exercise values (p<0.01). * denotes statistical significance from pre-exercise values (p<0.05). ^ 
denotes statistical significance from 0 h post-exercise (p<0.05). White bars =PLA group; black bars = 
IBU group.  
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Figure 2.3: Immunohistochemical analysis of skeletal muscle samples following a bout of resistance 
exercise. Sections were probed with antibodies raised against leucocyte cell surface markers (green; 
Figure 3A– MPO, Figure 3B – CD66b, Figure 3C – CD68) and dystrophin (red), while DAPI was used 
to stain nuclei (blue). Scale bars = 50µm. 
 
2.4.3 Serum proteins: 
Serum CK activity demonstrated a main effect for time (P < 0.01) with no effect for treatment 
(P = 0.843) or time x treatment interaction (P = 0.494) (Figure 2.4A). LSD comparisons revealed 
that serum CK increased from pre-exercise values at 2 h post-exercise and peaked at 24 h post-
exercise (Figure 2.4B). Similarly, serum myoglobin concentration showed a main effect for time 
(P < 0.01) with no effect for treatment (P = 0.710) or time x treatment interaction (P = 0.666) 
(Figure 2.4C). LSD comparisons demonstrated that the biggest increase in serum myoglobin 
concentrations occurred at 1 h post-exercise and remained significantly elevated up to 3 h post 
exercise (Figure 2.4D). 
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Figure 2.4: Blood derived proteins creatine kinase (A and B) and myoglobin (C and D). Values 
depicted are mean values ± SEM. Figures A and C represent data divided into two treatment 
groups; figures B and D represent collapsed data. *denotes statistical significance from pre-exercise 
values (p<0.05). ** denotes statistical significance from pre-exercise values (p<0.01). ^ denotes 
statistical significance from 1, 2 and 3 h post exercise (p<0.05). White bars = PLA; black bars = IBU. 
 
2.4.4 Correlation analysis: 
In general, large inter-individual differences were seen in the appearance of all of the leucocyte 
cell types. Results from the Spearman rank correlation test showed no correlation between the 
histochemical appearance of inflammatory leucocytes, biological markers of muscle damage 
and subjective markers of muscle soreness (Table 2). Anecdotally, three subjects were 
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identified as the highest responders in the appearance of cell surface markers applicable for 
localization of neutrophils (one subject within the placebo group, and two subjects within the 
ibuprofen group).  However, these subjects showed no significant increase in CK, myoglobin or 
subjective markers of muscle damage when compared with the other subjects. Interestingly, 
subject 5 recorded the highest number of CD66b+ cells and MPO+ cells, whereas he presented 
with the lowest subjective rating for DOMS.  
 
Table 2.2: Spearman rank correlation analysis. Values depicted are the correlation coefficient 
with 90% confidence intervals in parenthesis. Statistical significance was set at p < 0.05. No 
statistically significant correlations were observed.  
 
  CK MYO CD68 CD66b MPO DOMS 
CK - 
0.59         
(-0.01 - 0.91) 
-0.46 
(-0.88 - 0.8) 
0.15 
(-0.42 - 0.61) 
0.36 
(-0.14 - 0.73) 
0.01 
(-0.60 - 0.62) 
MYO - - 
0.01 
(-0.55 - 0.52) 
0.14 
(-0.42 - 0.69) 
0.35 
(-0.21 - 0.67) 
-0.33 
(-0.74 - 0.24) 
CD68 - - - 
0.05 
(-0.46 - 0.56) 
-0.27 
(-0.75 - 0.33) 
-0.37 
(-0.82 - 0.25) 
CD66b - - - - 
0.41 
(-0.13 - 0.84) 
-0.37 
(-0.78 - 0.16) 
MPO - - - - - 
0.08 
(-0.49 – 0.56) 
DOMS - - - - - - 
 
CK, creatine kinase; MYO, myoglobin; MPO, Myeloperoxidase; DOMS, delayed-onset muscle 
soreness. 
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2.5 Discussion: 
The main finding of this study was that ibuprofen, a non-selective COX inhibitor, had no effect 
on the histological detection of leukocytes following an acute bout of traditional resistance 
exercise. Serum CK and myoglobin, and muscle soreness also did not change in response to 
ibuprofen. Furthermore, no correlation was observed between the accumulation of 
inflammatory leucocytes, increases in CK or myoglobin, and sensations of DOMS. These 
observations suggest that the intramuscular infiltration of inflammatory white blood cells, or 
an increase in serum levels of intramuscular proteins, are not predictive of post-exercise 
muscle soreness. 
 
The current study focused on the acute local inflammatory response to exercise-induced 
muscle damage. Our protocol was effective in inducing muscle soreness as shown in Figure 2.1. 
An increase in the histological appearance of CD66b+ and MPO+ cells occurred at 3 h post 
exercise, while no effect of the NSAID treatment was observed. CD66b is a highly specific cell 
surface marker for detecting human neutrophils, and this is the first paper to show a small but 
significant increase in the intramuscular number of CD66b+ cells following acute resistance 
exercise. Paulsen et al. (2013) were unable to identify any change in the number of CD66b+ 
cells in the elbow flexors at 1 h, 2, 4 or 7 days following 70 maximal eccentric contractions [97]. 
The discrepancy between the two trials may be the result of a combination of methodological 
differences, such as the timing of muscle biopsy samples, the mode of exercise and the muscle 
group sampled. A small but significant increase in the number of MPO+ cells at all sampled time 
points was also observed, with a peak in expression at 3 h post exercise. MPO has typically 
been used to detect changes in neutrophils, and an increased number of MPO+ cells have been 
reported following high-force eccentric muscle contractions [98, 247]. However, MPO is also 
expressed on the lysosomes of monocytes and has been detected on basophils and 
eosinophils, perhaps providing a reason why there were a higher number of MPO+ cells when 
compared to CD66b+ cells detected in the present study [97]. 
 
No change was identified in the number of CD68+ cells. CD68 cell counts are widely used as a 
marker of monocyte/macrophage infiltration. However, CD68 may also be expressed on other 
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cell types including satellite cells and fibroblasts [97]. Other researchers have been able to 
identify a change in CD68+ cells following exercise-induced muscle damage [98, 160, 247]. Each 
of these studies have used a high-force maximal eccentric muscle contraction protocol, which 
may suggest that the detection of CD68+ cells is dependent on the extent of skeletal muscle 
damage.   
 
Previous research exploring the effect on NSAIDs on post-exercise inflammation has produced 
equivocal findings. Earlier research from in-vivo rodent trials demonstrated a blunted 
inflammatory response to eccentric muscle contractions following the administration of both 
selective and non-selective NSAIDs [104, 105, 248, 249]. However, these findings are yet to be 
supported in human trials [140, 147, 160]. Petersen et al. (2003) found no effect of oral 
ibuprofen administration on the appearance of CD68+ cells 24 h following 100 eccentric muscle 
contractions [160]. Similarly, Tokmakidis showed no effect of ibuprofen on circulating white 
blood cells 24 h following an eccentric exercise protocol [140]. Paulsen et al. (2010) proposed 
the concept of an inflammatory threshold, suggesting that NSAIDs may only influence post-
exercise inflammation in response to a sufficiently strong inflammatory stimulus [93]. It was 
suggested that the absence of an intramuscular prostaglandin response to exercise, specifically 
PGE2, could explain the lack of an NSAID effect on leucocyte recruitment [93, 132]. 
Interestingly, our group recently reported an increase in serum PGE2 in samples that were 
obtained during the same exercise trials as those currently reported [102]. This change in 
serum PGE2 was blunted by the administration of ibuprofen and suggests that in the presence 
of a blunted prostaglandin response to exercise, NSAID treatment had no effect on leucocyte 
recruitment within skeletal muscle. Although this finding does not refute the possibility of an 
inflammatory threshold, based on our previous findings [102], it is reasonable to suggest that 
the presence of an exercise-induced serum prostaglandin response is not the required 
underlying mechanism for neutrophil infiltration of muscle during the early hours of post-
exercise recovery. 
 
In accordance with previous studies, resistance exercise resulted in an increase in serum CK 
and myoglobin, and subjective muscle soreness [250]. Although large inter-individual variations 
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in the human response to exercise can make it difficult to establish causal relationships, there 
was no relationship between the appearance of leucocytes and blood-derived markers of 
muscle damage or sensations of muscle soreness. Interestingly, the subject with the highest 
number of CD66b+ and MPO+ cells presented with the lowest subjective rating of DOMS. These 
findings provide support for the assumption that leucocyte recruitment and inflammation do 
not consistently cause DOMS. 
  
From animal studies, it appears that cellular events in post-exercise inflammation, occur 
concomitantly with the onset of DOMS [24, 240]. The mechanistic link has been proposed to be 
a leucocyte-mediated release of cytotoxic substances and reactive oxygen species as a bi-
product of phagocytosis [251]. Furthermore, the prostaglandin response to exercise has been 
shown to occur concurrently to the onset of DOMS, and is known to influence both the 
recruitment of inflammatory leucocytes and neural afferents to pain [102]. However, in line 
with the current findings, the accumulation of inflammatory leucocytes in human skeletal 
muscle tissue during exercise recovery appears to be both spatially and temporally out of 
phase with the development of DOMS [93]. Malm et al. [252] explored the concept that the 
activation of local leucocytes present in the epimysium may be involved in the regulation of 
DOMS. This hypothesis has since received support from both rodent [253] and human trials 
[61, 254] and presents a promising area for future research. 
 
2.6 Conclusion: 
This is the first study to demonstrate that ibuprofen administration has no effect on the 
histological appearance of inflammatory white blood cells following an acute bout of 
traditional resistance exercise. Ibuprofen administration had no effect on blood markers of 
muscle damage or subjective muscle soreness, and no significant correlations between 
leucocyte numbers and post-exercise muscle damage or soreness was observed. Future 
research needs to explore the possibility of an inflammatory threshold above which NSAID 
administration influences post-exercise inflammation. The underlying cause of post-exercise 
muscle soreness also remains largely unknown. Future investigations are needed to determine 
the role that inflammation plays in exercise-induced DOMS. 
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CHAPTER 3: 
 
Intramuscular inflammatory lipid profile response to an acute bout of resistance exercise in 
humans. 
 
Vella L, Markworth JF, Maddipati KR, Cameron-Smith D, Russell AP. Intramuscular 
inflammatory lipid profile in response to an acute bout of resistance exercise in humans. 
Submitted for review to Frontiers in Physiology: Exercise Physiology on 20/11/2016.  
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3.1 Abstract: 
 
Purpose: Classic eicosanoid species including prostaglandins (PG) and leukotrienes (LT) play 
essential roles in initiating and regulating acute inflammation. Recent identification of novel 
classes of bioactive lipid mediators derived from long-chain (LC) polyunsaturated fatty acids 
(PUFA), collectively termed specialized resolving mediators (SPM) has led to the proposal of an 
active biochemical pathway for resolution of the acute inflammatory response. Chapter 3 
investigated the human intramuscular lipid mediator profile at rest and in response to an acute 
bout of unaccustomed resistance exercise. Methods: Fourteen male subjects completed a bout 
of lower body resistance exercise. Muscle biopsy samples were taken from the m.vastus 
lateralis before and at 2, 4 and 24 h post-exercise. Intramuscular lipid mediator composition 
was analysed via liquid chromatography–mass spectrometry (LC-MS)-based targeted 
lipidomics. Results: A total of 129 unique lipid mediators were reliably identified in human 
skeletal muscle tissue. Post-exercise recovery was characterized by increased levels of COX-
derived thromboxane (TXB2 and 12(S)-HHTrE) and prostaglandin metabolites (2,3-dinor PGE1 
and 15d-D12,14-PGJ3), LOX derived leukotrienes (LTB4 and 20-COOH LTB4), 
hydroxyeicosatetraenoic acids (5-HETE, 12-HETE, tetranor 12-HETE and 15-HETE), 
monohydroxylated- docosahexaenoate (HDoHE) species (4-HDoHE, 7-HDoHE and 8-HDoHE), 
and CYP derived epoxyeicosatrienoic acids (5,6-EpETrE) / vicinal diol dihydroxyeicosatrienoic 
acids (11,12-DiHETrE and 14,15-DiHETrE). Conclusion: This research utilised a targeted 
lipidomics approach to profile the human skeletal muscle lipid mediator response to an acute 
bout of resistance exercise. The profile suggests that the activation of classical pro-
inflammatory eicosanoids such as PG and LT species, as well as novel lipid intermediates in 
SPM biosynthesis derived from both LOX and CYP pathways, form a highly complex self-
resolving model of acute inflammation following an acute bout of resistance exercise.  
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3.2 Introduction: 
Skeletal muscle is a remarkably heterogeneous tissue with the capacity to adapt and respond 
to external stress. It is well established that intense resistance exercise can lead to 
improvements in muscle strength through changes in muscle fiber type, myofibrillar 
hypertrophy and neuromuscular mechanisms [1]. However, unaccustomed exercise, especially 
when comprising a large eccentric component, can cause skeletal muscle injury and initiate an 
acute inflammatory response [24, 31, 240]. Experimental models targeted at manipulating the 
post-exercise inflammatory response have identified that exercise-induced inflammation is a 
key regulatory feature in the normal process of tissue regeneration and adaptation following 
acute muscle damage [103, 161, 255]. This suggests that molecular signaling events occurring 
early during acute inflammation play an active role in promoting the restoration of normal 
tissue function and promote skeletal muscle adaptation following an exercise stimulus. 
 
The humoral and local muscular changes that occur during exercise-induced inflammation 
closely resemble that of an acute phase response to cellular stress. As observed in chapter 2, a 
resistance exercise stimulus triggers the production of pro-inflammatory signaling molecules, 
establishing a chemotactic gradient and the diapedesis as well as the infiltration of 
inflammatory leukocytes [85, 246]. These chemoattractants consist of lipid-derived mediators 
such as leukotrienes (LTs) and prostaglandins (PGs), as well as protein mediators, including 
cytokines and chemokines [168]. The usual outcome of an acute inflammatory response is its 
successful resolution and repair of damaged tissue [174]. Traditionally, the resolution of 
inflammation was thought to be a passive process involving the dilution and catabolism of pro-
inflammatory mediators leading to exodus of leukocytes from the site of muscle damage. 
However, with the discovery of novel classes of lipid-derived mediators, the resolution of acute 
inflammation has evolved to be seen as an active and finely controlled biochemical and 
metabolic process that may provide a critical link between cellular stress and tissue 
regeneration/adaptation [185, 186].  
 
Lipid mediators are biosynthesized endogenously from essential omega-6 (n-6) and omega-3 
(n-3) polyunsaturated fatty acids (PUFA) and are involved in a wide range of physiological and 
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pathophysiological processes [186]. The majority of research has focused on classic 
prostaglandins (synthesized via cyclooxygenase (COX) enzymes, COX-1 and COX-2) and 
leukotrienes (synthesized via the lipoxygenase (LOX) enzyme, 5-LOX), which are derived from 
the n-6 PUFA arachidonic acid (AA). These lipids play a diverse role in stimulating acute 
inflammation by controlling local blood flow, vascular permeability, cytokine production, 
leucocyte chemotaxis and pain [102]. More recently, a second class of eicosanoids also 
generated from AA, termed lipoxins (LX) [172, 175, 176], as well as newly identified 
eicosapentaenoic (EPA) (E-Series) and docosahexaenoic acid (DHA) (D-Series) derived resolvins 
(Rv), protectins (PD) [166, 169-171, 177, 178], and maresins (MaR) [168, 173] have been shown 
to play pro-resolution functions following acute inflammation. These novel lipid mediators, 
collectively termed specialized pro-resolving mediators (SPMs), act to block acute 
inflammatory signals by inhibiting pro-inflammatory cytokine production and subsequent 
neutrophil chemotaxis [173, 182]. They simultaneously promote the nonphlogistic infiltration 
of blood monocytes/macrophages and stimulate tissue macrophages to phagocytize and clear 
apoptotic neutrophils whilst promoting wound healing [175, 181]. 
 
SPMs are formed during inflammatory transcellular interactions, involving the sequential 
actions of two or more cell types expressing the required LOX and/or COX enzymes in a 
compartmentalized manner. During the time-course of inflammation, cell-cell interactions 
between platelets, leucocytes, the vasculature and resident tissue cells facilitates the 
transcellular biosynthesis of unique SPMs [101].  The temporal regulation of these lipids is 
therefore specific to the tissue type and the inciting inflammatory stimulus[185, 186]. For 
example, LX biosynthesis involves cellular interactions between 5-LOX expressing neutrophils 
with 12-LOX expressing platelets or 15-LOX expressing M2 monocytes [184]. Recent findings 
from Markworth et al. (2013) demonstrated that pro-resolving lipid mediators, including 
lipoxins, resolvins and protectins, are elevated in human blood serum samples following an 
acute bout of resistance exercise [102]. The present study used the same targeted lipidomics 
approach to characterize the local time-course changes of eicosanoid and docosanoid species 
in human skeletal muscle tissue following an acute bout of resistance exercise. The primary 
aim was to identify which species of lipids are present within skeletal muscle tissue, and hence 
may be locally generated and acting, following an acute bout of resistance exercise. It was 
46 
 
hypothesized that there would be a rapid increase in pro-inflammatory prostaglandin and 
leukotriene biosynthesis, followed by the activation of SPMs at the onset of inflammation 
resolution. Identification of the lipid mediator profile of skeletal muscle and ability of exercise 
stress to modulate intramuscular bioactive lipids will help to contribute to the understanding 
of a biologically active inflammatory resolution pathway that may be essential to muscle 
recovery and adaptation following an inflammatory event. 
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3.3 Methods: 
3.3.1 Subjects: 
As previously described [256], fourteen healthy men aged 18-25 years were recruited to 
participate in the acute exercise study. A subset of 12 male participants, for which sufficient 
muscle biopsy tissue remained, were included in the analysis performed here. Exclusion criteria 
included participation in regular resistance exercise within one year prior to commencing the 
study, and/or the consumption of any nutritional or purported muscle building supplements. 
Each participant also completed a medical history questionnaire to identify any potential risk 
factors that would prevent the subjects from completing strenuous exercise.  
 
3.3.2 Ethics approval: 
Each participant was provided with a written and oral explanation of the nature of the study 
and potential risks of the experimental procedures before providing written consent to 
participate. All procedures involved in the study were formally approved by the Deakin 
University Human Research Ethics Committee (DUHREC 2004-017) and muscle biopsy 
procedures were performed in order with Helsinki declaration.  
 
3.3.3 Familiarization: 
For the 24 h preceding exercise, subjects consumed a standardised diet (20% fat, 14% protein, 
and 66% carbohydrate) [257]. At least seven days prior to the trial day, each subject completed 
a familiarization session on the Cybex NORM dynamometer (Cybex International Inc. UK). The 
session involved performing isokinetic maximal voluntary contractions (iMVC) during 
concentric and eccentric knee extension exercise. Maximal force production measured as peak 
torque (N.m) was determined at 60°/s over 12 maximal concentric and eccentric contractions. 
Subjects were provided with verbal encouragement throughout the test to ensure maximal 
effort.  
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3.3.4 Experimental design: 
On the morning of the trial, subjects reported to the laboratory in an overnight fasted state 
having abstained from alcohol, caffeine and tobacco for the previous 24 h. Participants rested 
in a supine position for 30 min, following which a resting muscle biopsy sample was collected. 
Each participant then completed an acute bout of concentric and eccentric isokinetic unilateral 
knee extension exercise on the Cybex NORM dynamometer. Subjects completed three sets of 
12 maximal voluntary repetitions at a constant speed of 60°/s with 2 mins of rest between 
each set. In a previous research project, this exercise stimulus was shown to trigger an increase 
in pro-inflammatory gene expression, STAT-3 phosphorylation and nuclear translocation, and 
STAT-3 target gene expression [257]. Subjects were instructed to contract maximally during 
each repetition and were provided with verbal encouragement throughout each set. Further 
muscle biopsy samples were obtained from the exercised leg at 2 and 4 h after completion of 
the exercise protocol. The following morning, subjects reported to the laboratory again in an 
overnight fasted state for a final follow up 24 h post-exercise muscle biopsy sample. 
 
3.3.5 Muscle biopsy procedure: 
Muscle biopsy samples were obtained from vastus lateralis under local anaesthesia (Xylocaine 
1%) using a percutaneous needle biopsy technique modified to include suction [245]. A section 
of excised tissue was rapidly snap frozen in liquid nitrogen and stored at -80°C for further 
analysis. Repeat muscle biopsy samples were collected from the same leg through separate 
incisions separated byat least 2 cm from the previous biopsy site to minimize the risk of any 
localized inflammation arising from the biopsy procedure confounding exercise-induced 
inflammation.  
 
3.3.6 Liquid chromatography-mass spectrometry: 
Muscle biopsy samples were weighed and homogenized in 1 ml phosphate buffered saline (50 
mM phosphate containing 0.9% sodium chloride, pH 7.4) using Zirconium beads on a high-
frequency oscillator (Precellys homogenizer, Bertig Instruments). The homogenates were 
centrifuged at 6,000g for 10 min and the supernatant was collected for the extraction fatty acyl 
lipid mediators using C18 solid phase extraction cartridges as described earlier [258-260]. Fatty 
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acyl lipid mediator extracts were subjected to LC-MS analysis essentially as described before 
[258]. Under the LC-MS conditions employed, the detection limit for most of the lipid 
mediators was 1 pg on the column and the quantitation limit was 5 pg on the column with a 
signal/noise ratio >3. Tissue weights from each sample (range: 14-70 mg, average: 43 mg, 
inter-quartile range: 32-56 mg) were used for normalization of the LC-MS data and the data are 
reported as ng per gram of tissue. 
 
3.3.7 Statistics: 
Statistical analysis was performed using IBM SPSS Statistics Version 22 (IBM United Kingdom 
Limited, Hampshire, England). Data were analyzed using a one-way repeated measures 
ANOVA. The sphericity adjustment was checked, and if required, a Greenhouse-Geisser epsilon 
correction was applied. In the instance, a metabolite verged achieving a main effect for time (P 
< 0.1), a post-hoc analysis was run using a Bonferonni correction. Data are presented as mean 
± standard error of the mean (SEM). Statistical significance was set at P < 0.05. This research 
was an exploratory study and as such statistical power calculations based off a predicted mean 
and standard deviation scores were unable to be completed. Sample size was determined by 
the availability of existing muscle sample from a previous clinical trial exploring the effect of an 
acute resistance exercise protocol on markers of post-exercise muscle damage [257].  
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3.4 Results: 
3.4.1 Lipidomic analysis: 
Lipid mediator profiles of human skeletal muscle tissue were generated via LC-MS. A total 129 
unique lipid mediators were reliably detected (Supplemental Table 1, displayed in Appendix D). 
However, many of these lipids were very lowly expressed or below the limits of quantification 
of the assay (signal/noise ratio >3) in particular sample sets. Therefore, only lipid species that 
were quantified in all post-exercise samples were statistically analysed. A main effect for time 
was observed in a range of lipid-derived inflammatory mediators and their downstream 
metabolites during post-exercise recovery. Peak concentration was generally identified at 2 h 
post-exercise, however we were often unable to detect the specific time points at which these 
changes became significant. 
 
3.4.1.1 Cyclooxygenase pathway: 
COX enzymes catalyse the first step in the conversion of AA to prostaglandins (PGE2, PGF2ɑ, 
PGD2 and PGI2) and thromboxane (TXA2). TXA2 is a highly unstable and non-enzymatically 
decomposes to TXB2 and 12(S)-HHTrE. Both metabolites serve as surrogate marker of TXA2 
biosynthesis. Both of these inactive metabolites were detected within skeletal muscle tissue 
and were significantly increased post-resistance exercise (P < 0.05) with the greatest 
concentrations identified at 2 h post exercise (Figure 3.1). There were no significant changes 
detected in any of the primary prostaglandins derived from AA. PGE2 and PGF2ɑ were the most 
abundant prostaglandins in skeletal muscle tissue, detected at concentrations of 1.13 ng/g and 
0.68 ng/g respectively at rest. Post-exercise, both PGE2 and PGF2ɑ were elevated 2 h post 
exercise, however, the increase did not reach statistical significance (PGE2: P = 0.075, PGF2ɑ: P = 
0.078) (Figure 3.1). PGD2 levels were very low and often below detectable limits, while PGI2 
(measured as the stable non-enzymatic hydrolysis product 6-keto-PGF1α) was not detected. 
Within muscle tissue, PGF2α and PGE2 were present at considerably higher concentrations 
compared to their inactive circulating secondary (15-keto-PGE2/PGF2α) and tertiary (13,14-
dihydro-15-keto-PGE2/PGF2α) enzymatic degradation products. However, downstream 
metabolites of other prostaglandin species were identified in muscle. A bioactive downstream 
metabolite of the EPA-derived PGD3, 15-Deoxy-Δ12,14-prostaglandin J3, was detected at 
concentrations of 2.93 ng/g in resting muscle and increased significantly during the acute 
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stages of post-exercise recovery with a peak response observed at 2 h post (P < 0.05) (Figure 
3.1).  
 
Figure 3.1: Metabolites of the cyclooxygenase pathway derived from arachidonic acid. Values depicted 
are mean values ± SEM. *denotes a main effect for the exercise intervention (p < 0.05). 
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3.4.1.2 Lipoxygenase pathway: 
Lipoxygenase isoform expression has been characterized in various cell types involved in acute 
inflammation including neutrophils (5-LOX), platelets (12-LOX) and monocytes (15-LOX) [261]. 
5-LOX metabolises AA to 5-hydroperoxyeicosatetranoic acid (5-HpETE), which is either reduced 
to 5-hydroxyeicosatetraenoic acid (5-HETE) or further metabolised to the potent neutrophil 
chemoattractant leukotriene B4 (LTB4). In resting skeletal muscle tissue, LTB4 was below the 
level of detection in the majority of samples analysed and when detected it was generally 
present only at very low concentrations (≤1ng/g). However, LTB4 was consistently detected at 
much more abundant levels within muscle tissue (~3ng/g) during post-exercise recovery, 
specifically at the 2 h time point, however this failed to reach statistical significance (Figure 
3.2). 5-HETE also verged on a time-dependent increase (P = 0.085). Post-hoc analysis verged on 
a significant increase in intramuscular 5-HETE to concentrations of 8.99 ng/g at 2 h post-
exercise when compared to resting levels of 3.38 ng/g) (P = 0.058) (Figure 3.2). Further, 20-
COOH-LTB4, a downstream metabolite of LTB4 showed a significant increase, with the highest 
response occurring at 2 h post exercise (P < 0.05) (Figure 3.2). In addition to AA, the 5-LOX 
enzyme also has the capacity to oxidize the omega-3 fatty acids DHA and EPA. 
Monohydroxylated-DHA (HDoHE) products of the 5-LOX pathway including 4-
hydroxydocosahexanoic acid (4-HDoHE) and 7-hydroxydocosahexanoic acid (7-HDoHE) were 
detected in resting muscle at concentrations of 2.23 ng/g and 0.98 ng/g respectively. Both 4-
HDoHE and 7-HDoHE showed a significant increase with peak muscle concentrations of 3.76 
ng/g and 1.54 ng/g respectively observed at 2 h post-exercise (P < 0.05) (Figure 3.3). The 5-LOX 
product of EPA, 5-HEPE was similarly detected within skeletal muscle tissue but at 
concentrations of 0.52 ng/g, approximately 10 times lower than the corresponding AA product 
5-HETE. Intramuscular 5-HEPE was not significantly influenced by resistance exercise. 
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Figure 3.2: Metabolites of the lipoxygenase pathway derived from arachidonic acid. Values depicted are 
mean values ± SEM. *denotes a main effect for the exercise intervention (p < 0.05). ^ denotes statistical 
significance compared to pre-exercise values (p < 0.05).  
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Figure 3.3: Metabolites of the lipoxygenase pathway derived from docosahexaenoic acid. Values 
depicted are mean values ± SEM. *denotes a main effect for the exercise intervention (p < 0.05).   
 
The 12-LOX enzyme is expressed primarily in platelets and metabolizes AA to form 12-
hydroxyeicosatetraenoic acid (12-HETE), which can stimulate leucocyte chemotaxis and 
platelet aggregation [262-264]. Additionally, in one key pathway of LX biosynthesis, 5-LOX 
derived LTA4 is converted to LXA4 and LXB4 via the sequential action of platelet 12-LOX. 12-
HETE was by far the most abundant monohydroxylated-FA product detected in resting muscle, 
present at concentrations of ~20 ng/g. We found 12-HETE increased with time (P < 0.05) with 
peak concentrations of 63.81 ng/g observed at 2 h post-exercise (Figure 3.2). Similarly, muscle 
tetranor 12-HETE, a downstream metabolite of 12-HETE increased significantly post-exercise (P 
< 0.05), with the greatest response at 2 h post-exercise (Figure 3.2). The 15-LOX enzyme is 
highly expressed in eosinophils, epithelial cells and alternatively activated M2 macrophages 
and acts to convert AA to 15-hydroxyeicosatetranoic acid (15-HETE) [265]. While 15-HETE did 
not achieve a main effect for time overall, post-hoc analysis showed a significant increase at 2 
h post-exercise (6.50 ng/g) when compared to pre-exercise levels (3.84 ng/g) (P = 0.013) 
(Figure 3.2). 
 
LOX metabolites of the n-3 PUFA DHA have been established to be key pathway markers and 
intermediates in the biosynthesis of SPMs. The 12-LOX enzyme converts the 22-carbon DHA to 
14-hydroperxydocosahexanoic acid (14-HpDoHE) which is reduced to 14-HDoHE or 
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metabolised to MaR1/2 via further action of 12-LOX. Thus, 14-HDoHE is considered a key MaR 
pathway activation marker. Similarly, 15-LOX converts DHA substrate to 17-H(p)DoHE, a key 
intermediary step in the biosynthesis of both the D-series resolvins and protectins. We 
detected 14-HDoHE in resting muscle at concentrations of 0.68 ng/g whereas 17-HDoHE was 
not found to be present at detectable levels. There was no significant effect of exercise on 14-
HDoHE or 17-HDoHE. Nevertheless, peak intramuscular concentrations of 1.60 ng/g 14-HDoHE 
were observed at the 2 h post-exercise time-point. MRM transitions corresponding to mature 
SPMs including lipoxins (LXA4 and  LXB4), E-series resolvins (RvE1 & RvE3), D-series resolvins 
(RvD1, RvD2 and RvD5), protectins (PD1 and 10S,17S-DiHDoHE) and maresins (MaR1) were 
additionally monitored by our LC-MS/MS assay. However, mature SPMs were not found to be 
present at detectable levels locally within muscle tissue biopsies at rest or throughout 24 h 
post-exercise recovery.  
 
3.4.1.3 Epoxygenase pathway: 
The cytochrome P-450 (CYP) enzymes metabolize n-6 PUFA AA to a family of 
epoxyeicosatrienoic acid (EpETrE) regioisomers. Once formed, these EpETrEs are rapidly 
metabolized by the soluble epoxide hydrolase (sEH) enzyme to form corresponding vicinal 
diols, dihydroxyeicosatrienoic acids (DiHETrEs). 5,6-EpETrE was the only primary enzymatic 
epoxy AA-metabolite that showed an effect for the exercise intervention, with concentrations 
increasing 3-fold to ~15ng/g at 2h post-exercise (P < 0.05) (Figure 3.4). Whilst 8,9-EpETrE, 
11,12-EpETrE, 14,15-EpETrE were also found in relative abundance in skeletal muscle tissue at 
rest (~3-10 ng/g), they did not display a significant effect of exercise. Alternatively, 
downstream products of the sEH enzyme, 11,12-DiHETrE and 14,15-DiHETrE were present at 
lower absolute concentrations in resting muscle (~1 ng/g), but significantly increased in 
response to exercise with a peak response at 2 h of recovery (P < 0.05) (Figure 3.4). 5,6-
DiHETrE and 8,9-DiHETrE regioisomers were also detected at low levels in resting muscle, 
however no effect of the exercise intervention was observed.  
 
CYP epoxidase enzymes also have the capacity to metabolise the n-6 linoleic acid to bioactive 
products. Linoleic acid derived 9,10-DiHoME, is a leukotoxin generated by neutrophils during 
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the oxidative burst, and showed a main effect for the exercise intervention (Figure 3.5). 
Similarly, 12(13)-DiHOME, an isoleukotoxin with wide-ranging effects in inflammation, showed 
a main effect for the exercise intervention (Figure 3.5). 
 
 
Figure 3.4: Metabolites of the epoxygenase pathway derived from arachidonic acid. Values depicted are 
mean values ± SEM. *denotes a main effect for the exercise intervention (p < 0.05). 
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Figure 3.5: Metabolites of the epoxygenase pathway derived from linoleic acid. Values depicted are 
mean values ± SEM. *denotes a main effect for the exercise intervention (p < 0.05). 
 
3.5 Discussion: 
The present study explored the intramuscular lipid mediator response following an acute bout 
of resistance exercise. A total of 129 unique lipid mediators were identified within skeletal 
muscle tissue. The post-exercise response was characterized by changes in lipid derivatives of 
the COX-1 and -2, LOX (5-, 12-, 15-LOX), and CYP pathways. Peak induction of both pro-
inflammation and SPMs occurred at 2 h post-exercise. The findings from this study identify a 
complex lipid response to resistance exercise that may play an essential role in regulating the 
onset and resolution of acute exercise-induced skeletal muscle inflammation.  
 
This was the first paper to use a targeted lipidomics approach to extensively characterize the 
lipid mediator profile of skeletal muscle tissue at rest and in response to acute exercise. The 
majority of human research exploring the effect of exercise on lipid species has focused 
primarily on a select few prostaglandins, specifically PGE2 and PGF2ɑ, likely due to their 
complex role in regulating acute inflammation, perceptions of pain and purported role in 
muscle cell growth/regeneration [132-135].  Although some studies have reported elevated 
circulating levels of PGE2 following exercise-induced muscle injury [102, 117-119], these 
findings have not yet been replicated in skeletal muscle tissue [93, 132]. PGF2ɑ has been shown 
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to increase locally within skeletal muscle tissue following both eccentric [132] and isotonic 
resistance exercise protocols [133] and plays a significant role in in-vitro myofibre hypertrophy 
[266] and post-exercise muscle protein synthesis [107]. Further, recent research from our 
group found a significant increase in serum levels of the circulating PGF2ɑ metabolite 15-keto-
PGF2ɑ early (1 h) following resistance exercise in humans [102]. While the increase in muscle 
PGE2 or PGF2ɑ failed to reach statistical significance, they were the most abundant AA derived 
PGs detected within muscle and both markers showed a strong trend for an effect of the 
exercise intervention (P = 0.075 and P = 0.078 respectively). Further, increase in TXA2 
(measured as TXB2 and 12(S)-HHTrE) post-exercise with peak responses at the 2 h time-point 
may reflect a pro-aggregatory, pro-thrombotic circulatory effect that  occurs in response to 
both maximal aerobic [267] and resistance exercise protocols [102].  
 
The other major metabolic pathway leading to the formation of lipid species involved in the 
regulation of inflammation is the lipoxygenase pathway. Increases in the 5-LOX derived LTB4 
has been reported in blood serum samples following acute resistance exercise [102] and high 
speed running [268]. LTB4 is a potent neutrophil chemoattractant and a powerful stimulator of 
vasoconstriction and blood vessel permeability [269]. Expression of 5-LOX is essentially limited 
to bone-marrow derived cells including inflammatory neutrophils and 
monocytes/macrophages [270]. It is therefore not surprising that in the present study LTB4 was 
very lowly expressed in skeletal muscle tissue prior to exercise. At 2 h post-exercise, LTB4 was 
detectable in the majority of subjects, and a downstream derivative, 20-COOH LTB4, 
demonstrated a main effect for the exercise intervention. A less well-described branch of the 
5-LOX pathway involves the metabolism of n-3 PUFA DHA to form mono-hydroxylated fatty 
acids 4-HDoHE and 7-HDoHE. These fatty acids were found in abundance in skeletal muscle 
tissue and increased during post-exercise recovery, however no such change was observed 
previously in blood serum samples [102].  
 
In addition to 5-LOX, metabolites of the human platelet type 12-LOX enzyme 12-HETE and its 
downstream derivate tetranor 12-HETE were also elevated within muscle during post-exercise 
recovery. Both metabolites are pro-inflammatory in nature and have been shown to act 
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transcellularly to modify the responsiveness of neutrophils to other chemotactic factors [271]. 
We previously observed a similar increase in 12-HETE and downstream tetranor 12-HETE in 
human blood serum samples during recovery from resistance exercise [102]. Interestingly 12-
LOX expressing platelets have been implicated in the transcellular biosynthesis of pro-
resolution LX mediators through interactions with 5-LOX expressing PMNs. This pathway 
involves leucocyte-platelet interactions during which the 5-LOX derived leukotriene 
intermediate LTA4 is taken up by 12-LOX expressing platelets for subsequent conversion to 
LXA4 [272, 273]. Further, the 15-LOX pathway has been implicated as a second the endogenous 
route of LX biosynthesis species. 15-LOX is highly expressed in alternatively activated 
macrophages and epithelial cells. The secretion of 15-LOX product 15-HETE can be taken up by 
5-LOX expressing cells and converted to LXA4 and LXB4 [274]. In this study we demonstrated a 
significant increase in 15-HETE at 2 h post-exercise, a finding which has been replicated in 
human blood serum samples [102].   Our finding of simultaneous induction the primary 
products of both the 5-LOX/12-LOX and 15-LOX/5-LOX pathways locally within skeletal muscle 
during post-exercise recovery would presumably be a permissive environment for local LX 
biosynthesis to occur. However, LXA4 or LXB4 were unable to be detected locally within muscle 
biopsy homogenates. Nevertheless, these local changes within the exercised musculature 
suggests that skeletal muscle tissue may potentially contribute to the exercise-induced 
systemic lipoxin response previously reported [102]. 
 
The CYP pathway is a third, perhaps less well-known, branch of the AA metabolic pathway. The 
increase in epoxyeicosatrienoic acid regioisomer 5-6-EpETrE and dihydroxyeicosatrienoic acids 
11,12-DiHETrE and 14,15-DiHETrE in skeletal muscle supports observations made in serum 
samples when measured during the early stages of post-exercise inflammation [102]. The 
physiological function of these derivatives remains unexplored in skeletal muscle tissue. 
However, in vascular smooth muscle and endothelium cells they play anti-inflammatory roles 
through in the inhibition of prostaglandin and cytokine induced inflammatory responses [275]. 
CYP enzymes also metabolise linoleic acid via epoxidation to form epoxyoctadecmonoeic acids 
(EpOMEs). EpOMEs are rapidly hydrolysed by the sEH enzyme to form DiHOMEs [276]. EpOMEs 
and DiHOMEs are leukotoxins that play a role in the suppression of neutrophil respiratory burst 
activity, vasodilation and cellular apoptosis [277, 278]. A cycling based intervention comprising 
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of a 75km time trial had no effect on 9-10,DiHOME 1.5 h and 21 h post-exercise in plasma 
samples of competitive road cyclists [277]. Alternatively, a bout of acute resistance exercise 
triggered an increase in 9(10)-EpOME and 9-10,DiHOME in serum samples [102]. Results from 
the present study showed an increase in 9-10,DiHOME and 12(13)-DiHOME suggesting that 
discrepancies in the previous literature may be due to the differences in the type of exercise 
performed and the training status of the subjects used in each study. 
 
Collectively, these findings demonstrate an increase in lipid derived mediators of the COX, LOX 
and CYP pathways during post-exercise muscle recovery. The concept of a biologically active 
inflammatory resolution programme governed by lipid derivatives was first proposed in a TNF-
ɑ-stimulated model of acute inflammation in the murine air pouch [185]. Within this model, 
early formation of LTB4 and PGE2 at the onset of inflammation was succeeded by a class-
switching of eicosanoids to LXA4. During this process, interactions between inflammatory and 
host tissue cells enabled the biosynthesis of resolution mediators [185]. Alternatively, in a 
model of zymosan-A stimulated murine peritonitis, the onset of inflammation was 
characterized by a concomitant increase in LTB4 and LXA4 followed by a late appearance of 
PGE2 at the onset of resolution [186]. These findings demonstrate that the temporal regulation 
of lipids and their role in inflammation is likely cell-type and stimulus specific. Recent work 
from our group profiled the human lipid response to acute resistance exercise in serum 
samples [102]. This study showed an increase in key prostaglandin, leukotriene, lipoxin and 
resolvin species during the early stages of acute inflammation (1-3 h), followed by an increase 
in 15-LOX derivatives and some prostaglandin metabolites (6-keto-PGF1ɑ and 13,14dh-
15kPGE2) at 24 h post- exercise [102]. One of the limitations of the present study was the lack 
of statistical power preventing post-hoc analysis of the observed effect of the exercise 
intervention. However, for all intramuscular lipid derivatives peak expression occurred at 2 h 
post-exercise, which appears consistent with findings from serum samples [102]. Interestingly 
lipid species that require transcellular interactions, including lipoxins, resolvins and protectins, 
were either undetected, or very lowly expressed in skeletal muscle tissue. These lipids were 
detectable previously in abundance in human serum samples during post exercise recovery 
and are known to play a vital role in the active resolution of acute inflammation [102].  
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3.6 Conclusion: 
This is the first study to profile the lipid mediator response to acute resistance exercise in 
skeletal muscle tissue. An increase in lipids derived from the COX, LOX and CYP pathways was 
observed during the early stages of post-exercise muscle recovery. Peak induction of AA 
derived classical pro-inflammatory markers PGE2, PGF2ɑ, and both upstream and downstream 
markers of LTB4 occurred at 2 h post-exercise. Further various derivatives of the 5-LOX (4-
HDoHE and 7-HDoHE), 12-LOX (12-HETE and tetranor 12-HETE) and 15-LOX (15-HETE) 
pathways were identified in abundance in skeletal muscle tissue post-exercise and may 
resemble transient cellular intermediates for the formation of pro-resolution lipoxin and 
resolvin species. In alternative models of acute inflammation, these lipids are involved in 
coordinating a biologically active inflammatory resolution programme that has been 
mechanistically linked to processes tissue healing. Future research exploring the physiological 
significance and function of these intramuscular lipids in both skeletal muscle and 
serum/plasma samples post-exercise, will be useful in further characterizing the significance of 
the intramuscular inflammatory response in post-exercise muscle recovery. 
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CHAPTER 4: 
 
Ibuprofen supplementation and its effects on NF-κB activation in skeletal muscle 
following resistance exercise. 
 
Vella L, Markworth JF, Peake JM, Snow RJ, Cameron-Smith D, Russell AP. Ibuprofen 
supplementation and its effects on NF-κB activation in skeletal muscle following resistance 
exercise. Physiological Reports, 2014 Oct 24; 2:10. doi: 10.14814/phy2.12172 (Appendix B).  
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4.1 Abstract: 
Purpose: Resistance exercise triggers a subclinical inflammatory response that plays a pivotal 
role in skeletal muscle regeneration. Nuclear factor-κB (NF-κB) is a key stress signaling 
transcription factor that regulates acute and chronic states of inflammation. The classical NF-
κB pathway regulates the early activation of post-exercise inflammation; however there 
remains scope for this complex transcription factor to play a more detailed role in the muscle 
regeneration process. Methods: Sixteen volunteers completed a single bout of lower body 
resistance exercise with the ingestion of three 400 mg doses of ibuprofen or a placebo control. 
Muscle biopsy samples were obtained prior to exercise and at 0, 3 and 24 h post-exercise. 
Samples were analysed for key markers of NF-κB activity. Results: Phosphorylated p65 protein 
expression and p65 inflammatory target genes were elevated immediately post-exercise. 
These responses were independent of the two treatments. These changes did not translate to 
an increase in p65 DNA binding activity. NF-κB p50 protein expression and NF-κB p50 binding 
activity were lower than pre-exercise at 0 and 3 h post-exercise, but were elevated at 24 h 
post-exercise.  Conclusion: These findings provide novel evidence that two distinct NF-κB 
pathways are active in skeletal muscle after resistance exercise. The initial wave of activity 
involving p65 resembles the classical NF-κB pathway and is associated with the onset of an 
acute inflammatory response. The second wave of NF-κB activity comprises the p50 subunit, 
which has been previously shown to resolve acute inflammation in rodent inflammatory 
models. The current study showed no effect of the ibuprofen treatment on markers of the NF-
κB pathway, however examination of the within group effects of the exercise protocol suggests 
that this pathway warrants further research. 
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4.2 Introduction: 
Unaccustomed resistance exercise causes skeletal muscle damage that impairs muscle function 
and promotes sensations of pain. The precise signaling mechanisms that initiate muscle repair 
following exercise-induced damage remain a topic of ongoing debate (previously reviewed by 
Paulsen et al. [279]). The onset of muscle damage triggers a complex interplay of intracellular 
events that involve myofibre injury, acute inflammation and cellular repair.  At a symptomatic 
level, inflammation in skeletal muscle is characterised by swelling and soreness [279]. 
Consequently post-exercise inflammation is often ascribed as a cause of delayed-onset muscle 
soreness (DOMS). DOMS typically occurs 2448 hours post-exercise, and is accompanied by a 
secondary reduction in muscle force-generating capacity. Treatment of DOMS has focused on 
reducing inflammation; however this may be detrimental to processes of cellular repair [103]. 
Attenuating exercise-induced inflammation using non-steroidal anti-inflammatory drugs 
reduces skeletal muscle protein synthesis [280] and impairs satellite cell proliferation [87]. To 
develop more efficacious treatments for DOMS, a better understanding of the mechanisms 
that govern inflammation and tissue repair in skeletal muscle after exercise is required. 
 
The nuclear factor-kappa B (NF-κB) transcription factor acts as a central regulator of 
inflammatory signaling pathways. The NF-B family consists of five subunits, including NF-κB1 
(p105/p50), NF-κB2 (p100/p52), RelA (p65), RelB and cREL that share an amino terminus Rel 
homology domain. The Rel domain permits DNA binding, nuclear localization, dimerization and 
interaction with its own inhibitory protein IκB [190, 191, 194]. Under basal conditions RelA 
(p65), cREL and RelB subunits remain sequestered within the cytoplasm bound to an inhibitory 
IB protein. The IB family that regulates NF-B includes the subunits IκBβ, IκBα, IκBγ IκBε, and 
Bcl-3. Unlike the Rel proteins, subunits p50 and p52 are synthesized as large precursor proteins 
(p105 and 100, respectively) that require proteolytic processing to permit nuclear localization. 
These subunits lack a REL domain, to initiate gene transcription, and hence are primarily 
considered as repressors of gene transcription [194, 281].  
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Upon stimulation, the IκB kinase complex (IKK) controls the degradation of IκB and its 
precursor proteins, thereby enabling the NF-κB REL subunits to control gene transcription. The 
IKK complex consists of two catalytic kinases IKKα and IKKβ, and a regulatory IKKγ subunit.  
 
IKKβ activates the classical NF-κB signaling pathway through the phosphorylation and 
subsequent degradation of the inhibitor IκBα [192, 199]. The classical pathway typically 
comprises p65:p50 heterodimers, and is essential for the activation of acute inflammation by 
controlling the transcription on inflammatory cytokines and acute phase proteins [192, 199]. 
More recently an alternative NF-κB pathway has been described, which is dependent on IKKα 
[282]. Alternative signaling involves the activation of a secondary NF-κB inducing kinase (NIK), 
and has been linked to the activation of both p52 and p50 subunits. The functional significance 
of IKKα-dependent gene expression in acute inflammation is not yet well established. 
However, preliminary research in rat muscle tissue suggests p50 homodimers may play a 
crucial role in the resolution of acute inflammation [283, 284]. Transgenic rodents expressing 
enhanced p50-p50 DNA binding showed reduced expression of inflammatory cytokines and 
impaired leucocyte recruitment during inflammatory resolution [285]. Further, p50-p50 
complexes bind to distinct κB response elements in COX-2 promoter regions, and have shown 
to regulate COX-2 expression through association with transcriptional co-activators of the 
C/EBP family [286, 287]. These findings implicate that a biphasic NF-κB activation patterns may 
represent a key regulatory pathway in the expression of COX derived inflammatory resolution 
mediators, as identified in chapter 3. 
      
Despite the importance of inflammation in tissue regeneration post-exercise, very little is 
known about how NF-κB activity is regulated in skeletal muscle after acute exercise. A transient 
increase in various components of the classical NF-κB signaling pathway is observed in rat 
muscle post-exercise [233, 234, 288-290]. In contrast, a decrease in NF-κB DNA binding at 0 
hours post-exercise with a return to near baseline 1 hour post-exercise was observed in human 
muscle following a traditional resistance exercise model [238]. Recent work from our 
laboratory, using a similar resistance exercise model, demonstrated an increase in NF-κB 
binding to the promoter region of key inflammatory cytokines at 2 hours post-exercise, with a 
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return to baseline levels at 4 hours post-exercise  [239]. These findings suggest that a transient 
NF-κB response contributes to acute post-exercise inflammation.   
 
To enhance our understanding of the cellular mechanisms that regulate both the onset and 
resolution of post-exercise inflammation, the current study aimed to investigate changes in the 
activity of the subunits that comprise the classical and alternative NF-κB signaling pathways. It 
was hypothesized that the regulation of NF-κB post-exercise would involve two distinct waves 
of activation. Specifically, we hypothesized that the classical NF-κB pathway (involving p65-p50 
heterodimers) would be activated soon after exercise during the early phases of inflammation, 
while the alternative pathway (comprising p50 homodimers) would be activated at later time 
points after exercise that correspond with the resolution of acute inflammation [284, 285].  It 
was further hypothesized that the administration of ibuprofen would blunt both waves of NF-
κB activation, providing a potential mechanism through which anti-inflammatory medication 
might attenuate exercise-induced inflammation in skeletal muscle. 
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4.3 Methods: 
4.3.1 Participants: 
As previously described in chapter 2, sixteen healthy male subjects were recruited to 
participate in the study (characteristics shown in Table 1) [102]. All participants completed a 
medical history questionnaire that was used to identify and exclude participants with a 
diagnosed condition or illness that prevented them from completing strenuous exercise. 
Exclusion criteria included participation in a lower body resistance exercise program within the 
last 6 months to ensure a muscle damage response from the exercise stimulus, and/or chronic 
treatment with anti-inflammatory drugs. Current use of prescription medication or nutritional 
supplements also excluded subjects from participating.  
 
Table 4.1: Subject characteristics and strength testing data. Values are mean values ± SEM. No 
significant differences were observed between the two groups.  
  Characteristics Strength (1RM) 
  
Age (y) Height (m) 
Body mass 
(kg) 
BMI Squat (kg) Leg Press (kg) 
Leg 
Extension 
(kg) 
PLA 
23.9                              
± 1.3 
1.89                              
± 0.1 
86.9                             
± 4.5 
24.5                            
± 1.2 
94.9                     
± 5.4 
237                                   
± 17 
236                             
± 18 
IBU 
23.0                             
± 0.5 
1.89                               
± 0.1 
89.1                             
± 4.4 
24.8                         
± 0.8 
91.9                             
± 6.0 
240                                       
± 15 
196                                  
± 22 
 
 
4.3.2 Ethics approval: 
Prior to participation each subject received written and oral information regarding the nature 
of the experiment before providing written consent to participate. All procedures involved in 
this study were approved by the Deakin University Human Research Ethics Committee 
(DUHREC 2010-019). All muscle sampling procedures were performed in accordance with the 
Helsinki declaration. 
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4.3.3 Familiarization and strength testing: 
Each participant completed a familiarization session at least 7 days prior to completing the 
exercise trial. Participants performed repetition maximum testing to determine the 
experimental exercise load (80% of 1 repetition maximum (1RM)). The maximal weight each 
subject could lift was determined for the Smith machine-assisted squat, the leg press, and the 
leg extension. These data were substituted into the validated Brzycki equation to predict 1RM 
for each participant [244, 291]. The participants were required to abstain from any further 
exercise until completion of the trial.  
 
4.3.4 Experimental procedures: 
The participants reported to the laboratory in an over-night fasted state, having abstained 
from caffeine, tobacco and alcohol for the preceding 24 h. Following 30 min of supine resting a 
pre-exercise muscle biopsy was taken. Participants then completed a 10 min warm up 
consisting of low intensity cycling on a bicycle ergometer, and one low resistance set for each 
exercise at approximately 30-50% of the participants 1RM. Each participant then completed a 
single bout of intense resistance exercise. This session consisted of 3 sets of 8-10 repetitions of 
a bilateral Smith machine assisted squat, 45-degree leg press and leg extension. These 
exercises were all performed at 80% 1RM. The exercises were performed sequentially as a 
circuit, with 1 min rest between each exercise, and 3 min rest between sets. We have 
previously used this exercise protocol, and demonstrated that it activates inflammatory 
signaling pathways [239]. Following the completion of the exercise bout, the participants 
rested in a supine position while muscle biopsy samples were collected. The participants 
returned to the laboratory the following morning in an over-night fasted state for a final 
muscle biopsy sample. Standardized meals were provided to participants the night preceding 
the trial (carbohydrate 57%, fat 22%, protein 21%), in the laboratory immediately following the 
3 h muscle biopsy (carbohydrate 71%, fat 13%, protein 16%), and an evening meal 
(carbohydrate 64%, fat 27%, protein 18%). 
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4.3.5 NSAID administration: 
Prior to the exercise bout, the participants were randomly assigned to either the ibuprofen 
(NSAID) group (n = 8) or the placebo group (PLA) (n = 8). Participants in the NSAID group 
consumed the maximum recommended over-the-counter dose of 1200 mg of ibuprofen as 
three doses of 400 mg throughout the trial day. The first dose was administered upon arriving 
to the laboratory on the first morning of the trial, immediately prior to the first muscle biopsy 
sample. Participants were instructed to consume two additional doses at 2:00pm and 8:00 pm 
the same evening. This dosing structure was prescribed to optimise levels of circulating 
ibuprofen to biologically active levels throughout the course of the trial day. This protocol has 
previously been validated by our research group in this same group of study participants [102]. 
Alternatively, the placebo consumed a gelatin capsule containing powdered sugar, identical in 
appearance to the ibuprofen capsule. 
 
4.3.6 Sample collection: 
Muscle biopsy samples were obtained under local anaesthesia (Xylocaine 1%) from the vastus 
lateralis muscle of either leg using the percutaneous needle biopsy technique modified to 
include suction [245]. Samples were obtained prior to exercise, immediately following exercise 
and at 3 h and 24 h post-exercise. The muscle biopsy sample obtained immediately post-
exercise was taken within 1-2 min of the completion of the exercise protocol, and will herein 
after being referred to as 0 h post-exercise. The muscle biopsy procedure has been shown to 
trigger a local inflammatory response [62]. To minimize interference from the biopsy 
procedure, samples prior to exercise and at 24 h post-exercise were taken from the same leg, 
while muscle samples obtained at 0 and 3 h post-exercise were taken from the opposite leg. 
Samples within the same leg were taken at least 5 cm from the previous site. We have 
previously reported that this technique is effective for minimizing cytokine gene expression 
and NF-B activity in response to muscle biopsies [239]. Excised tissue was immediately 
immersed in liquid nitrogen and stored at 80°C until further analysis. 
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4.3.7 Protein extraction and quantification: 
Muscle samples were homogenized in ice cold RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA supplemented with protease and 
phosphatase inhibitors including 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 mM 
Na3VO4 & 1mM NaF). The homogenate was agitated for 1 h at 4°C and centrifuged at 13,000  
g at 4°C for 15 min. The resultant supernatant was removed and stored at 80°C until further 
analysis. Total protein concentration was determined using a BCA protein assay kit according 
to the manufacturer’s instruction (Pierce, Rockford, IL). Protein samples (50 µg) were 
denatured in loading buffer and separated by a 10% SDS-PAGE and transferred to a PVDF 
membrane. Membranes were blocked for 90 min at room temperature in 5% BSA/Tris buffered 
saline with 0.1% Tween 20 (TBST). Primary antibodies [phosphorylated NF-κB p65 Ser536, total 
NF-κB p65, NF-κB p100/p52, NF-κB p105/p50, NF-κB cREL and β-actin (all obtained from Cell 
Signaling Technologies, Arundel, QLD)] were diluted to 1:1,000 in 5% BSA/TBST, applied and 
incubated overnight at 4°C with gentle agitation. Membranes were washed for 30 min in TBST 
and probed with HRP conjugated secondary antibodies diluted to 1:2,000 in 5%BSA/TBST, and 
incubated for 1 h at room temperature. Proteins were visualised by using Western Lighting 
enhanced chemiluminescence (Perkin Elmer Lifesciences, Boston, MA). Signals were captured 
using a Kodak Digital Image Station 2000M (model: 440CF; Eastman Kodak, Rochester, NY) and 
quantified by densitometry band analysis using Kodak Molecular Imaging Software (Version 
4.0.5, © 1994-2005, Eastman Kodak). Phosphorylated NF-κB p65 protein was normalized to 
total p65 protein (Supplementary Figure 4.1A). NF-κB p50 protein expression was normalized 
to its precursor protein p105 (Supplementary Figure 4.1B). NF-κB p52 and cREL protein was 
normalized to β-actin (Supplementary Figure 4.1C).   
 
4.3.8 RNA extraction and RT-PCR: 
Total cellular RNA was extracted as previously described [257] using the ToTALLY RNA Kit 
(Ambion, Austin, TX). RNA quality and concentration were determined using the Agilent 2100 
Biolanalyzer (Agilent Technologies, Palo Alto, CA). First strand cDNA was generated from 0.5 µg 
total RNA using the AMV RT kit (Promega, Madison, WI). RT-PCR was performed in duplicate 
using the Biorad CFX384 system (Biorad, Hercules, CA), containing 5XHOT FirePol® EvaGreen 
Mix (Integrated Science, Sydney, NSW), forward primer, reverse primer, sterile nuclease free 
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water and cDNA (0.125 ng/μL). Data were analysed using a comparative critical threshold (Ct) 
method, where the amount of the specified target gene normalised to the amount of 
endogenous control, relative to the control value is given by 2-ΔΔCt. The endogenous control 
used in this experiment was GAPDH. The efficacy of GAPDH as an endogenous control was 
examined using the equation 2-ΔCt. Primers were designed using Primer Express software 
package version 3.0 (Applied Biosystems). Gene sequences were obtained from GenBank 
(Table 2). Primer sequence specificity was confirmed using BLAST. A melting point dissociation 
curve was generated by the PCR instrument for all PCR products to confirm the presence of a 
single amplified product. 
 
Table 4.2: Primer sequences were designed using Primer Express Software v 3.0 (Applied 
Biosystems) using sequences accessed through Genbank and checked for specificity using 
nucleotide-nucleotide BLAST search. 
        
Gene Accession No.  Primer Sequence 
GAPDH NM_21130 Forward CAT CCA TGA CAA CTT TGG TAT CGT 
  Reverse CAG TCT TCT GGG TGG CAG TGA 
MCP-1 NM_002982 Forward TCC CAA AGA AGC TGT GAT CTT CA 
  Reverse CAG ATT CTT GGG TGG AGT GA 
IL-6 NM_000600 Forward GCG AAA GGA TGA AAG TGA CCA T 
  Reverse AGA CAA GCC CAG CAA TGA AAA 
IL-8 NM_000584 Forward CTG GCC GTC GCT CTC TGG 
  Reverse TTA GCA CTC CTT GGC AAA ACT 
TNF-α X_02910 Forward GGA GAA GGG TGA CCG ACT CA 
  Reverse TGC CCA GAC TCG GCA AAG 
COX-2 U_20548 Forward GAA TCA TTC ACC AGG CAA ATT G 
    Reverse TGG AAG CCT GTG ATA CTT TCT GTA CT 
 
 
4.3.9 Nuclear extraction and Transcription Factor (TF) Assay: 
Nuclear and cytoplasmic proteins were extracted from 20 mg of muscle tissue using a NE-PER 
Nuclear and Cytoplasmic Extractions Reagents (Pierce, Rockford, IL), according to the 
manufacturer’s instructions. Western blot analysis probed for GAPDH, α-tubulin and Lamin A 
was performed to ensure the nuclear extract was not contaminated by cytoplasmic proteins 
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(Supplementary Figure 2). A Transcription Factor Assay detecting specific transcription factor 
DNA binding activity was performed according to manufacturer’s instructions (Cayman 
Chemical, Ann Arbour, MI). Briefly, 10 µg of nuclear protein were loaded into a well containing 
an immobilized NF-B consensus sequence (5’GGGACTTTCC-3’) and incubated overnight at 
4°C. Primary antibodies for NF-B subunits p65 and p50 were loaded in to each well and 
incubated at room temperature for 1 h. Each well was flushed using a diluted wash buffer for 
30 min.  Following a secondary 30 min wash, samples were incubated with secondary HRP-
conjugated antibody for a further 1 h at room temperature. To quantify transcription factor 
binding, a developing solution containing a 3,3’,5,5’-Tetramethhylbenzidine (TMB) solution was 
added to each well and incubated for 45 min at room temperature. DNA binding was then 
quantified using photospectrometry with absorbance measurements taken at 450 nm using a 
Multiscan RC plate reader (Labsystems, Finland) and Gen5 Data Analysis Software (BioTek, 
Winooski, VT). 
 
4.3.10 Statistics: 
Data are expressed as means ± SEM. Prior to analysis the data displaying a lack of normality 
were log transformed to stabilise variance. Data were analysed using a two-way ANOVA with 
repeated measures for time. The sphericity adjustment was checked, and if required, a 
Greenhouse-Geisser epsilon to the residual degrees of freedom was applied. A data point was 
considered to be a statistical outlier where a z-score exceeded a pre-determined threshold of ± 
4.00. Where appropriate we explored within-group pair-wise comparisons between individual 
time-points using the Least Significant Differences of means at P < 0.05 to determine 
statistically significant changes [292, 293]. Statistical analyses were performed using GenStat 
for Windows 16th Edition (VSN International, Hemel Hempstead, UK).  
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4.4 Results: 
4.4.1 Protein expression: 
Expression of NF-κB phosphorylated p65 (Ser 536) increased over time (time effect p=0.006), 
but this response was overall not different between the groups (interaction effect p=0.253, 
treatment effect p= 0.176). Nevertheless, LSD pairwise comparisons indicated that the main 
increase from baseline was in the placebo group at 0 h post-exercise. Within the placebo group 
phosphorylated p65 protein expression remained elevated at 3 h post-exercise and returned to 
baseline by 24 h (Figure 4.1A). No significant changes were observed in the ibuprofen group by 
LSD comparisons. There was no effect of time or treatment for NF-κB total p65 (Figure 
Supplementary Figure 4.1A). There was a trend toward a significant time  treatment 
interaction (p=0.057) for the protein expression of the p50 subunit, although a main effect for 
time (p=0.376) or treatment (p=0.865) was not achieved. Further analysis revealed a statistical 
outlier in the ibuprofen group at the 24 h time point. When this subject was removed from the 
analysis, this trend was weaker (p=0.115) (Figure 4.1B). LSD comparisons indicated an increase 
in p50 protein expression was observed at 24h post exercise in the placebo group only (Figure 
4.1B). There were no main or interaction effects for the NF-κB p50 precursor protein p105 
(Supplementary Figure 4.1B) or for p52 and cREL subunits (Figure 4.1C and Figure 4.1D).  
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Figure 4.1: Protein expression of NF-κB subunits p65, p50, p52 and cREL. Representative Western blots 
for p-p65 (A), p50/p105 (B), p52 (C) and cREL (D) measured in muscle biopsy samples. Data are mean 
arbitrary units ± SEM. * denotes statistical significance from pre-exercise values in the placebo group; ^ 
denotes statistical significance from 24 h post-exercise in the placebo group (p<0.05). White bars = 
placebo group; black bars =ibuprofen group. 
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Supplementary Figure 4.1: Protein expression of total NF-κB p65, NF-κB p105 and β-actin. Data 
are mean arbitrary units ± SEM. White bars = placebo group; black bars =ibuprofen group. 
 
4.4.2 Transcription Factor assay: 
To determine subunit-specific DNA binding of NF-κB following exercise, transcription factor 
binding assays were performed for p50 and p65 subunits. NF-κB p50 showed a main effect for 
time (p=0.035), with no time  treatment interaction (p=0.851) or main effect for treatment (p 
=0.488) (Figure 4.2B). LSD comparisons identified a significant increase in p50 binding that 
occurred at 24 h post-exercise when compared to 0 and 3 h post-exercise within the placebo 
group. This coincided with the increase in p50 protein expression (Figure 4.1B). No change in 
p65 DNA binding was observed, despite an increase in phosphorylated p65 protein expression 
(Figure 4.2B).  
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Figure 4.2: NF-κB subunits p65 (A) and p50 (B) binding to nuclear protein. Data are mean arbitrary units 
± SEM. # denotes statistical significance from 0 h post-exercise in the placebo group; $ denotes 
statistical significance from 3 h post-exercise in the placebo group. White bars = placebo group; black 
bars =ibuprofen group. 
 
4.4.3 RT-PCR: 
The mRNA levels of IL-6 (Figure 4.3A), IL-8 (Figure 4.3B) and MCP-1 (Figure 4.3C) demonstrated 
a main effect for time (p<0.01), with the highest elevation in expression levels at 3 h post-
exercise after significant increases at 0 h post-exercise. TNF-α mRNA remained unchanged 
after exercise (Figure 4.3D). COX-2 mRNA showed a main effect for time (p<0.01), increasing at 
0, 3 and 24 h post-exercise (Figure 4.3E). There were no significant interaction effects or main 
effects for treatment for the inflammatory cytokines or COX-2 mRNA expression. Consistently, 
LSD pairwise comparisons revealed similar changes over time from baseline within both 
groups, demonstrating no effect of the ibuprofen supplementation protocol on exercise-
induced cytokine expression. 
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Figure 4.3: RT-PCR analysis of NF-κB target genes IL-6 (A), IL-8 (B), MCP-1 (C), TNF-α (D) and COX-2 (E) in 
skeletal muscle cDNA. Data are mean arbitrary units ± SEM. * denotes statistical significance from pre-
exercise in the same treatment group; # denotes statistical significance from 0 h post-exercise in the 
same treatment group; ^ denotes statistical significance from 24 h post-exercise in the same treatment 
group (p<0.05). White bars = placebo group; black bars =ibuprofen group.  
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4.5 Discussion: 
The current study aimed to explore the regulation of the different NF-κB subunits following a 
single bout of lower body resistance exercise, and investigate the mechanism through which 
ibuprofen treatment may influence post-exercise inflammation.  The results of this study 
provide preliminary evidence that an alternative NF-κB signaling pathway comprising 
predominately p50 subunits is activated 24 h post-exercise. This pathway appears distinctly 
different to the activation of NF-κB p65 subunit that occurs during the early stages of acute 
post-exercise inflammation.  
 
Phosphorylated NF-κB p65 protein expression was significantly elevated in the placebo group 
when measured at 0 and 3 h post-exercise, and returned to baseline levels at 24 h post-
exercise. These findings support those of previous research showing a post-exercise increase in 
key components of the classical NF-κB signaling pathway in skeletal muscle, including 
phosphorylated NF-κB p65 protein [234, 239], phosphorylated IκBα protein [233, 239] and NF-
κB p65 DNA binding activity [236, 294]. In the present study, the increase in phosphorylated 
NF-κB p65 protein expression was not associated with an increase in p65 transcription factor 
binding activity at 0, 3 and 24 h post-exercise. However, NF-κB regulated cytokine genes 
including MCP-1, IL-6 and IL-8 were increased at 3 h post-exercise. Previous work from our 
group showed a transient increase in NF-κB p65 binding to the promoter region of genes 
coding for inflammatory cytokines at 2 h after traditional resistance exercise that returned to 
basal levels at 4 h [239]. This research performed a series of electrophoretic mobility shift 
assays that looked specifically NF-κB binding to genes coding MCP-1, IL-6 and IL-8 and thus 
differences in the methodology, particularly the timing of muscle biopsy samples and the 
different experimental methods used to quantify DNA binding, may explain conflicting results.  
Research models using an eccentric resistance exercise model could demonstrate an increase 
in p65 DNA binding to nuclear protein at 3 h post-exercise [294, 295]. By contrast, research 
from Durham et al  showed a decrease in NF-κB DNA binding activity immediately post-
exercise, which returned to baseline levels at 1 h post-exercise [238]. Collectively, these 
findings suggest that the activation of NF-κB DNA binding occurs transiently within the first few 
hours of exercise. Changes in NF-κB activity in skeletal muscle may depend on the mode of 
exercise and training status of participants.  
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This research also provides novel evidence for a potential role of NF-κB p50 activation as a 
component of a biologically active inflammation-resolution program as outlined in chapter 3. 
In our initial analysis of p50 protein expression, there was a trend towards a time  group 
interaction effect (p=0.057) but this trend was weaker (p=0.115) after removing a statistical 
outlier. Despite this weaker interaction, within-group analysis by LSD comparisons revealed 
that p50 protein expression was elevated in the placebo group at 24 h post-exercise. 
Coincident with this response, p50 transcription factor binding activity was highest at 24 h 
post-exercise. The biological significance of this delayed increase in NF-B p50 signaling during 
the latter stages of post-exercise recovery remains uncertain. However, in vitro work suggests 
that it may play a role in regulating the active resolution of acute inflammation in skeletal 
muscle [282, 283, 296]. In a model of carageenin-induced pleurisy in rats, Lawrence et al [283] 
provided preliminary evidence for a complex interplay between distinct NF-κB signaling 
pathways that control an acute and transient inflammatory response. They reported that the 
preliminary phase of NF-κB activation that occurred at 6 h was characteristic of the classical 
NF-κB pathway, and was associated with the onset of acute inflammation. The secondary 
phase was typical of the alternative NF-κB pathway, comprising p50 homodimers. Importantly, 
inhibiting this wave of activity caused a prolonged inflammatory response, delaying the 
resolution of key inflammatory mediators [283]. Findings from the present study support the 
concept of two functionally distinct waves of NF-κB activity following traditional resistance 
exercise. A primary wave consistent with classical NF-κB signaling pathways was observed 
during the early stages of post-exercise muscle recovery and the onset of inflammation. A 
secondary rise in NF-κB p50 expression occurred at 24 h post-exercise, at a time-point that 
could be indicative of inflammation resolution. Based on findings from chapter 3, a biologically 
active inflammation resolution program may exist followed exercise-induced muscle damage. 
Future work is warranted to determine how this secondary wave of NF-κB pathway activity 
influences post-exercise inflammation and skeletal muscle recovery.  
 
Supplementation with the NSAID ibuprofen was used to investigate whether manipulating the 
inflammatory response to exercise through the cyclooxygenase-prostaglandin pathway alters 
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post-exercise NF-κB signaling. Previous reports indicate that NF-κB can function upstream of 
COX-2 to control transcription of this gene [192, 297]. Alternatively, prostaglandin activity may 
also affect NF-κB [297-299]. In-vitro studies demonstrate that the effect of prostaglandins on 
NF-κB activity is specific to the class of prostaglandin. Prostaglandin E2 activates the classical 
NF-κB pathway, whereas prostaglandin A2, and prostaglandin J2 and its downstream analogues 
can inhibit NF-κB activation in response to pro-inflammatory stimuli [298-301]. Our group 
recently reported changes in prostaglandins in blood serum samples after traditional resistance 
exercise [102]. Interestingly, PGE2, PGA2 and PGD2 all peaked in expression at 2 h post-exercise. 
No significant time  group interaction effects for the change in p65 phosphorylation was 
observed; however, LSD comparisons suggested that phosphorylated p65 expression only 
seemed to increase in the placebo group. Similarly, the observed changes in p50 protein 
expression and DNA binding were only identified within the placebo group. These findings are 
supported by data from the study by Lawrence et al [283], which demonstrated no change in 
the secondary wave of NF-B DNA binding activity following the administration of an 
alternative COX inhibitor, NS398, in rats with pleurisy. While these findings do not offer any 
conclusive evidence that ibuprofen treatment inhibits the NF-κB pathway, it does provide 
justification to further explore this pathway as a potential mechanism through which ibuprofen 
treatment inhibits post-exercise inflammation. 
 
4.6 Conclusion: 
This research provides new insights into the regulation of NF-κB following a bout of acute 
resistance exercise. The primary finding from this study is that NF-κB activation follows a 
biphasic activation pattern that is subunit-specific. The first wave involves the classical NF-κB 
p65 subunit, and corresponds with the onset of an acute inflammatory response and an 
increase in inflammatory cytokine gene expression. The second wave is consistent with a 
previously identified secondary wave of NF-κB activity that involves the alternative p50 
subunit. Research in alternative models of inflammation suggests that this second wave of 
activity may be associated with an active inflammatory resolution program. Further research 
into the role of p50 signaling in skeletal muscle represents a key area for future research in 
order to better understand the mechanisms that regulate post-exercise inflammation. Analysis 
of the LSD to examine pair-wise within-group differences suggested that the observed changes 
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in both NF-κB p65 and p50 were detected only within the placebo group. The complex 
interplay between the NF-κB and the COX/prostaglandin pathway in exercise-induced muscle 
damage remains poorly understood, and should be a focus for future research. 
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CHAPTER 5 – GENERAL DISCUSSION AND FUTURE DIRECTIONS: 
5.1 – Introduction: 
The human response to resistance exercise presents a highly complex paradigm. Intense 
muscular contractions have the capacity to trigger large increases in muscle size and strength. 
However, following most bouts of intense exercise, there is often considerable muscle damage, 
inflammation and muscle soreness. Whilst recognising the complexity of the skeletal muscle 
response to exercise-induced muscle damage, the time-course of cellular events in post-
exercise muscle recovery appear to follow a well described schematic of events; (1) tissue 
injury via mechanical and metabolic stress, (2) release of vasoactive and chemotactic 
substances from damaged tissue, (3) migration and adhesion of systemic leucocytes to the 
injury site, and (4) tissue repair and adaptation. The accumulation of inflammatory leucocytes 
coincides with a secondary rise in histological and functional markers of muscle damage 
including DOMS and a reduction in force generating capacity [24, 31, 39, 42, 302, 303]. These 
findings have led researchers to propose that exercise-induced inflammation is a potential 
cause of secondary muscle damage, and led to the implementation of anti-inflammatory 
recovery strategies. However, with the past few years has been a growing recognition that 
interventions targeted at the inhibition of key pro-inflammatory mediator pathways, have also 
had deleterious effects of tissue adaptation and skeletal muscle repair [103, 106, 107, 161, 
255]. These findings rationalize the concept that cellular events occurring within acute 
inflammation form a key regulatory component of muscle regeneration and tissue repair. 
 
The overall aim of my PhD was to explore the possibility of an active post-exercise 
inflammatory resolution programme that may play a key role in establishing a biological link 
between skeletal muscle damage and tissue repair. Specifically, chapter 2 involved a clinical 
trial looking at the effect of ant-inflammatory medication on key markers of inflammation of 
muscle damage. This project was part of a wider trial that examined the effect of anti-
inflammatory medication of muscle hypertrophy signaling pathways. The aim of chapter 3 was 
to explore the human lipid profile in response to an acute resistance exercise. This paper 
identified various lipids involved in regulating the bioactive resolution of acute inflammation. 
These findings permitted the investigation of potential pathways that regulate both the 
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activation and resolution of acute inflammation. Chapter 4 examined the effect of an acute 
bout of resistance exercise on the classical and alternative NF-κB signaling pathways in skeletal 
muscle of young untrained men. 
5.2 – Summary of results: 
The aim for chapter 2 was to investigate the effect of oral ibuprofen administration on 
leucocyte infiltration and indirect markers of muscle damage, including circulating muscle 
proteins CK and myoglobin, and subjective muscle soreness. This was the first study to 
demonstrate that ibuprofen administration has no effect on the histological appearance of 
inflammatory white blood cells following an acute bout of traditional resistance exercise. We 
also found no effect of ibuprofen administration on blood markers of muscle damage or 
subjective muscle soreness, and no significant correlations between leucocyte numbers and 
post-exercise muscle damage or soreness.  
 
Chapter 3 sought to explore the possibly of a biologically active inflammatory resolution 
pathway that may provide a physiological link between processes of acute exercise-induced 
inflammation and skeletal muscle adaptation. Post-exercise recovery was characterized by 
increased levels of COX-1 derived TXB2 and 12(S)-HHTrE, COX-2 derived prostaglandin 
metabolites 2,3-dinor PGE1 and 15d-D12,14-PGJ3, LOX derivatives LTB4, 20-COOH LTB4, 5-HETE, 
12-HETE, tetranor 12-HETE and 15-HETE, HDoHE species 4-HDoHE, 7-HDoHE, and CYP derived 
5,6-EpETrE, 11,12-DiHETrE and 14,15-DiHETrE. This lipid profile suggests that novel lipid 
intermediates involved in the formation of specialized pro-resolution mediators form a highly 
complex self-resolving model of acute inflammation following a bout of resistance exercise. 
 
The aim of chapter 4 was to explore the regulation of NF-κB as a potential regulator of an 
active post-exercise inflammatory resolution programme. The primary finding from this study 
is that NF-B activation follows a biphasic activation pattern that is subunit-specific. The first 
wave involves the classical NF-B p65 subunit, and corresponds with the onset of an acute 
inflammatory response and an increase in inflammatory cytokine gene expression. The second 
wave is consistent with a previously identified secondary wave of NF-B activity that involves 
the alternative p50 subunit. These findings are consistent with those from alternative models 
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of acute inflammation and identifies NF-κB as a critically important regulator of post-exercise 
inflammation. 
 
5.3 – Future directions: 
This thesis represents a broad approach to exploring the possibility of a bioactive inflammatory 
resolution programme following exercise-induced muscle damage. The important outcomes 
from this research are; (1) leucocyte infiltration occurs following an acute resistance exercise 
stimulus, however does not appear to be associated with exercise-induced muscle soreness, 
(2) pro-resolution inflammatory mediators derived from omega-3 and omega-6 fatty acids are 
increased following a bout of resistance exercise, (3) the biphasic regulation of NF-κB, a key 
regulator of stress signaling pathways, coincides with the onset and resolution of acute 
inflammation. Collectively, these findings provide preliminary evidence for an active 
inflammatory resolution programme that may provide a biological link between processes of 
acute muscle damage, inflammation and soft-tissue regeneration. 
 
In chapter 2 I identified that the administration of a non-selective NSAID had no effect on the 
observed increase in white blood cell infiltration or indirect measures of muscle damage. 
Paulsen et al. (2010) proposed the concept of an inflammatory threshold, suggesting that 
NSAIDs may only influence post-exercise inflammation in response to a sufficiently strong 
inflammatory stimulus [93]. It was suggested that the absence of an intramuscular 
prostaglandin response to exercise, specifically PGE2, could explain the lack of an NSAID effect 
on leucocyte recruitment [93, 132]. Interestingly, in a follow up study within the same sample, 
NSAID administration blunted early translational pathways involved in skeletal muscle 
hypertrophy [161]. These findings present two potential paradigms. Firstly, despite the well-
established role for the inducible COX-2 enzyme in the animal muscle reparative response to 
acute damage [104-106, 111, 164], the constitutively active COX-1 may play an important 
function in the human adaptive response to exercise. Alternatively, NSAID administration may 
have the capacity to influence alternative signalling pathways within the exercise-induced 
inflammation-tissue repair paradigm.  
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These findings led our research team to explore the regulation of a novel family of n-3 and n-6 
derived lipid mediators known to play a role in acute inflammatory resolution. In addition to 
their role in regulating inflammation, lipid mediators have been implicated in processes of soft 
tissue regeneration and skeletal muscle adaptation [304]. Firstly, Markworth et al. [102] 
demonstrated elevated levels of pro-resolving lipoxins, resolvins and protectins in human 
blood serum samples during the early hours of post-exercise muscle recovery. Treatment with 
ibuprofen inhibited the lipid mediator response to exercise-induced cellular stress. In chapter 3 
I identified a similar increase in lipids derived from the COX, LOX and CYP pathways in skeletal 
muscle tissue following acute resistance exercise. In each research trial a unique lipid profile 
was identified in blood serum and skeletal muscle tissue samples. Future research exploring 
the functions of these lipids in exercise-induced muscle damage is necessary in understanding 
the physiological significance of acute inflammation in post-exercise skeletal muscle 
regeneration. At this stage the mechanism of action for lipid derived resolution mediators is 
not clear and requires further investigation. This can be explored further in-vivo using rodent 
models of muscle damage. Utilizing an eccentrically loaded muscle contraction, or an 
unloading/reloading muscle damaging protocol, lipoxin and resolvin species can be artificially 
over-expressed, or pharmacologically inhibited [171, 305, 306]. This research needs to consider 
the implications of modifying lipid mediator synthesis on the onset and resolution of acute 
inflammation, and what impact this has on downstream markers of skeletal muscle tissue 
regeneration. Further human trials need to consider the effect of dietary interventions on key 
markers of post-exercise muscle damage, inflammation and repair. Supplementation with n-3 
EPA and DPA has a highly divergent effect on the human lipid mediator profile, specifically 
resolvin and maresin species [307]. This avenue of research would explore the concept of 
recovery interventions designed to promote resolving mediators and biochemical pathways 
that are homeostatic and modulatory in their actions, to optimize the outcome of an acute 
inflammatory program. 
 
Chapter 4 identified NF-κB as a potential transcriptional regulator involved in both the onset 
and resolution of acute post-exercise inflammation. The primary finding from this study is that 
NF-κB regulation follows a biphasic activation pattern that is subunit-specific. The first wave 
involves the classical NF-κB p65 subunit, and corresponds with the onset of an acute 
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inflammatory response and an increase in inflammatory cytokine gene expression. The second 
wave is consistent with a previously identified secondary wave of NF-κB activity that involves 
the alternative p50 subunit. While research in alternative models of acute inflammation 
suggest this second wave of increased NF-κB activity may be associated with an active 
inflammatory resolution program, no research has explored the physiological significance of 
this pathway in acute post-exercise inflammation. Recent work from our group utilized a series 
of electrophoretic mobility shift assays (EMSA) to demonstrate an increase in NF-κB p65 
binding to the promoter region of genes coding for inflammatory cytokines in the early stages 
of exercise-induced inflammation [239]. This research model may provide an avenue to explore 
whether the secondary increase in key markers of the alternative NF-κB signaling pathway are 
involved in regulating a biologically active inflammatory resolution program. Potential targets 
of NF-κB p50 homodimers include the inducible COX-2 enzyme, transcription factor p53 and 
the pro-apoptotic Bcl2 homolog Bax [192, 210]. 
 
An inherent limitation of muscle biopsy studies is the test-retest reliability of muscle biopsies 
obtained from different sites along the vastus lateralis. The muscle biopsy protocol used 
throughout this thesis was used to minimize interference from the biopsy procedure on 
markers of acute inflammation [239]. However, previous research has demonstrated the 
regional differences in muscle hypertrophy/atrophy exist across an individual muscle length 
[308]. Further evidence suggests that intramuscular differences in fibre type have been 
observed across individual muscle biopsy samples from the vastus lateralis [309]. The absence 
of a non-exercise control group, and the inherent lack of test-retest reliability of the muscle 
biopsy protocol are acknowledged as accepted limitations of the current research.   
 
5.4 – Concluding remarks:  
This thesis presents preliminary evidence for a biologically active inflammatory resolution 
program that may provide a crucial link between processes of exercise-induced muscle 
damage, and tissue regeneration and adaptation. This concept would challenge the current use 
of anti-inflammatory therapies to promote post-exercise muscle recovery. Most of the anti-
inflammatory interventions studied to date, arise from our need to control the cardinal signs of 
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inflammation by inhibiting key pro-inflammatory mediator pathways. Experimental models 
targeted at inhibiting the post-exercise inflammatory response have identified that exercise-
induced inflammation is a key regulatory feature in the restoration of tissue structure and 
function.   
 
The overall aim of this thesis was to explore the regulation of a family of novel lipid derivatives 
that have been shown to play dual anti-inflammatory and pro-resolution functions in acute 
inflammation. In chapter 2 we demonstrated that the administration of ibuprofen had no 
effect on key inflammatory and muscle damage markers. These findings challenge the 
suitability of NSAID administration as an effective treatment strategy for reducing acute 
inflammation and muscle soreness following resistance exercise. Further research from within 
our laboratory [161], amongst others [87, 107, 130], have demonstrated a detrimental effect 
of anti-inflammatory interventions on post-exercise early translational signalling responses via 
the inhibition of eicosanoids derived from the COX pathway. Taken together, these findings 
suggest that inhibiting eicosanoid formation during acute post-exercise inflammation may 
directly affect muscle hypertrophy pathways without directly impacting on cellular 
inflammation. In chapter 3 we explored the regulation of lipid species during acute post-
exercise muscle recovery. We identified a post-exercise increase in eicosanoids and 
docosanoids species derived from COX, LOX and CYP pathways, presenting the possibility of a 
highly complex self-resolving model of acute inflammation following an acute bout of 
resistance exercise. For chapter 4, an in-depth analysis of the regulation of NF-κB, 
demonstrated a bi-phasic regulation pattern that coincides with the onset and resolution of 
acute inflammation. This thesis shows for the first time that events occurring early in acute 
post-exercise inflammation may engage an active and coordinated inflammatory resolution 
programme, governed by the production of specialized pro-resolution lipid mediators. Further 
work is required to elucidate the specific functions of each of these lipid variables and explore 
the efficacy of interventions designed to promote resolving mediators and biochemical 
pathways that will be homeostatic and modulatory in their actions.     
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Purpose:We investigated if oral ingestion of ibuprofen influenced leucocyte recruitment
and infiltration following an acute bout of traditional resistance exercise.
Methods: Sixteen male subjects were divided into two groups that received the
maximum over-the-counter dose of ibuprofen (1200mg d−1) or a similarly administered
placebo following lower body resistance exercise. Muscle biopsies were taken from
m.vastus lateralis and blood serum samples were obtained before and immediately after
exercise, and at 3 and 24 h after exercise. Muscle cross-sections were stained with
antibodies against neutrophils (CD66b and MPO) and macrophages (CD68). Muscle
damage was assessed via creatine kinase and myoglobin in blood serum samples, and
muscle soreness was rated on a ten-point pain scale.
Results: The resistance exercise protocol stimulated a significant increase in the number
of CD66b+ and MPO+ cells when measured 3 h post exercise. Serum creatine kinase,
myoglobin and subjective muscle soreness all increased post-exercise. Muscle leucocyte
infiltration, creatine kinase, myoglobin and subjective muscle soreness were unaffected
by ibuprofen treatment when compared to placebo. There was also no association
between increases in inflammatory leucocytes and any other marker of cellular muscle
damage.
Conclusion: Ibuprofen administration had no effect on the accumulation of neutrophils,
markers of muscle damage or muscle soreness during the first 24 h of post-exercise
muscle recovery.
Keywords: exercise recovery, NSAID treatment, inflammation, resistance exercise, leucocyte
INTRODUCTION
Unaccustomed resistance exercise often results in tissue damage and inflammation, leading
to delayed onset muscle soreness (DOMS) and a consequent reduction in force production
(Faulkner et al., 1993; Tidball, 1995). Animal models and in vitro studies have identified that local
and systemic inflammation exerts a regulatory influence during the different phases of muscle
recovery, including myofibrillar disruption, cellular necrosis, satellite cell activation, maturation
and subsequent regeneration, and adaptation (Fridén et al., 1981; Armstrong et al., 1991). Thus,
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post-exercise inflammation is intimately necessary and a key
feature of the normal process of tissue regeneration and
adaptation following acute muscle damage. However, excessive
inflammation is considered a potential cause of prolonged
post-exercise muscle soreness and may have a negative effect
on muscle recovery (Armstrong et al., 1991; Smith, 1991);
consequently strategies to reduce or counteract inflammation are
commonly implemented to aid in improving muscle recovery
after exercise (Urso, 2013).
Non-steroidal anti-inflammatory drugs (NSAIDs) are
commonly used as a treatment strategy in exercise and
sports medicine to assist with recovery from exercise-induced
inflammation, particularly following soft-tissue injury. NSAIDs
inhibit the cyclooxygenase (COX-1 and 2) enzymes and
consequently the formation of prostanoids (prostaglandins,
prostacyclins, and thromboxanes) that play a diverse role in
acute inflammation (Markworth et al., 2013). Prostanoids
stimulate an acute inflammatory process by controlling local
blood flow, vascular permeability, leucocyte infiltration, and
triggering sensations of pain (Markworth et al., 2013; Urso,
2013). In animal models of acute muscle damage, treatment
with NSAIDs blunts the infiltration of leucocytes into muscle
tissue (Lapointe et al., 2003; Bondesen et al., 2004) and causes
a reduction in creatine kinase (CK) (Mishra et al., 1995).
Consequently, NSAIDs can also inhibit myofiber regeneration,
satellite cell proliferation and differentiation, and overload-
induced muscle hypertrophy (Mishra et al., 1995; Bondesen
et al., 2004, 2006). These findings provide preliminary evidence
that NSAIDs compromise the physiological link between
processes of acute muscle damage, inflammation and cellular
regeneration.
Research into the effects of NSAIDs on exercise-induced
muscle damage and inflammation has produced equivocal
findings. In exercise models, NSAID administration has been
shown to attenuate post-exercise DOMS in some (Baldwin et al.,
2001; Tokmakidis et al., 2003; Paulsen et al., 2010), but not
all studies (Trappe et al., 2002; Krentz et al., 2008; Mikkelsen
et al., 2009; Hyldahl et al., 2010). While a precise cellular
mechanism for an analgesic effect of NSAIDs remains unclear,
it has been largely ascribed to their effect on prostaglandin
synthesis and the capacity of NSAIDs to interfere with aspects
of inflammatory cell function (Hersh et al., 2000; Peterson
et al., 2003). Previous research has demonstrated that oral
consumption of both ibuprofen, a non-selective NSAID and
acetaminophen, an analgesic also known as paracetamol, had no
effect on macrophage infiltration at 24 h following an eccentric
exercise protocol (Peterson et al., 2003). Similarly treatment with
naproxen, another non-selective NSAID, had no effect on the
infiltration of leucocyte common antigen positive cells following
a unilateral, isotonic resistance exercise protocol (Bourgeois et al.,
1999). Interestingly, Paulsen et al. (2010) suggested a blunting
effect of the COX-2 specific celecoxib following maximum
eccentric muscle contractions (Paulsen et al., 2010). This research
identified a tendency for higher monocyte/macrophage numbers
in subjects within the placebo group, and those subjects who were
identified as “high-responders” to the exercise protocol based on
the number of inflammatory leucocytes (Paulsen et al., 2010).
Although this is not a particularly robust finding, it has led to the
hypothesis that NSAIDs may influence leucocyte infiltration in
skeletal muscle when a sufficiently strong and early inflammatory
reaction is present (Paulsen et al., 2010). This hypothesis would
suggest that the intensity of the exercise stimulus and the
consequent muscle-damage response would be largely influential
in determining the effect of a pharmacologically based anti-
inflammatory intervention.
Conflicting findings also exist with regard to the effect
of NSAIDs on the regenerative capacity of skeletal muscle
following exercise-induced muscle damage. The non-selective
COX inhibitor ibuprofen blunted skeletal muscle protein
synthesis (Trappe et al., 2002) while local intramuscular
infusion of indomethacin (Mikkelsen et al., 2011) and the
oral administration of the COX-2 selective NSAID celecoxib
(Burd et al., 2010; Paulsen et al., 2010) had no such effect.
Similarly, treatment with indomethacin inhibited post-exercise
satellite cell proliferation (Mikkelsen et al., 2009). Recent work
from our group demonstrated that treatment with ibuprofen
inhibited early translational signaling responses involved in post-
exercise muscle hypertrophy (Markworth et al., 2014). A clear
mechanistic pathway for NSAIDs to influence the physiological
link between post-exercise inflammation and skeletal muscle
regeneration remains elusive.
These discrepancies in the research to date are likely due
to differences in the exercise protocol (concentric vs. eccentric
muscle contractions), the training status of subjects, the timing
of muscle biopsies, and the type of NSAID, the dosage
administered, and method of administration. Further research is
required to determine whether NSAID administration affects the
infiltration of leucocyte populations following exercise-induced
muscle damage and how this influences post-exercise adaptive
pathways. The aim of the present study was to investigate if
oral administration of the NSAID ibuprofen influenced skeletal
muscle leucocyte infiltration during the first 24 h after muscle-
damaging resistance exercises. We also aimed to explore how
any changes in leucocyte infiltration were related to markers
of muscle damage, including circulating muscle proteins CK
and myoglobin, and subjective markers of muscle soreness.
We hypothesized that the ingestion of ibuprofen following
acute resistance exercise would not influence the infiltration of
leucocytes, however it would attenuate sensations of DOMS.
MATERIALS AND METHODS
Participants
As described previously, 16 healthy male subjects were recruited
to participate in the study (Table 1; Markworth et al., 2013). It
is important to note that the purpose of the original study by
Markworth et al. (2013) was to profile the human eicosanoid
response to acute exercise in blood plasma samples, as opposed
to the aim of the present study which was to determine the
effect of oral ingestion of ibuprofen on leucocyte recruitment
and infiltration following an acute bout of traditional resistance
exercise.While the subjects and experimental design are the same
in both studies the aims and dependent variables reported are
different. Exclusion criteria included participation in a lower
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TABLE 1 | Subject characteristics and strength testing data.
Characteristics Strength (1 RM)
Age (y) Height (m) Body mass (kg) BMI Squat (kg) Leg press (kg) Leg extension (kg)
PLA 23.9 ± 1.3 1.89 ± 0.1 86.9 ± 4.5 24.5 ± 1.2 94.9 ± 5.4 237 ± 17 236 ± 18
IBU 23 ± 0.5 1.89 ± 0.1 89.1 ± 4.4 24.8 ± 0.8 91.9 ± 6.0 240 ± 15 196 ± 22
Values are mean values ± SEM. No significant differences were observed between the two groups. PLA, placebo; IBU, Ibuprofen; BMI, body mass index.
body resistance exercise program within the last 6 months to
ensure a muscle damage response from the exercise stimulus,
and/or previous chronic treatments with anti-inflammatory
medication. Participants also completed a medical screening to
identify any potential risk factors for them to perform strenuous
physical activity.
Ethics Approval
All procedures involved in this study were approved by
the Deakin University Human Research Ethics Committee
(DUHREC 2010-019) and muscle sampling procedures were
performed in accordance with the Helsinki declaration. Each
participant was provided with written and oral details of the
nature and requirements of the study and provided written
consent to participate.
Familiarization
Each participant completed a familiarization and strength testing
session at least 7 days prior to completing the exercise protocol.
Details of the familiarization session have been described
previously (Markworth et al., 2013). Briefly, subjects performed
repetition maximum testing for the Smith machine-assisted
squat, the leg press and the leg extension to determine their
experimental exercise load [80% of a 1 repetition maximum (1
RM)]. The maximum weight the subject could lift for 5–8 reps
was determined, and these data were entered into the Brzycki
equation to predict 1 RM (Whisenant et al., 2003). Subjects were
asked to abstain from any further activity until the completion of
the trial.
Experimental Procedures
The participants reported to the laboratory on the morning
of the trial in an overnight fasted state. They were asked to
abstain from caffeine, tobacco and alcohol for the 24 h preceding
the trial. Participants rested in a supine position for 30min,
following which the first muscle biopsy sample was taken.
Each participant then completed a 10min warm-up protocol
comprised of 5min of low intensity cycling on a stationary
bike, and one low-intensity set of each exercise at a weight of
each subject’s own choice within the range of 30–50% 1 RM.
The resistance exercise session consisted of three sets of 8–10
repetitions performed on a Smith machine assisted squat, a 45◦
leg press and a leg extension at 80% of a predicted 1 RM. The
exercises were performed as a circuit with 1min rest permitted
between exercises and 3min rest between sets. This protocol
has been used previously and has been a sufficient stimulus to
activate inflammatory signaling pathways (Vella et al., 2012) and
was implemented to replicate a commonly used exercise routine.
After exercise, the subjects rested while subsequentmuscle biopsy
samples were collected. After the 3 h biopsy, participants were
provided a standardized meal and were allowed to go home.
The following morning, participants reported to the laboratory
in an over-night fasted state for a 24 h muscle biopsy and blood
sample.
Standardized Meals
Standardized meals were provided to participants on the night
before the trial, (carbohydrate 57%, fat 22%, protein 21%),
immediately following the 3 h muscle biopsy (carbohydrate 71%,
fat 13%, protein 18%), and in the evening (carbohydrate 64%, fat
27%, protein 18%) on the day of the exercise trial. Participants
were permitted to drinkwater ad libitum andwere asked to report
if they could not finish their allocated meals. This nutrition plan
was included to ensure that each participant received the same
relative percentage of macro- and micro-nutrients.
NSAID Administration
Prior to exercise, participants were randomly assigned in
a double-blind method, to consume either the maximum
recommended dose of ibuprofen (IBU, n = 8) or a placebo
control (gelatin capsules identical in appearance containing
powdered sugar in place of ibuprofen) (PLA, n = 8). The IBU
group consumed three doses of 400mg of ibuprofen throughout
the trial day. The first dose was administered immediately prior
to the first muscle biopsy sample. Participants were instructed
to consume the following two doses at 6 and 12 h following
the exercise protocol. Follow-up phone calls from the research
team ensured compliance. To ensure this dosing structure was
appropriate to maintain biologically active levels of ibuprofen,
ibuprofen concentration was measured in blood serum samples
and these data are reported elsewhere (Markworth et al.,
2013).
Sample Collection
Venous blood samples were drawn prior to exercise, within 5min
post exercise (here-after referred to as 0 h post-exercise), and at 1,
2, 3, and 24 h post-exercise. Blood samples were drawn through
an indwelling catheter into VACUETTE serum tubes (Greiner,
Bio-One, Stonehouse UK). Whole blood was allowed to clot at
room temperature. Samples were then centrifuged at 1000 × g
for 10min. The serum layer was collected and stored at −80◦C
for subsequent analysis.
Muscle biopsy samples were obtained from the vastus
lateralis muscle under local anesthesia (Xylocaine 1%) using
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a percutaneous needle biopsy technique modified to include
suction (Buford et al., 2009). To minimize interference from
the biopsy procedure, samples prior to exercise and at 24 h post
exercise were taken from the same leg, while samples taken at
0 and 3 h post-exercise were taken from the contralateral leg.
Samples obtained within the same leg were taken at least 5 cm
from the previous incision site. We have previously reported
that this technique is effective for minimizing the risk of any
inflammation arising from the biopsy procedure confounding
exercise-induced inflammation (Vella et al., 2012). Tissue-Tek
immersed tissue was rapidly frozen in isopentane cooled liquid
nitrogen before storage at−80◦C.
Immunohistochemistry
Cross sections (8µm) of muscle tissue were cut using a
microtome at −20◦C (CM3050, Leica, Germany) and mounted
on microscope slides (Superfrost Plus, Thermo Scientific,
MA, USA), air-dried and stored at −80◦C. Each subject’s
muscle sections from all time points were mounted on the
same microscope slide. Serial muscle cross-sections were
stained with three different leucocyte antibodies, MPO (#0398,
DakoCytomation, Glostrup, Denmark; dilution 1:2000), CD66b
(#CLB-B13.9, Sanquin Reagents, Amsterdam, The Netherlands;
dilution 1:500), and CD68 (#EBM-11, DakoCytomation,
Glostrup, Denmark; dilution 1:300). Furthermore, the sections
were also stained with dystrophin antibody (ab15277, Abcam,
Cambridge, UK) for visualizing borders of muscle fibers.
Sections were fixed in 4% paraformaldehyde solution in a
staining jar for 5min at room temperature and rinsed twice
for 10min in phosphate buffered saline (PBS) containing 0.5%
Tween 20 (Sigma-Aldrich). The microscope slides were moved
into a humidified chamber and non-specific binding sites were
blocked with 1% bovine serum albumin (BSA) on the section for
45min at room temperature. Sections were incubated overnight
with leucocyte and dystrophin antibodies diluted in 1% BSA
at 4◦C. After overnight incubation, the slides were washed
three times for 10min in PBS-Tween in a staining jar. Slides
were moved back to the humidified chamber and sections
were incubated for 45min with secondary antibodies diluted
1:200 in 1% BSA at room temperature. Alexa Fluor R© 594
F(ab′)2 fragment of goat anti-rabbit and Alexa Fluor R©488 anti-
mouse IgG (Invitrogen, Eugene, Oregon, USA) were used as a
secondary antibodies. The fluorochrome-stained sections were
washed three times for 10min in PBS-Tween. After the last
washing in PBS-Tween, the sections weremounted on ProLong R©
Gold Antifade reagent with DAPI (Invitrogen, Eugene, Orgeon,
USA).
Muscle sections were visualized using a high-resolution
camera (DP72, Olympus, Japan) mounted on a microscope
(BX61, Olympus, Japan) with a fluorescence light source (X-
Cite 120PCQ, EXFO, Canada). The number of MPO, CD66b,
and CD68 positive cells (as well as the total number of muscle
fibers from the area included) was counted. Data was calculated
as percentage of MPO, CD66b, or CD68 positively stained cells
per 100 skeletal muscle fibers. Areas of sections that contained
freeze damage or were folded due to the cutting procedure were
not included in the analysis.
Biochemical Assays
Serum creatine kinase activity in pre- and post-exercise blood
samples was analyzed using an enzymatic assay (CK-NAC
kit, CDT14010, Thermo-Fisher Scientific Clinical Diagnostics,
Sydney, Australia) and an automated clinical analyser (Cobas
Mira, Roche Diagnostics, Germany). Serum myoglobin
concentration was also measured in these samples using an
immunoassay (Roche Diagnostics, Germany) and an automated
clinical analyzer (Cobas E411, Roche Diagnostics, Germany).
The intra-assay coefficient of variation was 10.4% for creatine
kinase and 1.7% for myoglobin.
Muscle Soreness Assessment
Upon arrival at the laboratory and prior to the first muscle
biopsy procedure, as well as 24 h following exercise prior to
the fourth and final muscle biopsy, subjects were asked to rate
their subjective muscle soreness on a 0–10 visual analog scale.
The subjects were instructed to contract, stretch, and palpate
the quadriceps muscle to assess general muscle soreness. In
both instances 0 was considered to represent no pain and
correspondingly a rating of 10 was considered to represent
intense pain.
Statistics
Data are expressed as means ± SEM. Prior to analysis the
data displaying a lack of normality were log transformed to
stabilize variance. Data were analyzed using a two-way ANOVA
with repeated measures for time. The sphericity adjustment
was checked, and if required, a Greenhouse-Geisser epsilon
correction was applied. Where no significant effect for treatment
was observed, we explored pair-wise comparisons between
individual time-points using the Least Significant Difference
(LSD) of means. Bivariate relationships were examined with
a Spearman rank correlation test. These statistical analyses
were performed using GenStat for Windows 16th Edition (VSN
International, Hemel Hempstead, UK). Confidence intervals
were calculated at 90% using a bootstrapping technique for non-
normally distributed data using SPSS Statistics Version 22 (IBM,
Portsmouth Hampshire, UK). Statistical significance was set at
P < 0.05.
RESULTS
Muscle Soreness
Muscle soreness showed a main effect for time (p < 0.01),
suggesting that the exercise protocol was sufficient to induce a
muscle stress response. No effect of ibuprofen treatment was
observed (Figure 1).
Immunohistochemistry
The number of MPO+ cells per 100 myofibers analyzed showed a
main effect for time (P < 0.01). No main effect for treatment
(P = 0.250) or time × treatment (P = 0.709) was observed
(Figure 2A). LSD pairwise comparisons indicated a significant
increase in MPO+ cells at all sampling time points post-exercise.
The greatest increase in MPO+ cells was observed at 3 h post-
exercise (Figure 2B). Similarly, the number of CD66b+ cells per
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FIGURE 1 | Subjective rating for delayed onset muscle soreness
(DOMS) Values depicted are mean values ± SEM. *denotes statistical
significance from pre-exercise values (p < 0.05). White bars, PLA group; black
bars, IBU group. This figure has been adapted from Vella et al. (2014).
100 myofibers showed a main effect for time (P < 0.05), with
no main effect for treatment (P = 0.149) or time × treatment
interaction (P = 0.907; Figure 2C). LSD pairwise comparisons
indicated a significant increase in the number of CD66b+ cells
at 3 h post exercise (Figure 2D). The number of CD68+ cells
per 100 myofibers analyzed showed no effect for time (P =
0.061), treatment (P = 0.530) or time × treatment interaction
(P = 0.688; Figure 2E). MPO+, CD66b+, and CD68+ cells were
observed within the endomysium and the perimysium, with no
cellular infiltration occurring at any time point. Representative
images for each cell surface marker are presented in Figure 3.
Serum Proteins
Serum CK activity demonstrated a main effect for time (P <
0.01) with no effect for treatment (P = 0.843) or time ×
treatment interaction (P = 0.494; Figure 4A). LSD comparisons
revealed that serum CK increased from pre-exercise values at
2 h post-exercise and peaked at 24 h post-exercise (Figure 4B).
Similarly, serum myoglobin concentration showed a main effect
for time (P < 0.01) with no effect for treatment (P =
0.710) or time × treatment interaction (P = 0.666; Figure 4C).
LSD comparisons demonstrated that the biggest increase in
serum myoglobin concentrations occurred at 1 h post-exercise
and remained significantly elevated up to 3 h post exercise
(Figure 4D).
Correlation Analysis
In general, large inter-individual differences were seen in the
appearance of all of the leucocyte cell types. Results from the
Spearman rank correlation test showed no correlation between
the histochemical appearance of inflammatory leucocytes,
biological markers of muscle damage, and subjective markers
of muscle soreness (Table 2). Anecdotally, three subjects were
identified as the highest responders in the appearance of cell
surface markers applicable for localization of neutrophils (one
subject within the placebo group, and two subjects within the
ibuprofen group). However, these subjects showed no significant
increase in CK, myoglobin or subjective markers of muscle
damage when compared with the other subjects. Interestingly,
subject 5 recorded the highest number of CD66b+ cells and
MPO+ cells, whereas he presented with the lowest subjective
rating for DOMS.
DISCUSSION
Themain finding of this study was that ibuprofen, a non-selective
COX inhibitor, had no effect on the histological detection of
leukocytes following an acute bout of traditional resistance
exercise. Serum CK and myoglobin, and muscle soreness
also did not change in response to ibuprofen. Furthermore,
no correlation was observed between the accumulation of
inflammatory leucocytes, increases in CK or myoglobin, and
sensations of DOMS. These observations suggest that the
intramuscular infiltration of inflammatory white blood cells, or
an increase in serum levels of intramuscular proteins, are not
predictive of post-exercise muscle soreness.
The current study focused on the acute local inflammatory
response to exercise-induced muscle damage. Our protocol was
effective in inducing muscle soreness as shown in Figure 1. It is
important to note that we have previously reported this exercise-
induced stress response (Vella et al., 2014). However, we felt it
was necessary to re-emphasize this response here. In the present
study we identified an increase in the histological appearance
of CD66b+ and MPO+ cells that peaked at 3 h post exercise
and found no effect of NSAID treatment. CD66b is a highly
specific cell surface marker for detecting human neutrophils, and
this is the first paper to show a small but significant increase
in the intramuscular number of CD66b+ cells following acute
resistance exercise. Paulsen et al. (2013) were unable to identify
any change in the number of CD66b+ cells in the elbow flexors
at 1, 2, 4, or 7 days following 70 maximal eccentric contractions
(Paulsen et al., 2013). Differences in the timing of muscle biopsy
samples may explain the discrepancy between the two trials, and
suggest that neutrophils may be involved in the acute phase
inflammatory response to resistance exercise. We also identified
a small but significant increase in the number of MPO+ cells
at all sampled time points, with a peak in expression at 3 h
post exercise. MPO has typically been used to detect changes
in neutrophils, and an increased number of MPO+ cells have
been reported following high-force eccentric muscle contractions
(Mahoney et al., 2008; MacNeil et al., 2011). However, MPO
is also expressed on the lysosomes of monocytes and has been
detected on basophils and eosinophils, perhaps providing a
reason why there were a higher number of MPO+ cells when
compared to CD66b+ cells detected in the present study (Paulsen
et al., 2013).
No change was identified in the number of CD68+ cells. CD68
cell counts are widely used as a marker of monocyte/macrophage
infiltration. However, CD68 may also be expressed on other cell
types including satellite cells and fibroblasts (Paulsen et al., 2013).
Other researchers have been able to identify a change in CD68+
cells following exercise-induced muscle damage (Peterson et al.,
2003; Mahoney et al., 2008; MacNeil et al., 2011). Each of
these studies have used a high-force maximal eccentric muscle
contraction protocol, which may suggest that the detection of
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FIGURE 2 | Immunohistochemistry data for muscle cells staining positive for myeloperoxidase (MPO), showing group specific data (A) and collapsed
data (B), CD66b showing group specific data (C), and collapsed data (D), and CD68 showing group data only (E). Data represent the mean number of
positively stained cells per 100 fibers analyzed ± SEM. **denotes statistical significance from pre-exercise values (p < 0.01). *denotes statistical significance from
pre-exercise values (p < 0.05). ∧denotes statistical significance from 0h post-exercise (p < 0.05). White bars, PLA group; black bars, IBU group.
CD68+ cells is dependent on the extent of skeletal muscle
damage.
Previous research exploring the effect on NSAIDs on
post-exercise inflammation has produced equivocal findings.
Earlier research from in-vivo rodent trials demonstrated a
blunted inflammatory response to eccentric muscle contractions
following the administration of both selective and non-selective
NSAIDs (Lapointe et al., 2002a,b; Bondesen et al., 2004, 2006).
However, these findings are yet to be supported in human
trials (Bourgeois et al., 1999; Peterson et al., 2003; Tokmakidis
et al., 2003). Peterson et al. (2003) found no effect of oral
ibuprofen administration on the appearance of CD68+ cells 24 h
following 100 eccentric muscle contractions (Peterson et al.,
2003). Similarly, Tokmakidis showed no effect of ibuprofen
on circulating white blood cells 24 h following an eccentric
exercise protocol (Tokmakidis et al., 2003). Paulsen et al. (2010)
proposed the concept of an inflammatory threshold, suggesting
that NSAIDs may only influence post-exercise inflammation in
response to a sufficiently strong inflammatory stimulus (Paulsen
et al., 2010). It was suggested that the absence of an intramuscular
prostaglandin response to exercise, specifically PGE2, could
explain the lack of an NSAID effect on leucocyte recruitment
(Trappe et al., 2001; Paulsen et al., 2010). Interestingly, our
group recently reported an increase in serum PGE2 in samples
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that were obtained during the same exercise trials as those
currently reported (Markworth et al., 2013). This change in
serum PGE2 was blunted by the administration of ibuprofen
FIGURE 3 | Immunohistochemical analysis of skeletal muscle samples
following about of resistance exercise. Sections were probed with
antibodies raised against leucocyte cell surface markers (green; A—MPO,
B—CD66b, C—CD68) and dystrophin (red), while DAPI was used to stain
nuclei (blue). Scale bars = 50µm.
and suggests that in the presence of a blunted prostaglandin
response to exercise, NSAID treatment had no effect on leucocyte
recruitment within skeletal muscle. Although this finding does
not refute the possibility of an inflammatory threshold, based
on our previous findings (Markworth et al., 2013), it is
reasonable to suggest that the presence of an exercise-induced
serum prostaglandin response is not the required underlying
mechanism for neutrophil infiltration of muscle during the early
hours of post-exercise recovery.
In accordance with previous studies, resistance exercise
resulted in an increase in serum CK and myoglobin, and
subjective muscle soreness (Nosaka et al., 2006). Although large
inter-individual variations in the human response to exercise
can make it difficult to establish causal relationships, there
was no relationship between the appearance of leucocytes
and blood-derived markers of muscle damage or sensations
of muscle soreness. Interestingly, the subject with the highest
number of CD66b+ and MPO+ cells presented with the lowest
subjective rating of DOMS. These findings provide support for
the assumption that leucocyte recruitment and inflammation do
not consistently cause DOMS.
From animal studies it appears that cellular events in post-
exercise inflammation, occur concomitantly with the onset of
DOMS (Armstrong et al., 1991; Faulkner et al., 1993). The
mechanistic link has been proposed to be a leucocyte-mediated
FIGURE 4 | Blood derived proteins creatine kinase (A,B) and myoglobin (C,D). Values depicted are mean values ± SEM. (A,C) represent data divided into two
treatment groups; (B,D) represent collapsed data. *denotes statistical significance from pre-exercise values (p < 0.05). **denotes statistical significance from
pre-exercise values (p < 0.01). ∧denotes statistical significance from 1, 2, and 3 h post exercise (p < 0.05). White bars, PLA; black bars, IBU.
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TABLE 2 | Spearman rank correlation analysis.
CK MYO CD68+ CD66b+ MPO+ DOMS
CK – 0.59 (−0.01 − 0.91) −0.46 (−0.88 − 0.8) 0.15 (−0.42 − 0.61) 0.36 (−0.14 − 0.73) 0.01 (−0.60 − 0.62)
MYO – – 0.01 (−0.55 − 0.52) 0.14 (−0.42 − 0.69) 0.35 (−0.21 − 0.67) −0.33 (−0.74 − 0.24)
CD68+ – – – 0.05 (−0.46 − 0.56) −0.27 (−0.75 − 0.33) −0.37 (−0.82 − 0.25)
CD66b+ – – – – 0.41 (−0.13 − 0.84) −0.37 (−0.78 − 0.16)
MPO+ – – – – – 0.08 (−0.49 − 0.56)
DOMS – – – – – –
Values depicted are the correlation coefficient with 90% confidence intervals in parenthesis. Statistical significance was set at p < 0.05. No statistically significant correlations were
observed. CK, creatine kinase; MYO, myoglobin; MPO, Myeloperoxidase; DOMS, delayed-onset muscle soreness.
release of cytotoxic substances and reactive oxygen species
as a bi-product of phagocytosis (Connolly et al., 2003).
Furthermore, the prostaglandin response to exercise has been
shown to occur concurrently to the onset of DOMS, and
is known to influence both the recruitment of inflammatory
leucocytes and neural afferents to pain (Markworth et al., 2013).
However, in line with the current findings, the accumulation
of inflammatory leucocytes in human skeletal muscle tissue
during exercise recovery appears to be both spatially and
temporally out of phase with the development of DOMS
(Paulsen et al., 2010). Malm et al. (2004) explored the
concept that the activation of local leucocytes present in the
epimysium may be involved in the regulation of DOMS.
This hypothesis has since received support from both rodent
(Gibson et al., 2009) and human trials (Crameri et al., 2007;
Raastad et al., 2010) and presents a promising area for future
research.
CONCLUSION
This is the first study to demonstrate that ibuprofen
administration has no effect on the histological appearance
of inflammatory white blood cells following an acute bout
of traditional resistance exercise. We also found no effect
of ibuprofen administration on blood markers of muscle
damage or subjective muscle soreness, and no significant
correlations between leucocyte numbers and post-exercise
muscle damage or soreness. Future research needs to explore
the possibility of an inflammatory threshold above which
NSAID administration influences post-exercise inflammation.
The underlying cause of post-exercise muscle soreness also
remains largely unknown. Future investigations are needed to
determine the role that inflammation plays in exercise-induced
DOMS.
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Abstract
Resistance exercise triggers a subclinical inflammatory response that plays a
pivotal role in skeletal muscle regeneration. Nuclear factor-jB (NF-jB) is a
stress signalling transcription factor that regulates acute and chronic states of
inflammation. The classical NF-jB pathway regulates the early activation of
post-exercise inflammation; however there remains scope for this complex
transcription factor to play a more detailed role in post-exercise muscle recov-
ery. Sixteen volunteers completed a bout of lower body resistance exercise
with the ingestion of three 400 mg doses of ibuprofen or a placebo control.
Muscle biopsy samples were obtained prior to exercise and at 0, 3 and 24 h
post-exercise and analysed for key markers of NF-jB activity. Phosphorylated
p65 protein expression and p65 inflammatory target genes were elevated
immediately post-exercise independent of the two treatments. These changes
did not translate to an increase in p65 DNA binding activity. NF-jB p50 pro-
tein expression and NF-jB p50 binding activity were lower than pre-exercise
at 0 and 3 h post-exercise, but were elevated at 24 h post-exercise. These find-
ings provide novel evidence that two distinct NF-jB pathways are active in
skeletal muscle after resistance exercise. The initial wave of activity involving
p65 resembles the classical pathway and is associated with the onset of an
acute inflammatory response. The second wave of NF-jB activity comprises
the p50 subunit, which has been previously shown to resolve an acute inflam-
matory program. The current study showed no effect of the ibuprofen treat-
ment on markers of the NF-jB pathway, however examination of the within
group effects of the exercise protocol suggests that this pathway warrants
further research.
Introduction
Unaccustomed resistance exercise causes skeletal muscle
damage that impairs muscle function and promotes sen-
sations of pain. The precise signalling mechanisms that
initiate muscle repair following exercise-induced damage
remain a topic of ongoing debate [previously reviewed by
Paulsen et al. (2012)]. The onset of muscle damage trig-
gers a complex interplay of intracellular events that
involve myofibre injury, acute inflammation and cellular
repair. At a symptomatic level, inflammation in skeletal
muscle is characterised by swelling and soreness (Paulsen
et al. 2012). Consequently post-exercise inflammation is
often ascribed as a cause of delayed-onset muscle soreness
(DOMS). DOMS typically occurs 24–48 h post-exercise,
and is accompanied by a secondary reduction in muscle
force-generating capacity. Treatment of DOMS has
focused on reducing inflammation; however this may be
detrimental to processes of cellular repair (Urso 2013).
Attenuating exercise-induced inflammation using non-ste-
roidal anti-inflammatory drugs reduces skeletal muscle
protein synthesis (Trappe et al. 2002) and impairs satellite
cell proliferation (Mikkelsen et al. 2009). To develop
more efficacious treatments for DOMS, a better
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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understanding of the mechanisms that govern inflamma-
tion and tissue repair in skeletal muscle after exercise is
required.
The nuclear factor-kappa B (NF-jB) transcription
factor acts as a central regulator of inflammatory signal-
ling pathways. The NF-jB family consists of five subunits,
including NF-jB1 (p105/p50), NF-jB2 (p100/p52), RelA
(p65), RelB and cREL that share an amino terminus Rel
homology domain. The Rel domain permits DNA bind-
ing, nuclear localization, dimerization and interaction
with its own inhibitory protein IjB (Delhalle et al. 2004;
Mourkioti and Rosenthal 2008; Bakkar and Guttridge
2010). Under basal conditions RelA (p65), cREL and RelB
subunits remain sequestered within the cytoplasm bound
to an inhibitory IjB protein. The IjB family that regu-
lates NF-jB includes the subunits IjBb, IjBa, IjBc IjBe,
and Bcl-3. Unlike the Rel proteins, subunits p50 and p52
are synthesized as large precursor proteins (p105 and 100,
respectively) that require proteolytic processing to permit
nuclear localization. These subunits lack a REL domain,
to initiate gene transcription, and hence are primarily
considered as repressors of gene transcription (Bonizzi
and Karin 2004; Bakkar and Guttridge 2010).
Upon stimulation, the IjB kinase complex (IKK) con-
trols the degradation of IjB and its precursor proteins,
thereby enabling the NF-jB REL subunits to control gene
transcription. The IKK complex consists of two catalytic
kinases IKKa and IKKb, and a regulatory IKKc subunit.
IKKb activates the classical NF-jB signalling pathway
through the phosphorylation and subsequent degradation
of the inhibitor IjBa (Zandi et al. 1997; Pahl 1999). The
classical pathway typically comprises p65:p50 heterodi-
mers, and is essential for the activation of acute inflam-
mation by controlling the transcription on inflammatory
cytokines and acute phase proteins (Zandi et al. 1997;
Pahl 1999). More recently an alternative NF-jB pathway
has been described, which is dependent on IKKa (Senftle-
ben et al. 2001). Alternative signalling involves the activa-
tion of a secondary NF-jB inducing kinase (NIK), and
has been linked to the activation of both p52 and p50
subunits. The functional significance of IKKa-dependent
gene expression in acute inflammation is not yet well
established. However, preliminary research in rat muscle
tissue suggests p50 homodimers may play a crucial role
in the resolution of acute inflammation (Bohuslav et al.
1998; Lawrence et al. 2001).
Despite the importance of inflammation in tissue
regeneration post-exercise, very little is known about how
NF-jB activity is regulated in skeletal muscle after acute
exercise. A transient increase in various components of
the classical NF-jB signalling pathway is observed in rat
muscle post-exercise (Hollander et al. 2001; Ji et al. 2004;
Ho et al. 2005; Spangenburg et al. 2006; Kramer and
Goodyear 2007). In contrast, a decrease in NF-jB DNA
binding at 0 h post-exercise with a return to near baseline
1 h post-exercise was observed in human muscle follow-
ing a traditional resistance exercise model (Durham et al.
2004). Recent work from our laboratory, using a similar
resistance exercise model, demonstrated an increase in
NF-jB binding to the promoter region of key inflamma-
tory cytokines at 2 h post-exercise, with a return to base-
line levels at 4 h post-exercise (Vella et al. 2012). These
findings suggest that a transient NF-jB response contrib-
utes to acute post-exercise inflammation.
To enhance our understanding of the cellular mecha-
nisms that regulate both the onset and resolution of post-
exercise inflammation, the current study aimed to investi-
gate changes in the activity of the subunits that comprise
the classical and alternative NF-jB signalling pathways.
We hypothesized that the regulation of NF-jB post-exer-
cise would involve two distinct waves of activation. Spe-
cifically, we hypothesized that the classical NF-jB
pathway, involving p65 and p50 dimers would be acti-
vated soon after exercise during the early phases of
inflammation, while the alternative pathway, comprising
mainly the p50 subunit would be activated at later time
points after exercise that correspond with the resolution
of acute inflammation (Bohuslav et al. 1998; Ishikawa
et al. 1998). We also hypothesized that the administration
of ibuprofen would blunt both waves of NF-jB activa-
tion, providing a potential mechanism through which
anti-inflammatory medication might attenuate exercise-
induced inflammation in skeletal muscle.
Methods
Participants
As previously described, sixteen healthy male subjects
were recruited to participate in the study (characteristics
shown in Table 1) (Markworth et al. 2013). All partici-
pants completed a medical history questionnaire that was
used to identify and exclude participants with a diagnosed
condition or illness that prevented them from completing
strenuous exercise. Exclusion criteria included participa-
tion in a lower body resistance exercise program within
the last 6 months to ensure a muscle damage response
from the exercise stimulus, and/or chronic treatment with
anti-inflammatory drugs. Current use of prescription
medication or nutritional supplements also excluded sub-
jects from participating.
Ethics approval
Prior to participation each subject received written and
oral information regarding the nature of the experiment
2014 | Vol. 2 | Iss. 10 | e12172
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before providing written consent to participate. All proce-
dures involved in this study were approved by the Deakin
University Human Research Ethics Committee (DUHREC
2010-019). All muscle sampling procedures were per-
formed in accordance with the Helsinki declaration.
Familiarization and strength testing
Each participant completed a familiarization session at
least 7 days prior to completing the exercise trial. Partici-
pants performed repetition maximum testing to deter-
mine the experimental exercise load (80% of 1 repetition
maximum (1RM)). The maximal weight each subject
could lift was determined for the Smith machine-assisted
squat, the leg press, and the leg extension. These data
were substituted into the validated Brzycki equation to
predict 1RM for each participant (Mayhew et al. 1995;
Whisenant et al. 2003). The participants were required to
abstain from any further exercise until completion of the
trial.
Experimental Procedures
The participants reported to the laboratory in an over-
night fasted state, having abstained from caffeine, tobacco
and alcohol for the preceding 24 h. Following 30 min of
supine resting a pre-exercise muscle biopsy was taken.
Participants then completed a 10 min warm up consisting
of low intensity cycling on a bicycle ergometer, and one
low resistance set for each exercise at approximately 30–
50% of the participants 1RM. Each participant then com-
pleted a single bout of intense resistance exercise. This
session consisted of three sets of 8–10 repetitions of a
bilateral Smith machine assisted squat, 45° leg press and
leg extension. These exercises were all performed at 80%
1RM. The exercises were performed sequentially as a cir-
cuit, with 1 min rest between each exercise, and 3 min
rest between sets. We have previously used this exercise
protocol and demonstrated that it activates inflammatory
signalling pathways (Vella et al. 2012). Following the
completion of the exercise bout, the participants rested in
a supine position while muscle biopsy samples were col-
lected. The participants returned to the laboratory the fol-
lowing morning in an over-night fasted state for a final
muscle biopsy sample. Standardized meals were provided
to participants the night preceding the trial (carbohydrate
57%, fat 22%, protein 21%), in the laboratory immedi-
ately following the exercise bout (carbohydrate 71%, fat
13%, protein 16%), as additional snacks throughout the
day and an evening meal (carbohydrate 64%, fat 27%,
protein 18%).
NSAID administration
Prior to the exercise bout, the participants were randomly
assigned to either the ibuprofen (NSAID) group (n = 8)
or the placebo group (PLA) (n = 8). Participants in the
NSAID group consumed the maximum recommended
over-the-counter dose of 1200 mg of ibuprofen as three
doses of 400 mg throughout the trial day. The first dose
was administered upon arriving to the laboratory on the
first morning of the trial, immediately prior to the first
muscle biopsy sample. Participants were instructed to
consume two additional doses at 2:00 pm and 8:00 pm
the same evening. This dosing structure was prescribed to
optimise levels of circulating ibuprofen to biologically
active levels throughout the course of the trial day. This
protocol has previously been validated by our research
group in this same group of study participants and the
same NSAID administration protocol (Markworth et al.
2013). Alternatively the placebo consumed a gelatin cap-
sule containing powdered sugar, identical in appearance
to the ibuprofen capsule.
Sample collection
Muscle biopsy samples were obtained under local anaes-
thesia (Xylocaine 1%) from the vastus lateralis muscle of
either leg using the percutaneous needle biopsy technique
modified to include suction (Buford et al. 2009). Samples
were obtained prior to exercise, immediately following
exercise and at 3 and 24 h post-exercise. The muscle
biopsy sample obtained immediately post-exercise was
taken within 1–2 min of the completion of the exercise
protocol, and will herein after be referred to as 0 h post-
exercise. The muscle biopsy procedure has been shown to
Table 1. Subject characteristics and strength testing data.
Characteristics Strength (1RM)
Age (y) Height (m) Body mass (kg) BMI Squat(kg) Leg press (kg) Leg extension (kg)
PLA 23.9  1.3 1.89  0.1 86.9  4.5 24.5  1.2 94.9  5.4 237  17 236  18
IBU 23.0  0.5 1.89  0.1 89.1  4.4 24.8  0.8 91.9  6.0 240  15 196  22
Values are mean values  SEM. No significant differences were observed between the two groups.
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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trigger a local inflammatory response (Malm et al. 2000).
To minimize interference from the biopsy procedure,
samples prior to exercise and at 24 h post-exercise were
taken from the same leg, while muscle samples obtained
at 0 and 3 h post-exercise were taken from the opposite
leg. Samples within the same leg were taken at least 5 cm
from the previous site. We have previously reported that
this technique is effective for minimizing cytokine gene
expression and NF-jB activity in response to muscle
biopsies (Vella et al. 2012). Excised tissue was immedi-
ately immersed in liquid nitrogen and stored at 80°C
until further analysis.
Subjective assessment of DOMS and range
of movement
Subjective assessment of muscle soreness (DOMS) and
range of movement were recorded prior to exercise and
at 24 h post exercise. Subjects were asked to rate their
levels of muscle soreness and range of movement on a
0–10 scale. In both instances 0 was considered as the best
possible result and a rating of 10 was considered to be
the worst result.
Protein extraction and quantification
Muscle samples were homogenized in ice cold RIPA buf-
fer (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl,
0.25% deoxycholic acid, 1% NP-40, 1 mmol/L EDTA
supplemented with protease and phosphatase inhibitors
including 1 mmol/L PMSF, 1 lg/mL aprotinin, 1 lg/mL
leupeptin, 1 mmol/L Na3VO4 & 1 mmol/L NaF). The
homogenate was agitated for 1 h at 4°C and centrifuged
at 13,000 9 g at 4°C for 15 min. The resultant superna-
tant was removed and stored at 80°C until further
analysis. Total protein concentration was determined
using a BCA protein assay kit according to the manufac-
turer’s instruction (Pierce, Rockford, IL). Protein samples
(50 lg) were denatured in loading buffer and separated
by a 10% SDS-PAGE and transferred to a PVDF mem-
brane. Membranes were blocked for 90 min at room
temperature in 5% BSA/Tris buffered saline with 0.1%
Tween 20 (TBST). Primary antibodies [phosphorylated
NF-jB p65 Ser536, total NF-jB p65, NF-jB p100/p52,
NF-jB p105/p50, NF-jB cREL and b-actin (all obtained
from Cell Signaling Technologies, Arundel, QLD)] were
diluted to 1:1000 in 5% BSA/TBST, applied and incu-
bated overnight at 4°C with gentle agitation. Membranes
were washed for 30 min in TBST and probed with HRP
conjugated secondary antibodies diluted to 1:2000 in 5%
BSA/TBST, and incubated for 1 h at room temperature.
Proteins were visualised by using Western Lighting
enhanced chemiluminescence (Perkin Elmer Lifesciences,
Boston, MA). Signals were captured using a Kodak Digi-
tal Image Station 2000M (model: 440CF; Eastman Kodak,
Rochester, NY) and quantified by densitometry band
analysis using Kodak Molecular Imaging Software (Ver-
sion 4.0.5, © 1994–2005, Eastman Kodak). Phosphory-
lated NF-jB p65 protein was normalized to total p65
protein (Fig. 2A). NF-jB p50 protein expression was
normalized to its precursor protein p105 (Fig. 2B). NF-
jB p52 and cREL protein was normalized to b-actin
(Fig. 2C).
RNA extraction and RT-PCR
Total cellular RNA was extracted as previously described
(Trenerry et al. 2007) using the ToTALLY RNA Kit (Am-
bion, Austin, TX). RNA quality and concentration were
determined using the Agilent 2100 Biolanalyzer (Agilent
Technologies, Palo Alto, CA). First strand cDNA was gen-
erated from 0.5 lg total RNA using the AMV RT kit
(Promega, Madison, WI). RT-PCR was performed in
duplicate using the Biorad CFX384 system (Biorad, Her-
cules, CA), containing 5XHOT FirePol EvaGreen Mix
(Integrated Science, Sydney, NSW), forward primer,
reverse primer, sterile nuclease free water and cDNA
(0.125 ng/lL). Data were analysed using a comparative
critical threshold (Ct) method, where the amount of the
specified target gene normalised to the amount of endog-
enous control, relative to the control value is given by
2DDCt . The endogenous control used in this experiment
was GAPDH. The efficacy of GAPDH as an endogenous
control was examined using the equation 2DCt . Primers
were designed using Primer Express software package ver-
sion 3.0 (Applied Biosystems, Mulgrave, Vic., Australia).
Gene sequences were obtained from GenBank (Table 2).
Primer sequence specificity was confirmed using BLAST.
A melting point dissociation curve was generated by the
PCR instrument for all PCR products to confirm the
presence of a single amplified product.
Nuclear extraction and Transcription Factor
(TF) Assay
Nuclear and cytoplasmic proteins were extracted from
20 mg of muscle tissue using a NE-PER Nuclear and
Cytoplasmic Extractions Reagents (Pierce, Rockford, IL),
according to the manufacturer’s instructions. Western
blot analysis probed for GAPDH, a-tubulin and Lamin A
was performed to ensure the nuclear extract was not
contaminated by cytoplasmic proteins. A Transcription
Factor Assay detecting specific transcription factor
DNA binding activity was performed according to
manufacturer’s instructions (Cayman Chemical, Ann
Arbour, MI). Briefly, 10 lg of nuclear protein were
2014 | Vol. 2 | Iss. 10 | e12172
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loaded into a well containing an immobilized NF-jB con-
sensus sequence (50GGGACTTTCC-30) and incubated
overnight at 4°C. Primary antibodies for NF-jB subunits
p65 and p50 were loaded in to each well and incubated at
room temperature for 1 h. Each well was flushed using a
diluted wash buffer for 30 min. Following a secondary
30 min wash, samples were incubated with secondary
HRP-conjugated antibody for a further 1 h at room tem-
perature. To quantify transcription factor binding, a
developing solution containing a 3,30,5,50-Tetrame-
thhylbenzidine (TMB) solution was added to each
well and incubated for 45 min at room temperature.
DNA binding was then quantified using photospectrome-
try with absorbance measurements taken at 450 nm
using a Multiscan RC plate reader (Labsystems, Finland)
and Gen5 Data Analysis Software (BioTek, Winooski,
VT).
Statistics
Data are expressed as means  SEM. Prior to analysis the
data displaying a lack of normality were log transformed
to stabilise variance. Data were analysed using a two-way
ANOVA with repeated measures for time. The sphericity
adjustment was checked, and if required, a Greenhouse-
Geisser epsilon to the residual degrees of freedom was
applied. A data point was considered to be a statistical
outlier where a z-score exceeded a pre-determined thresh-
old of  4.00. Where appropriate we explored within-
group pair-wise comparisons between individual time-
points using the Least Significant Differences of means at
P < 0.05 to determine statistically significant changes
(Mead 1988; Saville 1990). Statistical analyses were per-
formed using GenStat for Windows 16th Edition (VSN
International, Hemel Hempstead, UK).
Results
Subjective DOMS analysis showed a main effect for time
(time effect P < 0.01) with no effect for treatment. The
average post-exercise DOMS score was 4.81  0.5 and
the post-exercise ROM score was 3.3  0.5. This data
demonstrates that the exercise protocol induced a moder-
ate level of muscle soreness and this effect was irrespective
of ibuprofen treatment.
Expression of NF-jB phosphorylated p65 (Ser 536)
increased over time (time effect P = 0.006), but this
response was overall not different between the groups
(interaction effect P = 0.253, treatment effect P = 0.176).
Nevertheless, LSD pairwise comparisons indicated that
the main increase from baseline was in the placebo
group at 0 h post-exercise. Within the placebo group
phosphorylated p65 protein expression remained elevated
at 3 h post-exercise and returned to baseline by 24 h
(Fig. 1A). No significant changes were observed in the
ibuprofen group by LSD comparisons. There was no
effect of time or treatment for NF-jB total p65
(Fig. 2A).
There was a trend toward a significant time 9 treat-
ment interaction (P = 0.057) for the protein expression
of the p50 subunit, although a main effect for time
(P = 0.376) or treatment (P = 0.865) was not achieved.
Our analysis revealed a statistical outlier in the ibuprofen
group at the 24 h time point. When this subject was
removed from the analysis, this trend was weaker
(P = 0.115) (Fig. 1B). LSD comparisons indicated an
increase in p50 protein expression was observed at 24 h
post exercise in the placebo group only (Fig. 1B). There
were no main or interaction effects for the NF-jB p50
precursor protein p105 (Fig. 2B) or for p52 and cREL
subunits (Fig. 1C and D).
To determine subunit-specific DNA binding of NF-jB
following exercise, transcription factor binding assays
were performed for p50 and p65 subunits. NF-jB p50
showed a main effect for time (P = 0.035), with no
time 9 treatment interaction (P = 0.851) or main effect
for treatment (P = 0.488) (Fig. 3B). LSD comparisons
identified a significant increase in p50 binding that
occurred at 24 h post-exercise when compared to 0 and
3 h post-exercise within the placebo group. This coin-
cided with the increase in p50 protein expression
(Fig. 1B). No change in p65 DNA binding was observed,
despite an increase in phosphorylated p65 protein expres-
sion (Fig. 3B).
We sought to determine whether any increase in
NF-jB signalling coincided with an increase in down-
stream inflammatory cytokines, and if the administration
of ibuprofen influenced post-exercise cytokine expression.
The mRNA levels of IL-6 (Fig. 4A), IL-8 (Fig. 4B) and
MCP-1 (Fig. 4C) demonstrated a main effect for time
(P < 0.01), with the highest elevation in expression levels
at 3 h post-exercise after significant increases at 0 h post-
exercise. TNF-a mRNA remained unchanged after exer-
cise (Fig. 4D). COX-2 mRNA showed a main effect for
time (P < 0.01), increasing at 0, 3 and 24 h post-exercise
(Fig. 4E). There were no significant interaction effects or
main effects for treatment for the inflammatory cytokines
or COX-2 mRNA expression. Consistently, LSD pairwise
comparisons revealed similar changes over time from
baseline within both groups.
Discussion
The current study aimed to explore the regulation of
the different NF-jB subunits following a single bout of
lower body resistance exercise, and investigate the mech-
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anism through which ibuprofen treatment may influence
post-exercise inflammation. The results of this study
show for the first time that an alternative NF-jB signal-
ling pathway comprising mainly p50 subunits is acti-
vated 24 h post-exercise. This pathway appears distinctly
different to the activation of NF-jB p65 subunit that
occurs during the early stages of acute post-exercise
inflammation.
Phosphorylated NF-jB p65 protein expression was sig-
nificantly elevated in the placebo group when measured
at 0 and 3 h post-exercise, and returned to baseline levels
at 24 h post-exercise. These findings support those of pre-
vious research showing a post-exercise increase in key
components of the classical NF-jB signalling pathway in
skeletal muscle, including phosphorylated NF-jB p65
protein (Ji et al. 2004; Vella et al. 2012), phosphorylated
IjBa protein (Ho et al. 2005; Vella et al. 2012) and NF-
jB p65 DNA binding activity (Tantiwong et al. 2010;
Hyldahl et al. 2011). In the present study, the increase in
phosphorylated NF-jB p65 protein expression was not
associated with an increase in p65 transcription factor
binding activity at 0, 3 and 24 h post-exercise. However,
NF-jB regulated cytokine genes including MCP-1, IL-6
and IL-8 were increased at 3 h post-exercise. Previous
work from our group showed an increase in NF-jB p65
binding to the promoter region of genes coding for
inflammatory cytokines at 2 h after traditional resistance
exercise (Vella et al. 2012). This research performed a ser-
ies of electrophoretic mobility shift assays that looked
specifically NF-jB binding to genes coding MCP-1, IL-6
and IL-8 and thus differences in the methodology may
explain conflicting results. Furthermore, the discrepancy
in the results between our two trials may be explained by
the short half-life of NF-jB in the absence of an activat-
ing stimulus. In a HL60 cell line, the half-life of NF-jB
has been reported to be less than 30 min (Hohmann
et al. 1991). Likewise, the inhibitory IjBa protein has a
half-life of 25 min in Jurkat cells (Dodd et al. 2009).
Therefore, in the present study, NF-jB activation may
have returned to resting levels by 3 h post-exercise.
Research models using an extreme eccentric resistance
exercise model were able to demonstrate an increase in
p65 DNA binding to nuclear protein at 3 h post-exercise
(Hyldahl et al. 2011; Xin et al. 2013). By contrast,
A B
C D
Figure 1. Protein expression of NF-jB subunits p65, p50, p52 and cREL. Representative Western blots for p-p65 normalized to total p65
(A), p50 normalized to p105 (B), p52 normalized to b-actin (C) and cREL normalized to b-actin (D) measured in muscle biopsy samples. Data
are mean arbitrary units  SEM. *denotes statistical significance from pre exercise values in the placebo group; ^denotes statistical significance
from 24 h post-exercise in the control group (P < 0.05). White bars = placebo group; black bars = ibuprofen group.
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research from Durham et al. (2004) showed a decrease in
NF-jB DNA binding activity immediately post-exercise,
which returned to baseline levels at 1 h post-exercise.
Collectively, these findings suggest that the activation of
NF-jB DNA binding occurs transiently within the first
few hours of exercise. Changes in NF-jB activity in skele-
tal muscle may depend on the mode of exercise and
training status of participants.
This research also provides novel evidence for a
potential role of NF-jB p50 activation as a component
of inflammation-resolution. In our initial analysis of
p50 protein expression, there was a trend towards a
time 9 group interaction effect (P = 0.057) but this
trend was weaker (P = 0.115) after removing a statistical
outlier. Despite this weaker interaction, within-group
analysis by LSD comparisons revealed that p50 protein
A B
C
Figure 2. Protein expression of total NF-jB p65, NF-jB p105 and b-actin. Data are mean arbitrary units  SEM. White bars = placebo group;
black bars = ibuprofen group.
A B
Figure 3. NF-jB subunits p65 (A) and p50 (B) binding to nuclear protein. Data are mean arbitrary units  SEM. #denotes statistical significance
from 0 h post-exercise in the control group; $denotes statistical significance from 3 h post-exercise in the control group. White bars = placebo
group; black bars = ibuprofen group.
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expression was elevated in the placebo group at 24 h
post-exercise. Coincident with this response, p50 tran-
scription factor binding activity was highest at 24 h
post-exercise. The biological significance of this delayed
increase in NF-jB p50 signalling during the latter stages
of post-exercise recovery remains uncertain. However, in
vitro work suggests that it may play a role in regulating
the active resolution of acute inflammation in skeletal
muscle (Lawrence et al. 2001, 2005; Senftleben et al.
2001). In a model of carageenin-induced pleurisy in
rats, Lawrence et al. (2001) provided preliminary evi-
dence for a complex interplay between distinct NF-jB
signalling pathways that control an acute and transient
inflammatory response. They reported that the prelimin-
ary phase of NF-jB activation that occurred at 6 h was
characteristic of the classical NF-jB pathway, and was
associated with the onset of acute inflammation. The
secondary phase was typical of the alternative NF-jB
pathway, comprising p50 homodimers. Importantly,
inhibiting this wave of activity caused a prolonged
inflammatory response (Lawrence et al. 2001). Findings
from the present study support the concept of two
functionally distinct waves of NF-jB activity following
traditional resistance exercise. Future work is warranted
to determine how this secondary wave of NF-jB path-
way activity influences post-exercise inflammation and
skeletal muscle recovery.
We used ibuprofen supplementation to investigate
whether manipulating the inflammatory response to exer-
cise through the cyclooxygenase-prostaglandin pathway
alters post-exercise NF-jB signalling. Previous reports
indicate that NF-jB can function upstream of COX-2 to
control transcription of this gene (Pahl 1999; Poligone
and Baldwin 2001). Alternatively, prostaglandin activity
may also affect NF-jB (Rossi et al. 2000; Straus et al.
2000; Poligone and Baldwin 2001). In-vitro studies dem-
onstrate that the effect of prostaglandins on NF-jB activ-
ity is specific to the class of prostaglandin. Prostaglandin
E2 activates the classical NF-jB pathway, whereas prosta-
glandin A2, and prostaglandin J2 and its downstream
analogues can inhibit NF-jB activation in response to
pro-inflammatory stimuli (Castrillo et al. 2000; Rossi
et al. 2000; Straus et al. 2000; Lawrence et al. 2002). Our
group recently reported changes in prostaglandins in
blood serum samples after traditional resistance exercise
(Markworth et al. 2013). Interestingly, PGE2, PGA2 and
PGD2 all peaked in expression at 2 h post-exercise. We
did not find any significant time 9 group interaction
effects for the change in p65 phosphorylation; however,
LSD comparisons suggested that phosphorylated p65
expression only seemed to increase in the placebo group.
Similarly the observed changes in p50 protein expression
and DNA binding were only identified within the placebo
group. These findings are supported by data from the
study by Lawrence et al. (2001), which demonstrated no
change in the secondary wave of NF-jB DNA binding
activity following the administration of an alternative
COX inhibitor, NS398, in rats with pleurisy. While these
findings do not offer any conclusive evidence that ibupro-
fen treatment inhibits the NF-jB pathway, it does provide
justification to further explore this pathway as a potential
mechanism through which ibuprofen treatment inhibits
post-exercise inflammation.
There were several limitations to the present study that
need to be considered. Firstly, this analysis was run as
part of a larger study investigating the effects of ibuprofen
administration on multiple components of the post-exer-
cise inflammatory and hypertrophy response (Markworth
et al. 2013, 2014). Therefore, limited muscle sample
remained to complete further analyses. Future research
Table 2. Primer sequences were designed using Primer Express Software v 3.0 (Applied Biosystems) using sequences accessed through Gen-
bank and checked for specificity using nucleotide-nucleotide BLAST search.
Gene Accession No. Primer sequence
GAPDH NM_21130 Forward: CAT CCA TGA CAA CTT TGG TAT CGT
Reverse: CAG TCT TCT GGG TGG CAG TGA
MCP-1 NM_002982 Forward: TCC CAA AGA AGC TGT GAT CTT CA
Reverse: CAG ATT CTT GGG TGG AGT GA
IL-6 NM_000600 Forward: GCG AAA GGA TGA AAG TGA CCA T
Reverse: AGA CAA GCC CAG CAA TGA AAA
IL-8 NM_000584 Forward: CTG GCC GTC GCT CTC TGG
Reverse: TTA GCA CTC CTT GGC AAA ACT
TNF-a X_02910 Forward: GGA GAA GGG TGA CCG ACT CA
Reverse: TGC CCA GAC TCG GCA AAG
COX-2 U_20548 Forward: GAA TCA TTC ACC AGG CAA ATT G
Reverse: TGG AAG CCT GTG ATA CTT TCT GTA CT
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should consider the post-exercise regulation of upstream
markers including IKKa and IKKb.
Conclusion
This research provides new insights into the regulation of
NF-jB following a bout of acute resistance exercise. The
primary finding from this study is that NF-jB activation
follows a biphasic activation pattern that is subunit-spe-
cific. The first wave involves the classical NF-jB p65 sub-
unit, and corresponds with the onset of an acute
inflammatory response and an increase in inflammatory
cytokine gene expression. The second wave is consistent
with a previously identified secondary wave of NF-jB
activity that involves the alternative p50 subunit. Research
in alternative models of inflammation suggests that this
second wave of activity may be associated with an active
inflammatory resolution program. Further research into
the role of p50 signalling in skeletal muscle represents a
key area for future research in order to better understand
the mechanisms that regulate post-exercise inflammation.
Analysis of the LSD to examine pair-wise within-group
differences suggested that the observed changes in both
NF-jB p65 and p50 were detected only within the pla-
cebo group. The complex interplay between the NF-jB
and the COX/prostaglandin pathway in exercise-induced
muscle damage remains poorly understood, and should
be a focus for future research.
A B
C D
E
Figure 4. RT-PCR analysis of NF-jB target genes IL-6 (A), IL-8 (B), MCP-1 (C), TNF-a (D) and COX-2 (E) in skeletal muscle cDNA. Data are mean
arbitrary units  SEM. *denotes statistical significance from pre exercise in the same treatment group; #denotes statistical significance from 0 h
post-exercise in the same treatment group; ^denotes statistical significance from 24 h post-exercise in the same treatment group (P < 0.05).
White bars = placebo group; black bars = ibuprofen group.
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